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Summary 
 
Despite the tremendous progress in the fight against malaria during the last two decades, it 
remains one of the most important infectious diseases worldwide, leading to approximately 
500 000 lethal cases annually, mostly among young children. The emergence and spread of 
resistance of the Plasmodium parasites to all the drugs currently available on the market are 
a major threat to its control and eradication. It moreover emphasizes the dire need for new 
antimalarial agents with distinct modes of action. Previously, the medicinal chemistry team at 
the biotechnology company 4SC AG, Munich, presented a series of promising antimalarial 
compounds, optimized around an amicarbalide backbone. Two agents were selected out of 
this series as lead-compounds for further studies, namely SC81458 and SC83288.  
The work presented here aims to characterize the in vitro activity of the SC-lead compounds. 
First, it revealed them as potent inhibitors of P. falciparum blood stage parasites, acting 
preferentially on late stages. The lack of activity on the ring stages is reflected in their fast 
speed of action, yet not as fast as artemisinin, the fastest compound described so far, that 
acts on all blood stages. Importantly, the SC-lead compounds were unaffected by the most 
common resistance mechanisms to antimalarial drugs used in the clinic. Particularly, no 
cross-resistance mechanism between artemisinin and its derivatives and the SC-lead 
compounds was observed, and their antiplasmodial modes of action appeared to be distinct 
from each other.  
The second part of this work focused on the mode of action of the SC-lead compounds and 
the mechanisms of resistance that the parasite could develop. Although the Ca2+ ATPase 
pump PfATP6 was disproved as a direct molecular target of the SC-lead compounds, it was 
demonstrated to be implicated in a resistance mechanism. The F972Y mutation and the 
overexpression of the A108T, A109T variant led to a drastic decrease in the SC-lead 
compounds responsiveness. The F972Y substitution correlated with an in vitro fitness cost 
for the parasite, which was linked to a lower intracellular calcium resting concentration 
compared to its parental line. The molecular details of the disturbed calcium homeostasis 
and its correlation with the resistance to the SC-lead compounds remain to be unraveled.  
Overall, the findings of this work demonstrate the promising in vitro potency of the SC-lead 
compounds, particularly SC83288, and highly support its further development into 
(pre)clinical trials.  
Zusammenfassung 
IV 
 
Zusammenfassung 
 
Trotz der enormen Fortschritte in den letzten zwei Jahrzehnten im Kampf gegen Malaria bleibt sie eine 
der wichtigsten Infektionskrankheiten weltweit, die hauptsächlich bei Kleinkindern jährlich zu etwa 
500.000 Todesfällen führt. Das Auftreten und die Ausbreitung der Resistenz von Plasmodium-
Parasiten gegenüber allen sich derzeit auf dem Markt befindlichen Medikamenten ist eine große 
Bedrohung für die Kontrolle und Ausrottung der Malaria und betont außerdem die Notwendigkeit neue 
Malariamittel mit unterschiedlichen Wirkmechanismen zu finden. Zuvor präsentierte das medizinische 
Chemieteam des Biotechnologieunternehmens 4SC, München, eine Reihe vielversprechender 
Antimalaria-Wirkstoffe, die um ein Amicarbalid-Rückgrat optimiert wurden. Aus diesen Wirkstoffen 
wurden zwei Leitverbindungen, SC81458 und SC83288, für weitere Studien ausgewählt. 
Die vorliegende Arbeit über die in vitro-Aktivität der SC- Leitverbindungen offenbarte sie als potente 
Inhibitoren von P. falciparum-Blutstadienparasiten, die vorzugsweise auf späte Stadien wirken. Der 
Mangel an Aktivität auf Ringstadien spiegelt sich in ihrer schnellen Reaktionsgeschwindigkeit wider, 
welche jedoch nicht so schnell ist wie die von Artemisinin, der bisher schnellsten Verbindung, die auf 
alle Blutstadien wirkt. Ein wichtiger Faktor ist außerdem, dass die SC-Leitverbindungen nicht von den 
Resistenzmechanismen der am häufigsten in der Klinik verwendeten Malariamedikamente beeinflusst 
wurden. Insbesondere wurde kein Kreuzresistenzmechanismus zwischen Artemisinin und seinen 
Derivaten und den SC- Leitverbindungen beobachtet, und ihre antiplasmodialen Wirkmechanismen 
schienen sich voneinander zu unterscheiden. 
Der zweite Teil dieser Arbeit konzentrierte sich auf die Wirkmechanismen der SC- Leitverbindungen 
und die Resistenzmechanismen der Parasiten gegen diese Verbindungen. Obwohl die Ca
2+ 
ATPase-
Pumpe PfATP6 als direktes molekulares Target von SC- Leitverbindungen ausgeschlossen wurde, 
konnte ihre Beteiligung an einem Resistenzmechanismus gezeigt werden. Die F972Y-Mutation und 
die Überexpression der A108T, A109T-Variante führten zu einer drastischen Abnahme der 
Reaktionsfähigkeit der SC-Leitverbindungen. Die F972Y-Substitution korreliert mit in vitro-
Fitnesskosten für den Parasiten, einhergehend mit einer niedrigeren intrazellulären 
Calciumruhekonzentration im Vergleich zur parentalen Parasitenlinie. Die molekularen Details der 
gestörten Calciumhomöostase und ihre Korrelation mit der Resistenz gegenüber den SC-
Leitverbindungen müssen noch geklärt werden. 
Zusammengefasst, zeigen die Ergebnisse dieser Arbeit die vielversprechende in vitro-Wirksamkeit der 
SC- Leitverbindungen, insbesondere von SC83288, und unterstützen ihre Weiterentwicklung für (prä) 
klinische Studien.  
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1. Introduction 
1.1. Malaria – a major human infectious disease 
 Origin and history 1.1.1.
Malaria is one of the most important human pathogen borne diseases, along with 
tuberculosis and AIDS [1]. It occupies a unique place in human history and malaria´s long 
reign is attested by various ancient writings and artifacts [2]. Indeed, malaria can be traced 
back to ancient Mesopotamia and Egypt (3200 BC) [3], and can be followed through the 
Antiquity from the Indian Vedic period (1500 to 800 BC) as the “king of diseases”, to the 
earlier Greek times as Homer mentions malaria in his famous Iliad (around 750 BC), as well 
as Aristophanes in The Wasps (around 420 BC), Aristotle (384-322 BC), Sophocles (496-406 
BC) or even Plato (428-347 BC) [4]. Scholars were therefore clearly aware of the 
characteristic poor health, fever and enlarged spleens observed in population living in 
swamps areas [5]. These typical symptoms of the so-called Roman fever actually inspired 
the name mal´aria, literally “bad air” [2].  
The cause for malaria disease, i.e. the Plasmodium eukaryotic parasite located in human 
erythrocytes, was discovered in 1880 by the French army doctor (Charles Louis) Alphonse 
Laveran. He noticed crescent-shape bodies in the blood of a febrile soldier, nearly 
transparent to the exception of one small pigmented dot [2]. Laveran´s following work 
allowed him to further distinguish and characterize four distinct forms that would later prove 
to be different stages of the parasite erythrocytic life cycle [6] (see Section 1.2.1), and was 
later awarded with the Nobel Prize in Physiology or Medicine in 1907. Shortly after, in 1897, 
the British Surgeon-Major Ronald Ross demonstrated the transmission of avian malaria 
through the Anopheles mosquito [7]. He was similarly awarded the Nobel Prize in 1902 for 
discovering the mosquito stage of malaria. The latest Nobel Prizes associated with malaria 
were granted to the Swiss chemist Paul Müller in 1948, for discovering the potent insecticidal 
properties of dichloro-diphenyl-trichloroethane (DTT) against Anopheles mosquitos and its 
subsequent contribution to malaria control; and to the pharmaceutical chemist Tu Youyou in 
2015, for the discovery of artemisinin and dihydroartemisinin [8,9] and their significant 
breakthrough for the treatment of malaria over the 20th century. 
 
 Clinical manifestations 1.1.2.
Malaria infection results in a wide spectrum of outcomes, from the absence of symptoms, to 
mild or severe symptoms that may lead to the death of the patient. Malaria can be 
categorized according to the severity of these outcomes, i.e. as uncomplicated or severe. 
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Uncomplicated malaria can be defined as the absence of symptoms characteristic of severe 
malaria. As the symptoms of uncomplicated malaria are unspecific (Table 1.1), it might be 
difficult to distinguish from other febrile illnesses. If uncomplicated malaria is promptly and 
appropriately diagnosed and treated, the prognosis is favorable, and the infection rarely 
results in fatality. However, if a Plasmodium falciparum infection remains untreated, it might 
develop into severe malaria (Table 1.1), usually lethal if not treated.   
 Table 1.1: Principal symptoms of malaria, uncomplicated or severe [10]. 
Uncomplicated malaria Severe malaria 
Fever, chills and perspiration Cerebral malaria 
Headache Severe anemia 
Fatigue Acidosis and hypoglycemia 
Muscle and joint aches Respiratory distress 
Abdominal discomfort Pulmonary oedema  
Vomiting Acute kidney injury 
 Jaundice 
 
The broad range of clinical manifestations of malaria is primary due to the difference in the 
level of immunity between infected individuals. Immunity is generally correlated with the 
geographical transmission pattern, so that naïve infected individuals will develop symptoms 
whereas clinical immunity to malaria can be acquired in areas of stable transmission. 
 
 Global impact and eradication strategy 1.1.3.
Malaria was once prevalent in most of the inhabited world, as 90% of the population was 
estimated to live in malaria-affected regions before 1900 [11]. By the mid-20th century, 
malaria was eliminated from North America, Europe and Russia, and ceased to be a major 
health issue in most of the world [10]. Endemic areas however remain, principally in Sub-
Saharan Africa where malaria is still one of the largest factors in premature death [1,2]. To a 
lesser extent, malaria remains a prominent concern in South America and parts of South 
Asia [1]. Malaria gives rise to over 200 million cases annually, causing approximately 500 
000 deaths per year [1]. Malaria particularly affects pregnant women and young children, and 
more than 70% of malaria deaths occur in children under five years old [1]. Despite these 
figures, tremendous progresses have been achieved in the battle for malaria eradication. 
According to the latest estimates by the World Health Organization (WHO), global malaria 
case incidence was reduced by 41% and malaria-related mortality rates by 62% between 
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2000 and 2016 [1] (Figure 1.1). This general trend has been sustained over the last few 
years, as a global decrease in malaria incidence of 18% was observed between 2010 and 
2016 and the mortality rates dropped by 29% among all age groups, in particular by 35% 
among children under the age of five [1]. 
 
Figure 1.1: Countries endemic for malaria in 2000 and 2016. The number of indigenous 
cases was used as an indicator of whether a country is considered endemic for malaria. 
Countries with three consecutive years of zero indigenous cases are considered to have 
eliminated malaria. Cases were reported to the WHO by national malaria control programs 
(NMCPs). Since 2000, seventeen countries and territories, i.e. Argentina, Armenia, 
Azerbaijan, Costa Rica, Georgia, Iraq, Kyrgyzstan, Morocco, Oman, Paraguay, Sri Lanka, 
Syrian Arab Republic, Tajikistan, Turkey, Turkmenistan, United Arab Emirates and 
Uzbekistan, have been declared no longer endemic in 2016. This map was created using the 
online MapChart tool (https://mapchart.net/).Adapted from [12]. 
 
Aiming to accelerate the progresses in reducing the global malaria burden and highlighting 
the need for universal access to malaria prevention, diagnosis and treatment, the WHO 
developed the Global Technical Strategy for Malaria 2016-2030 (GTS) [13]. The GTS is 
based on two supporting elements, i.e. innovation and research, and strengthening of the 
enabling environment [13]. It sets the ambitious target of reducing malaria incidence and 
mortality by at least 90% from the levels in 2015 by the year 2030, and at least 35 countries 
where transmission occurred in 2015 should be malaria-free by the same deadline [13]. 
 
 
Countries endemic for 
malaria, 2016 
Countries not endemic 
for malaria, 2000 
Countries endemic in 2000, 
no longer endemic in 2016 
Not applicable 
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1.2. Plasmodium falciparum´s biology 
 
The genus Plasmodium includes nearly 200 species able to infect various hosts, from 
mammals to birds and reptiles [14]. Five species are known to develop in a human host, P. 
falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. Recent studies reported that the 
P. vivax-diagnosed human infection cases observed in the Atlantic Forest region of Rio de 
Janeiro state were actually caused by P. simium, a species previously thought to infect 
exclusively primates [15]. 
 
 Life cycle of Plasmodium falciparum 1.2.1.
The Plasmodium life cycle is a complex process. It involves both a cold-blooded insect 
vector, the female Anopheles mosquito where it replicates sexually and a warm-blooded 
vertebrate host where asexual replication occurs [16] (Figure 1.2).The life cycle of the five 
established human pathogenic Plasmodium species are similar, with only minor variations, 
and can be exemplified by the life cycle of P. falciparum.  
Female Anopheles mosquitoes ingest sexually differentiated gametocytes when feeding on 
an infected host. Inside the mosquito midgut, male gametocytes undergo DNA replication 
rounds and exflagellation to release eight motile microgametes from an erythrocyte. At the 
same time, the female gametocytes egress from the erythrocytes and develop into 
macrogametes.  Fertilization occurs, and the resulting diploid zygote further differentiates into 
a motile ookinete, settling between the midgut and the basal lamina. It further develops into 
an oocyst, inside which the parasite replicates through sporogony, producing thousands of 
haploid sporozoites. The oocyst ruptures and the freed sporozoites migrate through 
hemolymph and actively invade the salivary glands of the mosquito. These infective 
sporozoites are injected into the human host by mosquito bite during its next blood meal 
[16,17]. Once released into the skin, the sporozoites become actively motile and quickly 
enter the blood stream and are passively transported to the liver, where they actively invade 
hepatocytes. The liver stage is a phase of intense asexual replication, resulting in the 
formation of hundreds of merozoites [16,17]. Even though clinically silent, this phase 
represents the bottleneck of the infection [18]. In contrast to P. falciparum, P. ovale and P. 
vivax can form dormant liver stages, the hypnozoites. The latent nature of this stage is 
responsible for the reactivation of the parasite´s life cycle and the frequent relapses of the 
disease, even years after the initial infection [17]. The merozoites are released into the blood 
stream and rapidly invade red blood cells (RBC) and initiate their intraerythrocytic 
development.  
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Figure 1.2: Life cycle of Plasmodium falciparum in the human body and the Anopheles 
mosquito. Adapted from https://www.mmv.org/ 
 
This intraerythrocytic cycle, responsible for the clinical symptoms associated with malaria, 
lasts around 48 hours in P. falciparum, P. ovale and P. vivax, with small variations according 
to the different strains, 72 hours in P. malariae and 24 hours in P. knowlesi. The parasite 
develops inside a parasitophorous vacuole and undergoes yet another asexual replication 
round, characterized by three morphologically distinct successive stages, which can be 
observed under light microscopy after Giemsa staining (Figure 1.3) [19]: 
(1) The ring stages, observed between 6 to 22 hours post-invasion (p.i.). 
(2) The trophozoite stages, observed between 22 to 38 hours p.i. The parasite is highly 
metabolically active during this stage, synthetizing macromolecules, degrading 
hemozoin and synthetizing the hemozoin pigment. 
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(3) The schizont stages, observed between 38 to 48 hours p.i., are polynucleated and 
reflect the differentiation into future merozoites. Merozoites can be observed at 48 
hours p.i., just before invasion. 
 
Figure 1.3: Intraerythrocytic blood stages of Plasmodium falciparum in culture. P. 
falciparum intraerythrocytic development stages every 4 hours post-invasion, on thin blood 
smears stained with Giemsa. Adapted from [19]. 
 
After rupture of the host erythrocyte, each mature schizont releases 10 to 30 infectious 
merozoites, able to rapidly reinvade erythrocytes and start a new cycle. The infected 
erythrocyte rupture combined with the release of its contained cells debris, parasite´s 
antigens and hemozoin crystals into the host circulation activates the immune system, 
inducing the typical fever peaks associated with malaria [20]. 
During the asexual intraerythrocytic cycle, a small population of the parasites commit to 
sexual development. Gametocytes develop in erythrocytes through five morphological 
stages, and the mature crescent-shaped stages [16] are taken up by the female Anopheles 
mosquito during a blood meal, allowing the beginning of a new cycle. 
 
 Calcium homeostasis in P. falciparum: the role of PfATP6 1.2.2.
1.2.2.1. Calcium homeostasis in Plasmodium 
Ca2+ is a ubiquitous intracellular secondary messenger in eukaryotes, where the basic 
signaling principles are conserved. A resting cell actively pumps Ca2+ into the extracellular 
space and into internal stores in order to maintain a low cytosolic calcium concentration, 
whereas the efflux of Ca2+ into the cytosol triggers signaling cascades involved in numerous 
cellular processes [21]. The prompt removal of Ca2+ from the cytosol back to its basal level, 
by pumps and exchangers, ends the signals and prevents toxic effects caused by an 
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elevated intracellular calcium concentration. The flexibility of Ca2+ signaling, in terms of 
amplitude, speed and spatio-temporality, accounts for its universality [22]. The wide 
repertoire of proteins involved in downstream calcium signaling significantly varies among 
eukaryotic organisms, consistent with lineage-specific adaptations. Yeast, plant and animal 
cells are commonly used as model organisms for the investigation of Ca2+ signaling and 
related proteins. Because of the evolutionary divergence, Ca2+ signaling in Plasmodium 
combines both unique and conserved features compared to these characteristic to other 
eukaryotes. A detailed molecular understanding of Ca2+ homeostasis mechanisms and of 
how Ca2+ is integrated in broader second messenger signaling networks over the 
Plasmodium life cycle remains a challenge [21], as many canonical Ca2+ regulators, 
transporters and channels characterized in models organisms have not yet been identified in 
Plasmodium genomes. 
Nonetheless the necessity for Plasmodium to maintain a tight control of its Ca2+ intracellular 
concentration over its life cycle is established [21]. Calcium signaling is indeed virtually 
associated with every stages of the malaria parasite life cycle, from merozoite egress [23–25] 
and invasion [26–28], maturation of intraerythrocytic asexual stages [23,29–31], 
gametogenesis [32,33] and exflagellation [34], ookinete motility and oocyst formation [35,36], 
to sporozoite motility, invasion and liver stage development [37–39]. 
From the very low intracellular Ca2+ concentrations in the erythrocyte host (around 50 nM) to 
the high extracellular ones such as found in the blood plasma (around 1.8 mM), Plasmodium 
parasites have to face a wide range of Ca2+ surroundings, as well as to maintain a relatively 
high intracytosolic concentration varying from 100 nM to around 500 nM [40,41]. The 
endoplasmic reticulum (ER) is the main Ca2+ storage site in the parasite [41], and the 
mitochondrion was also proposed as a dynamic Ca2+ store [42] even though no clear 
orthologs of the mitochondrial Ca2+ uniporter have been identified in the Plasmodium 
genomes. Other organelles, such as acidocalcisomes [43] or the digestive vacuole [41] have 
been likewise suggested as calcium stores, although the understanding of their physiological 
relevance in Ca2+ signaling remains to be unraveled. Only a few Plasmodium proteins 
involved in Ca2+ homeostasis have been identified so far. Eukaryotic cells usually rely on 
ATPase pumps to transport Ca2+ into the extracellular space via plasma membrane ATPases 
(PMCAs) or into intracellular stores via the sarcoendoplasmic reticular Ca2+ ATPases 
(SERCAs). So far, no obvious orthologs of PMCAs or voltage-dependent Ca2+ channels have 
been identified in the Plasmodium genomes [44]. A divalent Ca2+/H+ antiporter could be 
identified in both P. berghei (PbCAX) and P. falciparum (PfCHA), and was suggested to be 
involved in vitro in the Ca2+ efflux system from the mitochondrion [42]. A SERCA-type Ca2+ 
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ATPase, PfATP6, has been identified in P. falciparum and its Ca2+-dependent activity has 
been characterized [21,45,46]. 
1.2.2.2. PfATP6: the P. falciparum SERCA 
PfATP6 is the only identified SERCA-pump ortholog in P. falciparum [47]. The pfatp6 gene 
(PF3D7_0106300) is located on chromosome 1, and is 4.3 Kb long (3684 bp in the coding 
sequence), composed of 3 exons and 2 introns (see Appendix I). PfATP6, a protein of 139.4 
KDa (see Appendix I), localizes in the ER and is responsible for the transport of Ca2+ ions 
from the cytosol into the ER of the parasite. 
PfATP6 conserves the key features of its well characterized rabbit ortholog SERCA1a 
(Figure 1.4). Indeed, PfATP6 displays the typical ten (putative) transmembrane domains, the 
two Ca2+-binding sites in the fourth and sixth transmembrane helices, and the characteristic 
catalytic domain in the cytosol. The catalytic domain presents the phosphorylation domain (P 
domain), the nucleotide-binding domain (N domain) where ATP is bound and the actuator 
domain (A domain) that transmits the conformational changes to the transmembrane 
domains [45,48].  
 
Figure 1.4: Predicted topological model of PfATP6. (A) Reconstruction of PfATP6 using 
the open-source visualization tool Protter [49], based on the predictive model described by 
Krishna et al. [50]. (B) Comparison of the structures of the mammalian SERCA1a (left) and 
PfATP6 (right). The A (actuator) domain is represented in yellow, the N (nucleotide-binding) 
domain in red and the P (phosphorylation) domain in blue. Amino acid sequences specific to 
PfATP6 are depicted as black loops with random coil, as no corresponding template 
structures were available for homology modeling. Obtained from [45]. 
 
A B 
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These features allow PfATP6 to be classified as a P-type ATPase, along with the SERCA 
pumps. Amino acid sequence analysis reveals an overall identity of 39% between SERCA1a 
and PfATP6, increased to 53% when the N domain sequences are excluded [45] (Figure 1.4 
B). The main divergence is therefore localized in the N domain, where PfATP6 displays 200 
additional amino acid residues compared to SERCA1a, predicted to form non-globular 
structures due to the abnormal quantity of poly-asparagine motifs (Figure 1.4 and Appendix I) 
compared to other eukaryotes [45].  
PfATP6 can be inhibited by the classical SERCA inhibitors, such as thapsigargin (Figure 1.5 
A) or cyclopiazonic acid (CPA) (Figure 1.5 B) [51]. The inhibition of PfATP6 blocks the ability 
of the parasite to pump Ca2+ into the ER, depleting this calcium store. This depletion in turn 
secondarily activates plasma membrane calcium channels and allows an influx of calcium, 
overall raising the cytosolic Ca2+ concentration [52]. 
                
Figure 1.5: Chemical structures of SERCA1a and PfATP6 inhibitors. (A) Thapsigargin. 
(B) Cyclopiazonic acid. 
 
Thapsigargin and CPA sensitivities and binding sites have been proven to be different in the 
mammalian SERCA and PfATP6 [53,54]. CPA is a more potent inhibitor of PfATP6 than 
SERCA1a, and the inverse can be observed for thapsigargin, marking CPA as a more 
appropriate tool to study PfATP6 inhibition in P. falciparum. 
 
1.2.2.3. The PfATP6 - artemisinin controversy  
Based on the structural similarities between thapsigargin and the potent antimalarial drug 
artemisinin, both sesquiterpene lactones, PfATP6 was proposed as the molecular target of 
artemisinin. This was supported by a study from the early 2000’s, suggesting a specific 
inhibition by artemisinin of heterologously expressed PfATP6 in Xenopus laevis oocyte 
Cyclopiazonic acid (CPA) Thapsigargin 
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membranes [55]. The same study also reported an antagonistic interaction between 
thapsigargin and artemisinin and a similar localization in the parasite [55]. These 
observations were supported by various in silico homology modeling and PfATP6 docking 
studies, claiming the ability of artemisinin to bind to PfATP6 through hydrophobic interactions 
[52,56,57]. However other studies similarly based on docking simulations found opposite 
results [58,59]. The original study was furthermore heavily criticized, particularly concerning 
the methodology, i.e. the lack of reliability of the heterologous expression system. The 
controversy continued in the malaria community until the early 2010’s, when recent studies, 
both in Saccharomyces cerevisiae and Xenopus laevis oocytes, disproved the hypothesis of 
artemisinin or derivatives directly inhibiting PfATP6 [46,60]. 
Similarly, as PfATP6 was proposed as a molecular target, a long expected molecular marker 
to monitor the emergence of artemisinin resistance was assumed to have been found [61]. 
However, no clear association between PfATP6 polymorphisms and artemisinins reduced 
susceptibility could be established, as reports, both in vitro and on field isolates, presented 
contradictory results [62–68]. More will be discussed about the latest findings on artemisinin 
mode of action and resistance (see Sections 1.3.1.4. and 1.3.2.). 
Although PfATP6 is now ruled out as a direct target of artemisinin, or as a component of 
resistance, it remains an attractive potential therapeutic target [45,69]. Not only the fruitless 
attempts to generate pfatp6 knock-out P. falciparum lines, probably marking PfATP6 as an 
essential protein [70], but also the relative homology to the SERCA1a, to which several 
characterized inhibitors have a clinical potential [71,72], support this statement. CPA, with its 
higher affinity to PfATP6 then to SERCA1a [53,54], can for instance be considered a 
reasonable starting point for a medicinal chemistry program, in order to further optimize its 
antiplasmodial properties and increase its specificity toward PfATP6.  
 
 Editing P. falciparum´s genome 1.2.3.
Since the establishment of the in vitro culture system in 1979 [73], tremendous progress has 
been achieved in the pursuit of transforming P. falciparum into a laboratory organism that 
can be genetically studied. Key developments include the establishment of transfection 
techniques in 1995 [74] and the sequencing of the full P. falciparum genome in 2002 [75,76]. 
Nevertheless, until the establishment of the CRISPR/Cas9 approach [77] in P. falciparum in 
2014 [78], genetic engineering methods have been limited, due to a lack of tools and 
inefficient transfection and integration [79]. Gene disruption used to require up to three 
months of continuous culture, with a limited success rate [79]. 
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Nowadays, genome editing in P. falciparum is mainly achieved using either the 
CRISPR/Cas9 (Figure 1.6 A) or the zinc-finger (Figure 1.6 B) technologies. Both approaches 
take advantage of DNA double-strand break repair (DSBR). DNA double-strand breaks 
(DSB) are virtually the most detrimental event a cell can encounter. A single DSB event 
leads to a general genome instability and can lead to cell death [80], particularly dramatic in 
single-cell haploid organisms, such as the blood-stages of P. falciparum. In eukaryotic cells, 
two types of responses can be involved in DSBR: either the homologous recombination 
(HR), considered error-free, or the more error-prone end-joining (EJ) pathway. The high 
fidelity of HR relies on the use of a homology sequence of DNA as a template to repair the 
break, whether it is a sister chromatid or a donor plasmid. The EJ repair pathway, which can 
be further separated into the classical non-homologous end joining (NHEJ) and the 
alternative microhomology-mediated end joining (MMEJ), does not use a homologous 
template but repairs the break by simply ligating broken DNA ends together (NHEJ) or by 
annealing the exposed homology sequences (MMEJ), increasing probabilities of insertions or 
deletions [80]. None of the genes involved in NHEJ have been identified in P. falciparum, 
strongly suggesting a lack of this particular DNA repair mechanism [80]. Although MMEJ 
events have been detected, they remain rare and the repairing system is considered 
inefficient [81,82]. These observations make genome editing based on DSB and HR repair 
an obvious and suitable choice in P. falciparum. 
 
Figure 1.6  : Site specific genome modification strategies in P. falciparum. (A) 
Components of the CRISPR/Cas9 system, as described in [78] and used in this study: the 
Cas9 endonuclease, directed to the desired location by RNA-DNA pairing by the single guide 
RNA (sgRNA). (B) Basis of the ZFNs editing, where the heterodimerization of the specifically 
engineered pair of ZFNs (ZFNL and ZFNR) each fused to half of nuclease domain of the 
FokI restriction enzyme leads to a functional nuclease. Adapted from [79]. 
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DSB can be generated by specifically engineered DNA endonucleases, designed to target 
investigator-defined DNA sequences. The CRISPR/Cas9 genome editing approach is based 
on a prokaryotic viral defense system, where short RNA sequences are used to target and 
degrade foreign nucleic acids [77]. This system can be adapted by fusing a specific genomic 
sequence displaying a unique protospacer-adjacent motif (PAM) with an RNA Cas9-binding 
domain. This single-guide RNA (sgRNA) allows a site-directed DSB by the RNA-guided Cas9 
endonuclease (Figure 1.6 A). Alternatively, the zinc-finger nucleases (ZFNs) can be used to 
introduce specific DSB. ZFNs act as heterodimers, left (ZFNL) and right (ZFNR), where each 
monomer is formed of a specifically engineered DNA-binding domain, also known as the zinc 
finger protein region, fused to the nuclease domain of the FokI endonuclease [83] (Figure 1.6 
B). In both methodologies, the genome is repaired by HR using a provided DNA template 
bearing the desired genetic modification(s) (Figure 1.6).  
Both the ZFNs and the CRISPR/Cas9 technologies allow permanently mutating, replacing, 
disrupting and tagging genes without altering the endogenous genomic locus with the 
introduction of a selection marker as it was previously done. They can then not only be used 
for introducing point mutations, but also to introduce sequences involved in gene down-
regulation systems, or in localization signaling.  
 
1.3. Antimalarial chemotherapies and drug resistance 
 Antimalarial drugs and their mode of action 1.3.1.
Despite constant efforts to develop a potent malaria vaccine and promising preliminary 
results of field testing [84,85], prevention and treatment of malaria still mainly rely on 
chemoprophylaxis and chemotherapy. The complex life cycle of Plasmodium, as previously 
illustrated by P. falciparum, offers multiple sites of action. An ideal drug would act on the 
asexual intraerythrocytic stages to treat the apparent symptoms, as well as on the 
gametocytes stages to limit further transmission, and on the liver stages, particularly on the 
hypnozoites generated by a P. vivax infection, to prevent recrudescence. Such a compound 
is not available yet, and drugs with different modes of action can be combined to act together 
on these distinct critical sites of the life cycle. 
Four main classes of antimalarial drugs are currently in use: quinoline analogs 
(arylaminoalcohols, 4-aminoquinolines and 8-aminoquinolines), artemisinins, antifolates, and 
an inhibitor of the respiratory chain.  
 
Introduction 
13 
 
1.3.1.1. Quinolines 
Quinoline antimalarials are the oldest compounds used for malaria treatment since the 
discovery and isolation of quinine (QN), an arylaminoalcohol obtained from the bark of the 
cinchona tree during the first part of the 19th century. Quinine, and its stereoisomer quinidine, 
were however not only difficult and onerous to naturally obtain but furthermore have later 
been associated with severe side effects [86–88].  
Efforts were placed to produce synthetic quinine and resulted in the development of 
chloroquine (CQ), a 4-aminoquinoline. CQ was the most widely used quinoline for the 
treatment of P. falciparum malaria worldwide, due to its high potency, safety, and low 
production costs. The emergence of CQ-resistant P. falciparum strains in South-East Asia in 
the late 1960’s [89], and the further spread to malaria endemic regions in Africa [90,91] led to 
the removal of CQ as a first-line treatment, to nowadays only be recommended for the 
treatment of uncomplicated non P. falciparum malaria in regions non affected with CQ-
resistance. 
Further quinoline analogs have been synthetized to overcome resistance in P. falciparum, 
such as, to cite only a few, amodiaquine, lumefrantrine, primaquine, tafenoquine or 
mefloquine. For every generation of derivative, chemical properties were optimized to 
improve pharmacological and pharmacokinetic properties, as well as reducing side-effects. 
Primaquine, an 8-aminoquinoline, is currently the only WHO-recommended drug for the 
treatment of relapsing infections induced by P. vivax hypnozoites [92], despite its short half-
life [93] and its association with hemolytic anemia in patient with glucose-6-phosphate-
dehydrogenase (G6PD) deficiency [94]. As the only available drug against young 
Plasmodium gametocyte stages, primaquine is also used for prophylaxis and to reduce 
transmission [92]. Tafenoquine, a primaquine analog with an extended half-life and similar 
efficacy, is currently under evaluation by the Medicine for Malaria Venture (MMV) for the 
treatment of P. falciparum and P. vivax [95,96]. 
Arylaminoalcohols and 4-aminoquinolines are known to exert their primary activity by 
preventing the hemozoin crystallization in the parasite digestive vacuole (DV), a heme 
detoxification process essential to the parasite survival [97,98]. Quinolines are weak bases 
and, when not protonated, are therefore able to diffuse through biological membranes. The 
acidic pH in the digestive vacuole (pH 5 – 5.2) promotes quinoline protonation, leading to a 
rapid accumulation [99]. Once entrapped in the DV, quinolines effectively inhibit hemozoin 
formation by forming a stable complex with the Fe3+ ion present in the heme 
ferriprotoporphyrin. The accumulation of the resulting free heme units in the DV is toxic and 
eventually lethal to the parasite [100]. 
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The mode of action of the 8-aminoquinolines is not yet known, and primaquine has been 
shown to act differently than the other quinolines and does not inhibit hemozoin formation 
[101]. 
 
1.3.1.2. Antifolates 
Antifolate drugs and their analogs interfere with folate synthesis, an essential pathway for 
Plasmodium DNA synthesis [102,103]. They target different enzymes of the folate synthesis 
pathway, particularly the dihydropteroate synthase (DHPS) and the dihydrofolate reductase 
(DHFR). Combining drugs, such as sulfadoxine, a competitive inhibitor of DHPS, and 
pyrimethamine, a competitive inhibitor of DHFR, results in a synergistic interference in the 
synthesis of tetrahydrofolate, a metabolite essential for the production of dTTPs and some 
amino acids such as methionine and glycine [102]. An additional antifolate, proguanil, inhibits 
DHFR through the formation of its active metabolite cycloguanil [104]. 
Although the sulfadoxine-pyrimethamine combination (SP) was adopted to resolve the 
widespread resistance to chloroquine, the resistance to SP paradoxically developed rapidly 
after its introduction in South-East Asia [105,106] and Africa [107,108]. Consequently, 
antifolate drugs are currently only used in combinations, for instance proguanil with 
atovaquone (see Section 1.3.1.3.) under the brand name Malarone® for a prophylactic 
purpose, or with artemisinins (see Section 1.3.1.4.) as the regimen of choice for intermittent 
preventive treatment in infants and pregnant women [92,109,110]. 
 
1.3.1.3. Inhibitor of the respiratory chain 
Atovaquone, an antimalarial drug of the paphthoquinone class, inhibits the respiratory chain 
in the Plasmodium mitochondrion. Atovaquone targets the cytochrome bc1 mitochondrial 
complex (PfCyt b1) and consequently disrupts the electron transport chain [111] without 
affecting the mitochondria of the human host [108]. The resulting collapse of the 
mitochondrial membrane potential leads to the inhibition of the pyrimidine biosynthesis, 
essential for the parasite [112]. The cytochrome bc1 mitochondrial complex is however 
subjected to high-frequency mutations, and resistance developed rapidly after the 
introduction of atovaquone as a monotherapy [108,113]. Atovaquone is therefore exclusively 
used partnered with proguanil, a synergistic combination [114], in an effort to delay 
atovaquone resistance. 
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1.3.1.4. Artemisinins and Artemisinin-based Combination Therapies 
Since the emergence of resistance to almost all used antimalarial drugs (Table 1.2), 
artemisinin and its derivatives have formed the backbone of malaria control since the early 
2000´s [92]. Artemisinin is a natural sesquiterpene trioxane lactone isolated from the leaves 
of the Chinese sweet wormwood plant Artemisia annua. To avoid the isolation step and 
increase artemisinin’s poor solubility, efforts led to the synthesis of the semi-synthetic 
derivative dihydroartemisinin (DHA), which itself served as a template for the synthesis of 
artesunate, artemether and arteether [115]. Artemisinin and its derivatives, or artemisinins, 
display a rapid onset of activity against all stages of intraerythrocytic Plasmodium, including 
early gametocytes [116,117], and hence are appropriate for the treatment of both 
uncomplicated and severe malaria [92].  
The antimalarial activity of artemisinins is associated with their endoperoxide bridge. The 
hemolytic Fe2+ ion is thought to catalyze the reduction of this endoperoxide bound [118], 
generating activated artemisinins free radicals. Once activated, the artemisinins radicals 
rapidly react with exposed nucleophilic groups in proteins, particularly enzyme active sites or 
unsaturated lipids. These alkylations [119–121] result in irreversible damages in the parasite 
[55,122]. The wide and unspecific effect of activated artemisinins is therefore difficult to 
associate with one particular target, and various organelles such as the mitochondrion [123], 
the endoplasmic reticulum [55,62,124] or the digestive vacuole [124–127] have been 
proposed as sites of damage. 
Regarding the development of resistance, artemisinins are advantaged by their extremely 
short half-lives of 1 to 3 hours [117]. Nonetheless, early artemisinins monotherapies in 
Cambodia already led to the emergence of P. falciparum strains with delayed or possibly 
reduced responsiveness to artemisinins [128]. This early resistance phenomenon is now 
threatening to spread across all of South-East Asia [129].  
To reduce the risk of developing resistance, artemisinin derivatives are partnered with other 
long-acting drugs that target different metabolic pathways, in the so-called artemisinin based 
combination therapies (ACT). The artemisinin derivative rapidly reduces the parasite burden 
and is protected against the emergence of resistance. Indeed, the surviving parasites 
potentially bearing mutations conferring resistance to artemisinins are further eliminated by 
the long-lasting partner drug [130]. The latest is however not protected against resistance 
development during the phase where the artemisinin derivative is already cleared and the 
concentration of the partner drug is slowly decreasing [131].  
Several ACT regimens have been recommended by the WHO as a first-line treatment for P. 
falciparum malaria, such as Coartem® (artemether-lumefantrine), Coarsucam® (artesunate-
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amodiaquine), Pyramax® (pyronaridine-artesunate), Ariplus® (artesunate-sulfadoxine-
pyrimethamine), Artekin® (dihydroartemisinin-piperaquine) or Mefliam Plus® (artesunate-
mefloquine) [92]. 
 
 Drug resistance mechanisms 1.3.2.
Resistance to antimalarial drugs is defined by the WHO as “the ability of a parasite strain to 
survive and/or multiply despite the administration and absorption of a drug given in doses 
equal to, or higher than those usually recommended, but within the limits of tolerance of the 
subject” [132]. This clinical definition proves itself to be sometimes difficult to measure in the 
field, as well as to translate in laboratory-adjusted in vitro assays [133]. Antimalarial 
resistance is therefore not strictly defined, and many aspects can change the perception of 
resistance. 
The development of drug resistance can be divided into two separate events: emergence by 
de novo mutations, and spread via drug selection pressure. P. falciparum parasites have 
developed resistance, to various extents, to all antimalarial drugs used so far (Table 1.2 and 
[133]). Historically, resistance almost always emerged from South-East Asia, in particular 
from Cambodia [134,135].   
Table 1.2: Dates of introduction and first reports of resistance to antimalarial drugs. 
Adapted from [108]. 
 
Drug resistance is likely to arise in instances of widespread exposure of the parasites to 
antimalarial drugs, as it was the case when the overuse of CQ created an optimal 
environment for the emergence and persistence of CQ-resistant parasites in the 1950´s. The 
use of subtherapeutic and/or uncontrolled antimalarial doses led to the residual presence of 
the drug in the subject´s circulation, creating favorable circumstances for the selection of fully 
Antimalarial drug Introduced First reported resistance Difference (years) 
Quinine 1632 1910 278 
Chloroquine 1945 1957 12 
Proguanil 1948 1949 1 
Sulfadoxine-Pyrimethamine 1967 1967 0 
Mefloquine 1977 1982 5 
Atovaquone 1996 1996 0 
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or partially resistant parasites [133]. Such lessons must imperatively be considered in the 
present on-going fight against drug resistance. 
The majority of used antimalarial drugs target specific metabolic pathways in the 
intraerythrocytic cycle of the parasite. Their efficacy is however compromised by the 
development of resistant Plasmodium strains, through de novo mutations. These mutations 
can interfere with the drug´s mode of action in diverse ways, usually by (i) reducing the 
access of the active compounds to their site of action, through altered transport of the drug, 
enzymatic inactivation or decreased conversion of the drug into its active compound, (ii) 
altering their molecular target and decreasing its affinity for the drug, or (iii) increasing the 
amount of a metabolite antagonizing the drug´s action [136].  
The characterized mechanisms of resistance in P. falciparum follow these general principles. 
For instance, resistance to pyrimethamine and sulfadoxine is mediated through mutations in 
their respective enzymatic target causing a decrease in affinity. Single nucleotide 
polymorphisms (SNP) in the pfdhfr gene leading to the S108N, N51I, C59R and I164L 
mutations have been identified in field isolated parasites with decreased pyrimethamine 
susceptibility [137–139], and were further confirmed to structurally modify PfDHFR and 
impair pyrimethamine binding [140]. Similarly, resistance to sulfadoxine was found to be 
correlated with polymorphisms in the pfdhps gene, leading to the mutations S436A/F, 
A437G, K540E, A581G, A613S/T [141–143]. In vivo combination of mutations in pfdhfr and 
pfdhps were associated with the sulfadoxine-pyrimethamine treatment failure, particularly in 
Africa [108]. 
Resistance to CQ is mediated through altered drug transport and reduction of the drug at its 
action site. CQ resistance has mainly been associated with mutations of the chloroquine 
resistance transporter (PfCRT), located in the membrane of the parasite´s DV. The 
polymorphisms leading to the K76T mutation in PfCRT has been shown to be the main 
determinant factor for CQ resistance [144–146], although other mutations are thought to 
balance the level of susceptibility. The positive charge on the original lysine residue at 
position 76 is assumed to prevent the binding of CQ to the active site of the transporter. The 
substitution into a neutral threonine residue therefore allows CQ to bind to PfCRT and be 
transported out of the DV, reducing the amount of CQ available to interfere with hemozoin 
crystallization [147,148]. 
The identification of artemisinins resistance markers has been a controversial topic over the 
last decades [119,120]. As mentioned above, PfATP6 has been extensively discussed as a 
component of artemisinins resistance. However, the correlation between artemisinins 
decreased susceptibility and polymorphisms in PfATP6 is being disputed, as some studies 
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confirmed this association [50,62–64], when others failed to [65,66,68,149]. Recently, 
multiple mutations in the propeller domain of the Kelch 13 protein (PfK13), beginning at 
amino acid residue 442, were associated with reduced susceptibility to artemisinins and 
extended clearance times [150–159]. These mutations show strong differences in their 
geographical distribution, consistent with multiple de novo mutational events. For instance, 
the C580Y mutation is prevalent at 50% in the Cambodia-Vietman-Laos region, whereas the 
F446I mutation is found to be dominant in samples from Thailand-Myanmar-China, with 20% 
of prevalence, and C580Y is only minimally found [116]. PfK13 mutations are now spread 
across South-East-Asia, and have reached India and some Central-Africa countries 
(Ethiopia, Mali, Senegal and Comoros) (Figure 1.7). It has been speculated that artemisinins 
inhibit the phosphorylation of phosphatidylinositol by the phosphatidylinositol 3-kinase 
(PfPI3K) in P. falciparum, overall decreasing the phosphatidylinositol 3-phosphate (PI3P) 
production and impairing lipid synthesis [160]. PfK13 is thought to polyubiquitinate PfPI3K, 
marking it for proteolytic degradation. When mutated, PfK13 fails to efficiently target PfPI3K 
to the proteasome, leading to its accumulation and to artemisinins resistance [161]. 
 
Figure 1.7: Current distribution of the mutations in PfKelch13. Prevalence in percent (%) 
of all the non-synonymous mutations within the propeller region of the PfK13 proteins alone 
or in combination, in Central Africa (left) and South-East Asia (right). Data obtain from the 
WorldWide Antimalarial Resistance Network (WWARN) online platform 
(http://www.wwarn.org/). 
 
The multi-drug resistance receptor 1 (PfMDR1) has been found to be associated with 
resistance to various antimalarial drugs. PfMDR1 is an ATP-binding cassette transporter 
localized to the membrane of the parasite´s DV, and can modulate the response to a wide 
range of structurally diverse drugs, including artemisinins and their partner drugs. PfMDR1 is 
suggested to import antimalarial drugs into the DV [162], reducing the amount of drug at its 
action site, and SNPs in pfmdr1 can modulate its affinity for a specific substrate [163]. 
Multiple SNPs and copy number variation in pfmdr1 have been associated to both in vivo and 
in vitro decreased susceptibility to drugs as various as QN, CQ, mefloquine, halofantrine, 
lumefantrine, artemisnin, artesunate, dihydroartemisinin, as well as to some ACT´s [164].  
≥ 5% any single mutation 
≥ 10% any combined mutations 
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 Future perspectives for antimalarial drugs 1.3.3.
It remains difficult to predict whether artemisinins resistance will spread as critically as 
resistance to CQ did decades ago. Nonetheless, this underlying threat, coupled with the 
creation of public-private partnerships such as the MMV and with financial support from 
philanthropic organizations such as the Wellcome Trust or the Bill & Melinda Gates 
Foundation, revived the field of antimalarial discovery. 
Various strategies can be followed towards development of novel antimalarial agents (Figure 
1.8), and either alone or combined, all the strategies endorsed promising drug candidates 
over the last decades. 
 
Figure 1.8: Various approaches for the development of new antimalarial agents. 
Adapted from [165]. 
The chemical optimization of existing and established antimalarial drugs, whether to improve 
pharmacological properties or to overcome resistance, has proven to be an effective 
approach, as illustrated by the development of the 4- and 8- aminoquinolines derived from 
quinine (see Section 1.3.1.1.). This development axis is still intensively exploited, and 
ferroquine, a ferrocene-containing analog of CQ, is currently under clinical evaluation as an 
antimalarial candidate [166,167]. Ferroquine has been shown to be active against CQ, 
amodiaquine and mefloquine resistant strains, due to its enhanced lipophilicity and hence 
increased ability to accumulate into the DV [168]. Similarly, the ozonide compounds have 
been derived from artemisinin, and display a trioxolane heterocycle in place of the trioxane 
present in artemisinins. Ozonides showed an improved efficacy against strains with reduced 
artemisinins susceptibility [169], and some are already marketed, such as OZ277, used in 
combination with piperaquine in India, under the brand name Synriam®. The representative 
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of the next generation of ozonides, OZ439 (Artefenomel), shows an increased bioavailability 
due to a higher susceptibility to heme degradation, and therefore a longer half-life [170]. 
OZ439 is currently evaluated in Phase II human clinical trials both as monotherapy or in 
combination with ferroquine [115, 116, MMV Artefenomel information sheet]. 
Exploiting compounds already proven to be active against other diseases is another widely 
used approach. Approved-drug repurposing is highly advantageous, as it allows cutting down 
the research timeline and costs of drug development. This strategy was for instance 
previously employed when tetracycline and macrolide antibiotics were adopted for 
prophylaxis and treatment of malaria [173,174]. More recently, the imidazolopiperazines, a 
family of folate inhibitors originally developed as antifungal and antihelminthic agents, are 
repurposed as antimalarials, to answer the growing resistance to the DHPS and DHFR 
inhibitors. Such a compound, KAF156, showing high potency against blood, gametocyte and 
liver stages of P. falciparum [175,176], is currently in phase I trial in malaria patients in Africa 
[MMV KAF156 information sheet]. 
Combining two pharmacophores with known antiplasmodial activity is a way to overcome 
resistance, by covalently linking two chemical moieties that act via different modes of action. 
This strategy can be illustrated by the development of SAR116242 (trioxaquine), a synthetic 
hybride between artemisinin and CQ pharmacophores, highly potent against sexual and 
asexual blood stages of both CQ-sensitive and resistant P. falciparum [177,178].  
SAR116242 is currently under preclinical assessment at Sanofi-Aventis.  
Finally, natural products have been a pillar for drug development over human history, and 
are constantly used as a source of molecular templates for developing new therapeutic 
agents. The recent progresses in developing highly efficient high-throughput screening 
technologies over the last decades made the exploitation of natural product libraries 
particularly effective. If natural products are rarely pharmacologically and pharmacokinetically 
adapted to be used as drug themselves, they however provide valuable hints and starting 
points for the development of new drugs. The emergence of a new antimalarial class, the 
spiroindolones is the results of such a screen of a natural compound library by Novartis 
[179]. One of the spiroindolone derivatives, KAE609 (cipargamin, formerly known as 
NITD609), highly potent against both P. falciparum and P. vivax in clinical isolates [179,180], 
is currently in Phase II of human clinical trials [165]. KAE609 was shown to interfere with the 
Na+ transporter PfATP4, fatally disrupting sodium homeostasis in the parasite [179]. PfATP4 
emerges as potential molecular target for rational drug design, further confirmed by the 
development of the clinical candidate (+)-SJ733 or the pyrazoleamide PA21A092, also 
inhibiting PfATP4 [181,182]. (+)-SJ733 is waiting for the recruitment of volunteers to enter the 
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first-in-human study [MMV (+)-SJ733 information sheet]. Identifying new molecular targets, 
such as PfATP4, and designing new chemical entities to interact with them is within the 
frame of the most scientifically sound approaches. The tremendous progress in deciphering 
the Plasmodium genomes and proteomes provided a solid basis to support such a rational 
design strategy. 
 
1.4. Development of the drug candidate SC83288 for the 
treatment of severe malaria  
 
The urgent need for novel antimalarial compounds, exploiting distinct molecular modes of 
action to the currently available antimalarial drugs was previously emphasized. In the field of 
drug development, diverse strategies can be followed, usually involving high-throughput 
screening at various steps of the entire development process. A drug candidate can be 
developed according to a rational design strategy, ligand- or structure-based, or following a 
wider phenotypic approach, i.e. “whole-cell”-based. The former relies on the identification of 
a therapeutic molecular target, and a precise structural knowledge of its active site to design 
potent inhibitors, whereas the latter aims on identifying compounds with a toxic effect on 
Plasmodium species (or any targeted organism), with lesser consideration for their mode of 
action. Several rounds of iterative structure-activity relationship analysis usually allow a 
selected compound, or hit-compound, to be further optimized into a pharmacologically and 
pharmacokinetically improved lead-compound [183]. Both approaches have already yielded 
promising results by identifying new classes of antimalarial compounds such as the 
spiroindolones [180], by phenotypic blood stage screen, or the ozonides by rational design 
[184,185].  
As many prominent companies and institutions are dedicating tremendous resources into 
antimalarial libraries high-throughput screening, such as the Genomic Institute of the 
Novartis Institute for Biomedical Research (NIBR), GlaxoSmithKline (GSK) or the St. Jude 
Children´s Research Hospital (SJCRH) [183], other research and screens are conducted at a 
smaller scale. Accordingly, the original strategy of the biotechnological company 4SC AG, 
Munich, Germany, was to identify new inhibitors of the P. falciparum lactate dehydrogenase 
(PfLDH) by in silico screening [186]. A first in silico screen through docking of a virtual library 
of small organic molecules into the binding pocket of PfLDH allowed the identification of a 
series of molecules with high scoring, further tested in a whole cell-based assay. The 
benzamidine derivative amicarbalide (Figure 1.9) was identified as a potent P. falciparum 
growth inhibitor. Amicarbalide was formerly used as a veterinary antiprotozoal drug 
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[187,188], before underlining safety issues forced regulatory agencies to remove it from the 
market. Despite its promising antiplasmodial activity, amicarbalide displayed only a marginal 
activity as a PfLDH inhibitor [186]. Nonetheless, amicarbalide became the starting point of 
medicinal chemistry program for the development of potent and pharmacologically optimized 
antimalarial drugs.  
        
Figure 1.9: Chemical structures of the hit- and lead-compounds. Adapted from [189]. 
 
Out of this process a lead-compound, SC09064 (Figure 1.9) emerged, where the east-side 
amidino group was substituted by a bulky 4´-sulfonamidomethyl benzene para-sulfonamido 
group [186,189]. The further optimization of the west side of the molecule led to the two lead-
compounds, SC81458 and SC83288 (Figure 1.9), after the functionalization of the amidine 
group with a piperazine ring, providing improved pharmacological properties [189]. SC83288, 
the second lead-compound, is considered a clinical development candidate for the treatment 
of severe malaria [189].  
Preliminary studies linked PfATP6 with a decrease in responsiveness to the SC-lead 
compounds [189], building one of the founding pillars of the work presented here.  
 
Amicarbalide 
SC09064 
SC81458 SC83288 
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1.5. Aim of the study 
 
Understanding the mode of action of a therapeutic molecule and identifying the components 
involved in resistance is not mandatory for a compound to be released on the market. 
However, gathering precise molecular insights on these aspects might be crucial as they 
may help to predict and control the molecule´s interactions with both its environment and with 
other drugs, once introduced in the field.  
This doctoral study contributes to the evaluation and further development of the SC-lead 
compounds, particularly the clinical development candidate SC83288, as antimalarial 
compounds. The aim of this work is two-fold. On the one hand it focuses on the 
characterization of the antiplasmodial activity of the SC-lead compounds. It provides a 
detailed characterization of the in vitro activity profile against cultured blood-stages P. 
falciparum parasites, as well as preliminary insight into their mode of action. On the other 
hand, this work confirms and details the role of the Ca2+ ATPase pump PfATP6 in the 
resistance of P. falciparum to SC83288, particularly in regard with calcium homeostasis.  
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2. Materials and methods 
2.1. Materials 
 Equipment  2.1.1.
Equipment  Company 
Analytical scales   Sartorius, Göttingen, Germany 
ApE  http://biologylabs.utah.edu/jorgensen/wayned/ape/ 
Autoclave   Tuttnauer Systec 2540, Wettenberg, Germany 
BD FACS Canto  BD Bioscences, Heidelberg, Germany 
Bioedit   http://www.mbio.ncsu.edu/BioEdit/bioedi 
Biofuge fresco  Heraeus Instruments, Hanau, Germany 
Biofuge pico   Heraeus Instruments, Hanau, Germany 
BioRad gel Dryer 583  BioRad, München, Germany 
Blot Scanner C-DiGit  Li-cor, Bad Homburg, Germany 
Camera S6X11  Rainbow CCTV, Ivrine, CA, USA 
ClustalW2  http://www.ebi.ac.uk/Tools/msa/clustalw2/ 
Confocal Leica TCS SP5   Leica Microsystems CMS GmbH, Jena, Germany 
Electroporator Gene Pulser® II   Biorad, München, Germany 
FIJI image analysis   http://fiji.sc/Fiji 
FlowingSoftware2.5.1  Cell Imaging Core, Turku Centre for 
Biotechnology, Finland 
Freezer -20°C LGex3410 
MedLine 
 Liebherr, Biberach, Germany 
Freezer -80°C HERAfreeze  Thermo Fisher Scientific, Dreieich, Germany 
Fridge LKexv 3910 MedLine  Liebherr, Biberach, Germany 
Fujifilm Bas cassette 2040  Fujifilm, Düsseldorf, Germany 
Fujifilm FLA-7000  Fujifilm, Düsseldorf, Germany 
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Gas burner gasprofi 1 micro   WLD-TEC 
Heat block, NoeBlock Mono I   NeoLab, Heidelberg, Germany 
Hybridizazion incubator Techne 
HB-1D 
 Bibby Scientific, Staffordshire, UK 
Icemachine   Ziegra, Isernhagen, Germany 
Incubator Heraeus B12/UB12  Thermo Fisher Scientific, Dreieich, Germany 
J2-MC   Beckman, Krefeld, Germany 
Kodak Digital Science 1D   Kodak, New York, USA 
L-60 Ultracentrifuge  Beckman, Krefeld, Germany 
Light optical microscope 
Axiolab.A1 
 Zeiss, Jena, Germany 
LightCycler® 2.0 Instrument  Roche, Mannheim, Germany 
Liquid nitrogen tank   Air Liquide, Ludwigshafen, Germany 
Magnetic sorter VarioMACS  Miltenyi Biotec, Bergisch Gladbach, Germany 
Magnetic stirrer   Heidolph, Schwabach, Germany 
Magnetic stirrers  IKA, Staufen, Germany 
Megafuge 1.0 R   Heraeus Instruments, Hanau, Germany 
Megafuge 2.0 R   Heraeus Instruments, Hanau, Germany 
Microwave oven   AEG, Nürnberg, Germany 
MiliQ water system Purist 
ultrapure 
 Rephile, Germany 
MS Excel 2010   Microsoft Corporation, CA USA 
MS Powerpoint   Microsoft Corporation, CA USA 
MS Word 2010   Microsoft Corporation, CA USA 
MVE Cryosystem 6000 
LS 6000 
 Thermo Fisher Scientific, Dreieich, Germany 
Taylor-Wharton, Husum, Germany 
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Particle counter Z1  Beckman Coulter, Krefled, Germany 
pDRAW32 software   AcaClone software 
pH-meter pH 7110   WTW, Weilheim, Germany 
Pipetman Gilson P10; P20; P200; 
P1000  
 Abimed, Langenfeld, Germany 
Pipetus Forty/Standard   Hirschmann Labortechnik, Eberstadt, Germany 
PlasmoDB  http://plasmodb.org/plasmo/ 
Plate reader FLUOstar OPTIMA  BMG Labtech, Ortenberg, Germany 
Power Pac 300, Power Pac 200  
EPS 1001, EPS 3501 
 Biorad, München, Germany 
Amersham (GE Healthcare), München, Germany 
Printer hp LaserJet 1300   Hewlett Packard, Heidelberg, Germany 
Protein Data Bank   http://www.rcsb.org/pdb/home/home.do 
PyroMark Q96 ID  QUIAGEN, Hilden, Germany 
RC5BPlus  Sorvall, Langenselbold, Germany 
Rotors JA20.2, JA20.1  Beckman instruments, Palo Alto, CA, USA 
Rotors SS-34; GS-3 , SM24  DuPont Instruments, Bad Homburg, Germany 
RS Series  Taylor-Wharton, Husum, Germany 
Semi-dry transfer cell Trans blot 
SD 
 BioRad, München, Germany  
Serial Cloner 2.6   http://serialbasics.free.fr/Serial_Cloner.html 
Shaker KS 501 digital  IKA, Staufen, Germany 
SigmaPlot 12.0  Systat Software Inc. 
Sonicator Sonoplus HD 2070  Bandelin, Berlin, Germany 
Spectrophotometer UVIKON 923   Kontron Instruments, München, Germany 
Sterile work bench Herasafe   Heraeus Instruments, Hanau, Germany 
Stop watch   Roth, Karlsruhe, Germany 
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Thermocycler Labcycler  SAensoquest, Göttingen, Germany 
UV table TFX-35M   Vilber Lourmat, Eberhardzell, Germany 
Vacuum workstation PyroMarkt 
Q96 
 QUIAGEN, Hilden, Germany 
Vortex Genie 2   Roth, Karlsruhe, Germany 
Water bath Julabo 7A   Julabo, Seelbach, Germany 
Zeiss Image Examiner   Zeiss, Jena 
 
 Disposables 2.1.2.
Diposable Company 
96-well plates, black, clear  Greiner Bio-One, Frickenhausen, Germany 
Aluminium foil  Roth, Karlsruhe, Germany 
Cell culture plates Greiner Bio-One, Kremsmünster, Germany 
Cellstar tubes Greiner bio one, Frickenhausen, Germany 
Coverslides  Roth, Karlsruhe, Germany 
Cryovials  Nalgene®, Wiesbaden, Germany 
Cuvettes  Sarstedt, Nümbrecht, Germany 
Electroporation cuvettes Gene Pulser Biorad, München, Germany 
Eppendorf tubes  Sarstedt, Nümbrecht, Germany 
Filter systems 500 ml Corning, Kaiserslautern, Germany 
Filters Millex GS (0.2 µm) Merck Millipore, Darmstadt, Germany 
Gloves TouchNTuff Ansell, München, Germany 
Immersion oil  Zeiss, Jena, Germany 
LightCycler capillaries  Roche, Mannheim, Germany 
MACS CS column Miltenyi Biotec, Bergisch Gladbach, 
Germany 
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Object slides  Marienfeld, Lauda-Königshofen, Germany 
Parafilm Bemis, Londonerry, UK 
PCR softtubes 0.25 ml  Biozym Scientific GmbH 
Petri dishes (10 ml diameter)  Greiner Bio-one, Frickenhausen, Germany 
Petri-dishes (25 ml diameter)  Greiner Bio-one, Frickenhausen, Germany 
Pipette tips  Corning incorporation, Bodenheim, Germany 
Plastic pipettes (1 ml; 2 ml; 5 ml; 10 ml: 25 
ml) 
Corning incorporation, Bodenheim, Germany 
PVDF membrane  Biorad, München, Germany 
PyroMark Q96 Plate low QUIAGEN, Hilden, Germany 
Sterile filtration devices  Corning incorporation, Bodenheim, Germany 
Thermo well PCR  Corning incorporation, Bodenheim, Germany 
Transfer pipettes Sarstedt, Nümbrecht, Germany 
 
 Chemicals 2.1.3.
The chemicals used in this study were obtained from the firms Roth, Merck, Sigma, Serva, 
Thermo and Applichem and were ordered directly or through the Heidelberg Medical Facility, 
unless mentioned otherwise. 
The SC-compounds, namely SC81458 and SC83288 were provided by the 4SC AG, 
München, Germany. 
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 Biological material 2.1.4.
Enzymes and protein markers 
Compound Company 
6 x DNA loading buffer Thermo Fisher Scientific, Dreieich, Germany 
EuroTaq polymerase BioCat GmbH, Heidelberg, Germany 
GeneRuler 1 kb ladder plus Thermo Fisher Scientific, Dreieich, Germany 
PageRuler Thermo Fisher Scientific, Dreieich, Germany 
Phusion Polymerase Fermentas, Germany 
Restriction enzymes New England Biolabs, Frankfurt am Main, 
Germany 
Shrimp Alkaline phosphatase New England Biolabs, Frankfurt am Main, 
Germany 
T4 ligase Thermo Fisher Scientific, Dreieich, Germany 
 
Kits  
Kit Company 
BM chemiluminescence blotting substrate 
POD 
Roche, Mannheim, Germany 
CloneJET PCR Cloning Kit Thermo Fisher Scientific, Dreieich, Germany 
DNeasy Blood&Tissue kit Qiagen, Hilden, Germany 
Gel Extraction/PCR purification kit Qiagen, Hilden, Germany 
High Pure Plasmid Isolation kit Roche, Mannheim, Germany 
In-Fusion® HD Cloning kit Clontech Laboratories, USA 
LightCycler FastStart DNA Master SYBR 
Green I  
Roche, Mannheim, Germany 
Plasmid MaxiPrep kit Qiagen, Hilden, Germany 
PyroMark Gold Q96 Reagents kit Qiagen, Hilden, Germany 
SuperScript® III First-Strand Synthesis Thermo Fisher Scientific, Dreieich, Germany 
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Supermix 
Calcium Calibration Buffer Kit #1 Thermo Fisher Scientific, Dreieich, Germany 
 
Fluorescent dyes 
Fluorescent dye Company 
Fluo4-AM Thermo Fisher Scientific, Dreieich, Germany 
FuraRed-AM  Thermo Fisher Scientific, Dreieich, Germany 
Hoechst 33342 Thermo Fisher Scientific, Dreieich, Germany 
CFDA SE Cell Tracer Thermo Fisher Scientific, Dreieich, Germany 
MitoTracker Orange CM-H2TMRos Thermo Fisher Scientific, Dreieich, Germany 
DRAQ5 Biostatus, Leicestershire, United Kingdom 
 
Antibodies 
Antibody Source Company 
Anti-HA tag monoclonal Mouse Roche, Mannheim, Germany 
Anti-mouse-POD monoclonal  Donkey Jackson ImmunoResearch, Suffolk, UK 
Anti-α-tubulin monoclonal Mouse Sigma Aldrich, München, Germany 
 
Parasites strains 
Strain Origine 
P. falciparum 3D7 The Netherlands  
P. falciparum 3D7 PfATP6 F972Y Generated by Maëlle Duffey during this 
study, Heidelberg, Germany 
P. falciparum Dd2 Indochina [190] 
P. falciparum Dd2 pHBIRH-ATP6(A108T, 
A109T)-HA 
Generated by Maëlle Duffey during this 
study, Heidelberg, Germany 
P. falciparum Dd2 pHBIRH-ATP6(WT)-HA Generated by Maëlle Duffey during this 
study, Heidelberg, Germany 
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P. falciparum HB3 Honduras [191] 
P. falciparum NF54  The Netherlands [192] 
P. falciparum NF54 PfK13 C580Y Provided by Prof. Lopez-Rubio, Montpellier, 
France [78] 
 
E. coli strains 
Strain Origine 
E. coli PMC 103 Provided by Prof. Cowman [193] 
E. coli XL-1-Blue Thermo Fisher Scientific, Dreieich, Germany 
E. coli XL10 Gold Agilent Technologies, Böblingen, Germany 
 
Plasmids 
All the plasmids used in this study are described in Appendix II. 
Plasmid  Origin 
pARL-0105800-HA Generated by Maëlle Duffey during this study, 
Heidelberg, Germany 
pARL-0105900-HA Generated by Maëlle Duffey during this study, 
Heidelberg, Germany 
pARL-0106000-HA Generated by Maëlle Duffey during this study, 
Heidelberg, Germany 
pARL-0106100-HA Generated by Maëlle Duffey during this study, 
Heidelberg, Germany 
pARL-0106200-HA Generated by Maëlle Duffey during this study, 
Heidelberg, Germany 
pHBIRH-ATP6-(A108T, A109T)-HA Generated by Maëlle Duffey during this study, 
Heidelberg, Germany 
pHBIRH-ATP6-(WT)-HA Generated by Maëlle Duffey during this study, 
Heidelberg, Germany 
pL6-HRA-guide6 Generated by Maëlle Duffey during this study, 
Heidelberg, Germany 
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pL6-HRAsi-guide6 Generated by Maëlle Duffey during this study, 
Heidelberg, Germany 
pL6-HRB-guide7 Generated by Maëlle Duffey during this study, 
Heidelberg, Germany 
pUF1-Cas9 Provided by Prof. Lopez-Rubio, Montpellier, France 
[78] 
 
Oligonucleotides 
The oligonucleotides used in this study were purchased from Thermo Fisher Scientific or 
Eurofins. 
 
- Oligonucleotide primers used for colony PCR and sequencing 
Number Name Sequence 
1 pJET-for CGACTCACTATAGGGAGAGCGGC 
2 pJET-rev AAGAACATCGATTTTCCATGGCAG 
3 pL6-guide-for GTAACCAAAATGCATAATTTTTCC 
4 pL6-guide-rev TAGGAAATAATAAAAAAGCACC 
5 pL6-HA-ribo-for-5´ ATTTAACTATATACTATGGAATAC 
6 pL6-HA-ribo-rev-3´ ACCAATAGATAAAATTTGTAGAG 
7 pARL-for CTATAATATCCGTTAATAATAAATACACGCAGTC 
8 pARL-rev CACAACATACACATTTTTACAG 
9 pHBIRH-for ACAAACCTACATATACATAC 
10 pHBIRH-rev TTTGTAATTTATGGGATAGC 
 
- Oligonucleotide primers used for qPCR 
Number Name Sequence 
11 Pf3D7_0105800-for  CGGAAGATTTTGAGAACAAC 
12 Pf3D7_0105800-rev  AATTTAATTCCCCTTTGCTC 
13 Pf3D7_0105900-for  CATATGAACAATTGGAGGCTC 
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14 Pf3D7_0105900-rev  CAATAATAAATTCCGTGTCGAATC 
15 Pf3D7_010600-rev  CGATATCCTTTTTCTCATTAGGTAC 
16 Pf3D7_010600-for  GAGCAGGTACCAAAGGTATTG 
17 Pf3D7_0106100-for  GTGCTTAGCCGCTTTTTCAG 
18 Pf3D7_0106100-rev  GAAGCAAAATTAGGTGGAACAC 
19 Pf3D7_0106200-for  TGACAACCCAAATGAAGCTATC 
20 Pf3D7_0106200-rev  CCTGAGCATCTAAAAAGTACTTC 
21 cDNA-ATP6 2-rev  GTCAAAGAATCAGATTCTCTAAAC 
22 cDNA-ATP6 3-for  GATGGATTACCAGCAACTGC 
23 cDNA- aTub-for  CAGTTGGAGGTGGAACAGG 
24 cDNA- aTub-rev  ATGGCCAACAGCAAAAATTC 
 
 
- Oligonucleotides primers for cloning in the pARL and pHBIRH vectors 
In blue, enzyme restriction sites.  
 
Number Name Sequence 
25 800-XhoI-for  CCGCTCGAGATGGCTACAAATAGTAATAATAACAACAG 
26 800-AvrII-rev  ATCGCCTAGGATTATTTTTAGGTCGTCTAAAAAATAGGAC 
27 900-XhoI-for  CCGCTCGAGATGCTGAAAGGATTTAAGCATATTTTAAAC 
28 900-AvrII-rev  ATCGCCTAGGTGTGCAGAGCGTGTGATC 
29 000-XhoI-for  CCGCTCGAGATGCGATCCAAATATTACAAGGAAG 
30 000-AvrII-rev  ATCGCCTAGGGGAGGAGAAGGCAAAGTGG 
31 100-XhoI-for  CCGCTCGAGATGAGTGAAATTCCCATGTG 
32 100-AvrII-rev  ATCGCCTAGGTATTTTAAAGGACACCGAAACGTAG 
33 200-XhoI-for  CCGCTCGAGATGGAAAATATAAATAGAGTAAATAAATATG
ACAAC 
Materials and methods 
35 
 
34 200-AvrII-rev  ATCGCCTAGGTATATATTTATAACATGTTAACATGTCAACG
TAC 
35 ScATPase6-
SpeI-for 
CCGACTAGTCACCATGGAAG 
36 ScATPase6-
SacI-rev 
ATCGGAGCTCTTAAACACCATGA 
37 ScATPase6-
mut1/2-for 
CTTAATTTTGAACACTACTGTTGGTG 
38 ScATPase6-
mut1/2-rev 
CACCAACAGTAGTGTTCAA AATTAA G 
 
- Oligonucleotides primers used for cloning of the CRISPR/Cas9 system 
In blue, enzyme restriction sites; in orange, homology regions for the InFusion cloning; in red, 
desired mutations; in green, shield mutations. 
 
Number Name Sequence 
39 ATPase6-HRA(-79)-SpeI-for GGACTAGTTTTCGTTGAACTTATTATATC 
40 ATPase6-HRA-855-BssHII-rev TTGGCGCGCGAATTGGATCTGAGAAATGT 
41 ATPase6-HRB-2269-SpeI-for GGACTAGTGCATTAAGAACACTTAGCTTTG 
42 ATPase6-HRB-3409-BssHII-rev TTGGCGCGCGTTATTCCATGCTTTACATTGGT 
43 ATPase6-620-1080-for (2) TTAAATACTACCGTAGGCGTGTGGCAAG 
44 ATPase6- 620-1080-rev (2) CTTGCCACACGCCTACGGTAGTATTTAA 
45 ATPase6-shield(guide7)-for GAAAGCATATATCCGATATTTAATTAG 
46 ATPase6-shield(guide7)-rev CTAATTAAATATCGGATATATGCTTTC 
47 ATP6 HRA sil-for TAATATTAAATGCCGCTGTAGGTG 
48 ATP6 HRA sil-rev CACCTACAGCGGCATTTAATATTA 
49 ATPase6-guide 6-for 
TAAGTATATAATATTTTAATATTAAATGCTGCC
GTGTTTTAGAGCTAGAA 
50 ATPase6-guide 6-rev TTCTAGCTCTAAAACACGGCAGCATTTAATAT
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TAAAATATTATATACTTA 
51 ATPase6-guide 7-for 
TAAGTATATAATATTTATTACTACTAATTAGATA
AGTTTTAGAGCTAGAA 
52 ATPase6-guide 7-rev 
TTCTAGCTCTAAAACTTATCTAATTAGTAGTAA
TAAATATTATATACTTA 
 
- Oligonucleotide primers used for the fitness assay and pyrosequencing 
Number Name Sequence 
53 PfATP6- for (Fit/PCR) CTATGGGTATTAATGGAACGGAGG 
54 PfATP6- rev2 (Fit/Biotin) CGTCAGTAACCAAATTTACCCAC 
55 PfATP6- for (Fit) GATGTATATATAATAATATGAAAGC 
 
 
 
 
 Buffers, media and solutions 2.1.5.
Buffer/Media/Solution Composition 
Albumax II 5% (w/v) Albumax II 
In RPMI 25 mM HEPES L-Glutamine 
(Gibco), filter sterilize 
Ampicillin stock, 1000 x  100 mg/ml in ddH2O 
Annealing buffer (pyrosequencing)  
 
20 mM Tris  
2 mM magnesium acetate  
Set pH to 7.6 with HCl and autoclave 
Binding buffer (pyrosequencing)  
 
10 mM Tris 
2 M NaCl 
1 mM EDTA 
Set pH to 7.6 with HCl and autoclave 
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Add 0.1% Tween 20 
Blocking solution  5% (w/v) skimmed milk in PBS 
Cell culture media 
     Non-transfectants 
      
 
 
     Transfectants 
 
10% human serum  
0.2 µg/ml Gentamycin 
0.2 mM Hypoxanthine 
In RPMI 25 mM HEPES L-Glutamine (Gibco) 
5% human 
5% Albumax II 
0.2 µg/ml Gentamycin 
0.2 mM Hypoxanthine 
In RPMI 25 mM HEPES L-Glutamine (Gibco) 
Coomassie destaining solution  
 
20% methanol 
7% acetic acid 
Coomassie staining solution  
 
50% methanol 
10% acetic acid 
0.5% Coomassie Blue R-250 
Cytomix 120 mM KCl 
0.15 mM CaCl2 
10 mM K2HPO4/KH2PO4, pH 7.6 
25 mM HEPES/2 mM EGTA, pH 7.6 
5 mM MgCl2 in ddH2O 
Adjust to pH 7.6 with KOH 
Filter sterilize 
Denaturation solution (pyrosequencing)  0.2 M NaOH 
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DNA loading buffer (6x) 60% glycerol 
60 mM EDTA 
0.25% Bromophenol Blue 
Fixation solution 1x PBS 
4% paraformaldehyde 
0.0075% gluteraldehyde 
Freezing solution 6.2 M glycerol 
0.14 M Na-lactate 
0.5 mM KCl 
Add ddH2O, adjust to pH 7.2 with 0.5 M 
NaHCO3, ph ) 
Filter sterilize 
IC50 lysis buffer 20 mM Tris base  
Adjust to pH 7.4 with concentrated HCl 
5 mM EDTA 
0.008% (w/v) Saponin 
0.08% (w/v) Triton X-100 
Mix, vacuum filter, store at RT 
LB  
 
1% (w/v) tryptone 
0.5% (w/v) yeast extract 
0.5% (w/v) NaCl 
Autoclave 
LB agar 10 g tryptone/peptone 
5 g yeast extract 
5 g NaCl 
15 g agar 
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In 1 l ddH2O, autoclave 
LB broth 10 g tryptone/peptone 
5 g yeast extract 
5 g NaCl 
In 1 l ddH2O, autoclave 
Lysis Buffer I 0.07% (w/v) saponin in PBS 
Protease inhibitors  
0.5 % (v/v) phosphatase cocktail inhibitors 
(Sigma) 
Lysis Buffer II 1x PBS 
8 M urea 
100 mM NaCl 
25 mM Tris, pH 8 
Protease inhibitors  
0.5 % (v/v) phosphatase cocktail inhibitors 
(Sigma) 
MACS buffer  
 
2 mM EDTA 
1 x PBS 
Autoclave 
Add 0.5% (w/v) BSA prior to use 
NZY+ Broth  
 
1% (w/v) NZ amine (casein hydrolysate) 
0.5% (w/v) yeast extract 
0.5% (w/v) NaCl 
Set pH to 7.5 with NaOH and autoclave 
Add the following filter-sterilized 
supplements prior to use: 
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12.5 mM MgCl2 
12.5 mM MgSO4 
0.4% (w/v) glucose 
Permeabilization solution 1x PBS 
0.1% Triton-100 
Protease inhibitors (PI)  
 
0.002% (w/v) leupeptin 
0.005% (w/v) aprotinin 
100 μM PMSF 
Protein loading buffer (2x) 
 
3% (w/v) SDS 
250 mM Tris pH 6.8 
20% glycerol 
0.1% Bromophenol blue 
Protein lysis buffer  
 
0.07% (w/v) saponin in PBS 
Protease inhibitors 
Ringer solution  
 
10 mM HEPES 
122.5 mM NaCl 
5.4 mM KCl 
1.2 mM CaCl2 
0.8 mM MgCl2 
1 mM NaH2PO4 
11 mM glucose 
Adjust to pH 7.4 with NaOH 
Sterilize by filtration 
RNA running buffer (20x) 41.86 g MOPS 
6.8 g NaOAc 
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3.8 g EDTA 
In 500 ml ddH2O 
RNase solution 1x PBS 
0.3 mg/ml RNase A 
SDS-PAGE running buffer 
 
25 mM Tris 
250 mM glycine 
0.1% (w/v) SDS 
SDS-PAGE transfer buffer  
 
39 mM Tris 
48 mM glycine 
0.038% (w/v) SDS 
SOB medium 20 g tryptone/peptone 
5 g yeast extract 
0.5 g NaCl 
5 g MgSO4 x 7 H2O 
In 1 l ddH2, autoclave 
SOC medium SOB + 20 mM D-Glucose, sterile 
Store at -20°C 
Sorbitol solution 5% (w/v) D-sorbitol in ddH2O 
Filter sterilize 
Stripping buffer  
 
1x PBS 
2% SDS 
100 mM β-mercaptoethanol 
Super Broth (SB) 35 g tryptone/peptone 
30 g yeast extract 
5 g NaCl 
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In 1 l ddH2O, autoclave 
SYBRGreen I Solution 1x PBS 
1:2 000 SYBRGreen I 
TAE buffer, 1 x 4 mM Tris-acetate 
1 mM EDTA, pH 8 
TB Buffer  
 
10 mM PIPES 
15 mM CaCl2 
250 mM KCl 
Set pH to 6.7 with KOH 
Add 55 mM MnCl2 
Sterilize by filtration 
TE Buffer 10 mM Tris/HCl, pH 8 
1 mM EDTA 
In ddH2O 
Filter sterilize 
Thawing solution I 12% NaCl in ddH2O 
Filter sterilize 
Thawing solution II 1.6% NaCl in ddH2O 
Filter sterilize 
Thawing solution III 0.9% NaCl 
0.2% glucose 
In ddH2O 
Filter sterilize 
Wash buffer (pyrosequencing)  
 
10 mM Tris 
Set pH to 7.6 with HCl and autoclave 
Materials and methods 
43 
 
WR99210 20 µM in RPMI 25 mM HEPES L-Glutamine 
WR99210 stock 10 mM in 20% DMSO (v/v) 
 
2.2. Methods 
 Cell culture of Plasmodium falciparum parasites 2.2.1.
2.2.1.1. In vitro culture conditions 
Intraerythrocitic stages of P. falciparum were maintained in continuous blood culture 
according to standard protocols [73]. Cultures were maintained in an incubator with a fixed 
atmosphere of 5% O2, 3% CO2, 92% N2 and 95% humidity at 37°C. Routine cultures were 
established at a hematocrit of 3% - 4% in final volumes of 14 ml or 35 ml in a 10 cm or 25 cm 
diameter petri dish, respectively. The parasitemia varied between 0.5% - 5% according to the 
need. The detailed composition of culture media is stated in Section 2.1.5. Parental strains 
were cultured in non-transfectant medium, containing 10% human serum. Transfected 
strains were cultured in transfectant medium, in which half of the serum was replaced by 
Albumax.  Hematocrit and parasitemia were adjusted for individual experiments according to 
the respective protocol. Cultures were surveyed regularly on Giemsa-stained thin blood 
smears. According to the need, the medium was exchanged to avoid accumulation of toxic 
parasite metabolites or cultures were diluted with fresh erythrocytes to decrease parasitemia.  
 
2.2.1.2. Morphological monitoring of parasites and determination of 
parasitemia 
Parasite cultures were examined on Giemsa-stained thin blood smears, allowing the 
determination of developmental stages, morphological alterations and parasitemia. Thin 
blood smears were prepared from 50 µl of concentrated erythrocytes on clean microscope 
slides and subsequently air dried; fixed in 100% methanol for 30 seconds, air dried and 
stained in a 10% Giemsa solution for 10 to 30 minutes. After staining, slides were washed 
under running water and air dried. Smears were analyzed with a light microscope using an oil 
immersion 100 x objective. The numbers of both infected and total erythrocytes were 
counted on ten consecutive fields (approximately a total of 1000 cells) and the parasitemia 
was calculated according to the formula:  
 
            [ ]   
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2.2.1.3. Parasites synchronization with sorbitol 
Synchronization of cultures to the ring stage was performed using the sorbitol method [194]. 
Sorbitol destroys trophozoite and schizont-stage parasites, which possess the tubovesicular 
network, by osmotic shock. Ring-stage parasites are still lacking this induced transport 
system and therefore survive sorbitol treatment. Whenever a synchronized trophozoite 
culture was required for an experiment, synchronization was performed approximately 16 to 
18 hours prior the experiment. Briefly, pelleted infected erythrocytes (0.5 to 1.5 ml) were 
resuspended in a prewarmed 5% sorbitol solution (8 to 10 ml) and incubated in a closed 
falcon tube at 37°C for 5 minutes (e.g. water bath or incubator). After incubation, cells were 
centrifuged (2100 rpm, 2 min, RT) and the supernatant sorbitol solution was removed. Cells 
were resuspended in culture medium, adjusted to the desired hematocrit and returned to 
culture. 
 
2.2.1.4. Cryopreservation and thawing of the parasites 
P. falciparum ring-stage parasites are suitable for cryopreservation in a designated freezing 
solution (for composition see Section 2.1.5.). Since the percentage of ring-stage parasites 
will affect the revival speed after thawing, a culture containing at least 5% of rings is 
suggested for freezing. The culture was pelleted, and the supernatant completely discarded. 
The remaining pellet was mixed with approximately 1/3 volume of freezing solution (e.g. 500 
µl cell pellet + 150 µl freezing solution) and incubated for 5 minutes at room temperature. 
Subsequently, another 4/3 volume of freezing solution was added (e.g. 600 µl) and the 
solution was thoroughly mixed. The cell solution was transferred to specific cryovials 
(approximately 500 µl per vial) and frozen at -80°C. Short-term storage was maintained in a -
80°C freezer, while cryovials were transferred to a liquid nitrogen tank for long-term storage. 
 
For thawing the parasites cultures, frozen cryovials were shortly warmed up in a 37°C water 
bath until the cell solution turned liquid. Then, 20 µl of Thawing Solution I was added 
dropwise and the resulting solution transferred to a fresh 15 ml falcon tube. Slowly, 9 ml of 
Thawing Solution II were added dropwise under steady rotation of the falcon tube. The 
solution was centrifuged (1900 rpm, 2 min, RT) and the supernatant discarded. The pellet 
was slowly resuspended in 7 ml of Thawing Solution III, which was added dropwise. The 
solution was centrifuged (1900 rpm, 2 min, RT), the supernatant removed, and the pellet 
resuspended in a few milliliters of culture medium. The cell solution was then transferred to a 
petri dish and fresh erythrocytes and fresh culture medium were added. All solutions were 
prewarmed at 37°C before starting the thawing procedure. 
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2.2.1.5. Magnetic purification of the parasites 
P. falciparum trophozoite and schizont stages were purified using the MACS system. The 
MACS CS column was washed twice with MACS buffer and inserted into the VarioMACS 
separator. The cultured was resuspended and applied to the top of the column. The flow was 
adjusted to 1 drop every 3 seconds. The column was washed with MACS buffer until the 
flow-through was clear. The column was removed from the separator and the enriched late 
stages iRBC were eluted in 10 ml of MACS buffer. The cells were centrifuged (2100 rpm, 2 
min, RT) and the pellet was resuspended in the appropriate buffer according to the 
experiment the cells were going to be used for.       
 
2.2.1.6. Plasmid DNA transfection of parasites 
Preparation of parasites: 
The transfection of P. falciparum was performed by electroporation of 3 to 5 % ring stage 
parasite culture. Parasites were synchronized a few days before transfection. Prior to 
transfection the parasite culture was resuspended, centrifuged (1900 rpm, 2 min, RT) and 
the supernatant was removed. 
Preparation of DNA: 
After isolation of the transfection plasmids using the Plasmid Maxi Kit (Qiagen), the 
concentration and quality was estimated by spectrophotometry and agarose gel 
electrophoresis. A volume equal to 75 µg of DNA was used for transfection. The DNA was 
precipitated by addition of a 1:10 volume of sodium acetate (3M, pH 4.5 – 4.8) and 2.5 
volumes of ethanol 99%. Short vortexing and incubation at -20°C for at least 30 minutes 
resulted in the visible condensation of DNA. After centrifugation at 13000 rpm at 4°C for 30 
minutes, the pellet was desalted with 0.5 ml of ethanol 70%. Finally, after further 
centrifugation (13000 rpm, 10 min, 4°C), the pellet was air-dried and resuspended in 30 µl of 
sterile TE-Buffer and stored at -20°c until transfection. Prior to transfection, the DNA was 
supplemented with 370 µl of sterile cytomix solution. 
Electroporation of infected red blood cells: 
A fresh culture dish containing 14 ml transfection medium and 0.5 ml of fresh erythrocytes 
was prepared in advance shortly before the transfection procedure. 200 µl of 3 to 5 % ring-
stage infected erythrocytes were combined with 400 µl of DNA/cytomix mixture, immediately 
transferred to an electroporation cuvette and electroporated in the gene pulser (Biorad) with 
0.31 kV and 0.950 µF at the highest capacity settings. Quickly afterward the sample was 
pipetted into the prepared culture plate and incubated at 37°C for 4 to 6 hours before 
changing the medium and replacing it by fresh transfection medium. 
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Selection procedure: 
One day after transfection the medium was exchanged and the positive selection marker(s) 
were added. Starting from the third day post-transfection, the transfection medium and the 
selection markers were exchanged daily for one week, during which the parasites 
disappeared from the blood smears. This was followed by a 3 to 5 weeks of selection period 
when fresh medium and markers were provided thrice a week until the parasites appeared 
again on the blood smears. 100 µl of fresh erythrocytes were added once per week. 
 
Stock   Final 
DSM1:   10 mM   1.5 μM 
WR 99210  20 μM   5 nM 
Blasticidin  10 mg/ml  varying from 2.5 to 15 µg/ml 
 
2.2.1.7. Cloning parasites by limiting dilution 
Clonal parasite populations were retrieved by limiting dilution of a culture in 96-well plate, 
with an initial inoculum of 0.25 to 0.5 parasites per well. Individual clones in single wells were 
detected by visual and microscopic approach after 2 to 5 weeks in culture.  
The starting parasitemia of the P. falciparum culture in 14 ml of medium at 3% hematocrit 
was carefully determined as a prerequisite for successful dilution of the parasites. Taking in 
account that 1 ml of a suspension at 50% hematocrit is considered to contain roughly 5.109 
erythrocytes, the total number of parasites in this starting culture was calculated from the 
parasitemia.  
From this information, a starting solution with 106 parasites per milliliter was prepared and 
subsequently diluted to obtain a working solution with 10 parasites per milliliter, using 1:10 
dilution steps in a final volume of 10 ml. From this dilution, two final working solutions of 5 
and 2.5 parasites per milliliter were prepared in a final volume of 15 ml or 10 ml of medium, 
using 1:2 dilution steps (Figure 2.1). 200 μl uninfected fresh erythrocytes (2% hematocrit) 
were added to those two solutions. The samples were repeatedly inverted to ensure proper 
mixing. 100 μl of these suspensions were seeded into 96-well plates (V-shape bottom), 
leading to 0.5 or 0.25 parasite per well respectively and incubated under the appropriate 
culture conditions.  
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Figure 2.1: Stepwise dilution process. A starting solution with 106 parasites per ml is first 
prepared and sequentially diluted by a factor 10 to obtain a working solution with 10 
parasites per ml in a final volume of 10 ml. Two final working solutions of 5 and 2.5 parasites 
per ml are then prepared by sequential dilution by a factor 2, in a final volume of 15 ml or 10 
ml of medium, respectively. 
 
Medium without selection marker was exchanged every second to fourth day until parasite 
appearance or for 2 to 5 weeks, and the haematocrit was increased by 1% each week. A 
dark color of the blood and a cloudy medium was usually indicative of parasitized wells, an 
observation further confirmed by microscopic analysis. Subsequently, the contents of 
parasitized wells were transferred to small culture plates to increase parasite numbers for 
freeze-downs and further investigations. 
 
 Microbiological methods 2.2.2.
2.2.2.1. Preparation of electro-competent PMC 103 E. coli bacteria 
To prepare electro-competent PMC 103 E. coli cells, 10 ml of Super Broth (SB) medium were 
inoculated with a single bacteria colony and incubated at 37°C under shaking conditions (230 
rpm) overnight. The next day, 600 ml of SB medium were inoculated with a 1:100 dilution of 
this starter culture (i.e. 6 ml in a total volume of 600 ml) and incubated at 37°C for 3.5 hours 
under shaking conditions (230 rpm). The culture was then centrifuged at 4000 rpm for 10 
minutes at 4°C. All the consecutive steps were carried out on ice with pre-chilled solution. 
The pellet was resuspended in equal volume of sterile water and centrifuged at 4000 rpm for 
15 minutes at 4°C. This washing step was repeated twice. The pellet was then resuspended 
in equal volume of 10% glycerol water and centrifuged at 4000 rpm for 15 minutes at 4°C. 
The supernatant was discarded; the pellet was resuspended in 1.2 ml of 10% glycerol water 
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and aliquoted in Eppendorf tubes and snap frozen with ethanol and dry-ice. The bacteria 
were stored at -80°C until further use.  
 
2.2.2.2. Preparation of chemo-competent XL-1-Blue E. coli bacteria 
To prepare chemo-competent XL-1-Blue E. coli cells, 250 ml of SOB medium were 
inoculated with 10 to 12 colonies and incubated at 37°C under shaking conditions (230 rpm) 
up to an optical density (OD600) of 0.6. The culture was allowed to rest on ice for 10 minutes 
before a centrifugation at 4000 rpm for 20 minutes at 4°C. All the consecutive steps were 
carried out on ice with pre-chilled solution. The pellet was resuspended in 80 ml of TB buffer, 
incubated on ice for 10 minutes and centrifuged at 4000 rpm for 10 minutes at 4°C. The 
supernatant was discarded, the pellet was resuspended in 20 ml of TB buffer and 1.4 ml of 
DMSO was added under slight agitation. The cells were then aliquoted in Eppendorf tubes, 
snap frozen with ethanol and dry-ice and stored at -80°C until further use.  
 
2.2.2.3. Transformation of electro-competent PMC 103 E. coli bacteria 
Plasmid DNA was introduced into electro-competent PMC 103 E. coli bacteria by 
electroporation. For this purpose, 50 µl of bacterial cells were thawed on ice and 
supplemented with 100 µl of 10% glycerol water. 10 µl of DNA were carefully added and the 
mixture was transferred into an electroporation cuvette. The electroporation was then 
performed at 2500 volts. 1 ml of prewarmed Super Optimal Broth with Catabolic repression 
(SOC) medium was directly added and the mixture was transferred to a 15 ml falcon tube 
and incubated for 1 h at 37°C under shaking conditions (230 rpm). Finally, the bacterial 
suspension was pelleted or directly plated onto selective LB agar plates and incubated 
overnight at 30°C. 
 
2.2.2.4. Transformation of chemo-competent XL1-Blue cells 
Plasmid DNA was introduced into chemo-competent XL-10-Gold Ultracompetent cells 
(Agilent Technologies) by heat shock. For this purpose, 50 µl of bacterial cells were thawed 
on ice. 10 µl of DNA were carefully added. After incubation on ice for 30 minutes, the cells 
were incubated for 45 seconds at 42°C, followed by 2 minutes cooling down on ice. The 
transformed bacteria were then supplemented with 900 µl of SOC medium, transferred to a 
15 ml falcon tube and incubated for 1 h at 37°C under shaking conditions (230 rpm). Finally, 
the bacterial suspension was directly plated onto selective LB agar plates and incubated 
overnight at 37°C. 
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2.2.2.5. Transformation of chemo-competent XL10-Gold Ultracompetent 
Cells 
Plasmid DNA was introduced into chemo-competent XL-10-Gold Ultracompetent cells 
(Agilent Technologies) by heat shock. For this purpose, 40 µl of bacterial cells were thawed 
on ice and supplemented with 1.6 µl of β-mercaptoethanol. The cells mixture was incubated 
on ice for 10 minutes. 10 µl of DNA were carefully added. After incubation on ice for 30 
minutes, the cells were incubated for 30 seconds at 42°C, followed by 2 minutes cooling 
down on ice. The transformed bacteria were then supplemented with 900 µl of NZY+ broth 
medium, transferred to a 15 ml falcon tube and incubated for 1 h at 37°C under shaking 
conditions (230 rpm). Finally, the bacterial suspension was directly plated onto selective LB 
agar plates and incubated overnight at 37°C. 
 
2.2.2.6. Isolation of plasmid DNA from bacteria (Miniprep) 
A single colony was inoculated into 10 ml of LB medium (supplemented with the appropriate 
antibiotic, i.e. 100 µg/ml of ampicillin) and grown overnight at 37°C with shaking at 230 rpm. 
Small scale plasmid DNA isolation was achieved using High Pure Plasmid Isolation kit 
(Roche), which is based on alkaline lysis and specific adsorption of released DNA onto glass 
fiber columns. According to the standard protocol the overnight bacteria culture was 
centrifuged at 3800 rpm for 5 minutes at room temperature, and the pellet was treated with 
suspension and lysis buffers and incubated for 5 minutes at room temperature. After addition 
of chilled DNA binding buffer and incubation for 5 minutes on ice, the suspension was 
centrifuged at 13000 rpm for 10 minutes at 4°C. The supernatant was transferred onto the 
column and centrifuged at 13000 rpm for 1 minute at room temperature. After two washing 
steps, the DNA was eluted with 50 µl of elution buffer and stored at -20°C. 
 
2.2.2.7. Isolation of plasmid DNA from bacteria (Maxiprep) 
A single colony was inoculated in 3 ml of LB medium (supplemented with the appropriate 
antibiotic, i.e. 100 µg/ml of ampicillin) and grown for 6 to 8 hour at 37°C with shaking at 230 
rpm. This starter culture was diluted 1:1000 in LB medium containing the appropriate 
antibiotic (i.e. 400 µl in 400 ml of LB medium) and grown overnight at 37°C under 230 rpm 
shaking. Large scale plasmid DNA isolation was performed using the Plasmid Maxi Kit 
(Qiagen) according to the manufacturer´s protocol. Briefly, cells from the overnight bacteria 
suspension were harvested by centrifugation (4000 rpm, 15 min, 4°C) and sequentially mixed 
and incubated with resuspension, lysis and neutralization buffers. Precipitation of genomic 
DNA, proteins and cell debris was carried out on ice. The supernatant containing the plasmid 
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DNA was separated from the debris by centrifugation (10800 rpm, 30 min, 4°C) and loaded 
onto and equilibrated tip. After several washing steps, DNA was eluted, precipitated with 
isopropanol and centrifuged (10800 rpm, 30 min, 4°C), and wash with ethanol 70%. The 
DNA pellet was air-dried, resuspended in an appropriated amount of water and stored at -
20°C. 
 
 Molecular Biology 2.2.3.
2.2.3.1. Genomic DNA isolation from P. falciparum parasites 
To isolate P. falciparum from erythrocytes, 14 ml of a trophozoite and schizont- rich culture 
(at least 5% parasitemia) were resuspended and transferred into a 15 ml falcon tube and 
centrifuged 2 minutes at 1900 rpm. The pellet was washed in PBS and centrifuged again 
under the same conditions. The pellet was resuspended in 10 ml of freshly prepared 0.1% 
Saponin in PBS, inverted several times and incubated on ice for 2 minutes. The lysate was 
centrifuged at 3800 rpm for 8 minutes at 4°C, and the supernatant was discarded. The pellet 
was washed with 10 ml of PBS and centrifuged in the same setting, and resuspended in 200 
µl of PBS and transferred in a 1.5 ml Eppendorf tube. 
The isolation of genomic DNA was carried out via DNeasy kit (Qiagen). Briefly, the parasites 
were lysed with 200 µl AL buffer and 20 µl of proteinase K, vortexed and incubated at 56°C 
for 10 minutes. 200 µl of ethanol (99%) were added and the mixture was thoroughly 
vortexed. The mixture was then transferred to a Mini Spin column and centrifuged at 8000 
rpm for 1 minute. The flow-through was discarded and 500 µl of AW1 buffer were added, 
followed by a centrifugation at 8000 rpm for 1 minute. Again, the flow-through was discarded 
and 500 µl of AW2 buffer were added, followed by a centrifugation at 13000 rpm for 3 
minutes. The column was then transferred to a fresh 1.5 ml Eppendorf tube, and 30 µl of 
water buffer were loaded to the membrane and incubated 1 minute at room temperature, 
followed by a centrifugation at 8000 rpm for 1 minute. The genomic DNA was stored at -
20°C. 
 
2.2.3.2. RNA isolation from P. falciparum parasites 
To isolate P. falciparum from erythrocytes, 5 plates of 25 cm diameter of a trophozoite and 
schizont- rich culture (35 ml, 3 to 5% parasitemia, 3 to 4% hematocrit) were resuspended 
and transferred into a 50 ml falcon tubes and centrifuged 2 minutes at 2000 rpm without 
breaks at 800 rpm, at 4°C. The supernatants were discarded, and the pellets were 
resuspended in the same volume of freshly prepared 0.2% Saponin in PBS. The tubes were 
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inverted several times and incubated on ice for 3 minutes. PBS was added up to 25 ml and 
the tubes were centrifuged for 8 minutes at 3800 rpm at 4°C. The supernatants were 
discarded, and the pellets were transferred in one 50 ml falcon tube and subsequently 
washed with PBS and centrifuged for 8 minutes at 3800 rpm at 4°C. 
To extract the RNA from the parasites, 1 to 2 ml of Trizol® were added to the pellet, mixed 
thoroughly by vortexing, and directly frozen at -80°C for at least 2 hours. The mixture was 
then thawed at 37°C and transferred in 1.5 ml Eppendorf tubes. 200 µl of chloroform per 
milliliter of Trizol® were added, the mixture was hand-shaken vigorously for 30 seconds and 
centrifuged at 10500 rpm for 30 minutes at 4°C. The upper aqueous phase containing mostly 
RNA was transferred to a fresh 1.5 ml Eppendorf tube. 500 µl of isopropanol per milliliter of 
Trizol® were added to the aqueous phase, the mixture was incubated at -20°C for at least 30 
minutes and subsequently centrifuged at 10500 rpm for 10 minutes at 4°C. The pellet was 
washed with ethanol 70% and centrifuged at 10500 rpm for 10 minutes at 4°C. The RNA 
pellet was then air-dried at room temperature to eliminate any trace of ethanol, and dissolved 
in a certain amount of Ribonuclease-free water, depending of the size of the RNA pellet, in a 
range of 20 µl to 100 µl. The concentration was measured by spectrophotometry and the 
RNA was stored at -80°C. The integrity of the RNA was assessed on a denaturing agarose 
gel (0.7% agarose). 
 
2.2.3.3. DNase treatment of the isolated RNA 
The freshly isolated RNA was rendered DNA-free using the The Ambion ®DNA-free kit 
(Invitrogen). Briefly, 5 µg of RNA were mixed with 1.5 µl of 10X DNase I Buffer and 1 μL 
rDNase I, adjusted to a total volume of 15 µl with nuclease-free water. The mixture was 
gently shaken by hand and incubated at 37°C for 30 minutes. 1.5 µl of DNase Inactivation 
Reagent was added before a subsequent incubation period of 5 minute at room temperature. 
The mixture was centrifuged at 10000 rpm for 2 minutes at 4°C and the supernatant was 
transferred in a fresh Eppendorf tube and stored at -80°C if not used directly for cDNA 
synthesis. 
 
2.2.3.4. Reverse transcription 
The cDNA was synthesized with SuperScript® III First-Strand Synthesis Supermix 
(Invitrogen). Briefly, 5 µg of DNase-treated RNA were mixed with 1 µl of oligo(dT)20 50 µM 
and 1 µl of annealing buffer, adjusted to a total volume of 10 µl with nuclease-free water, 
incubated for denaturation at 65°C for 5 minutes and placed on ice for 2 minutes. 10 µl of 2X 
First-Strand Reaction Mix and 2 µl of the SuperScrip III/RNaseOUT Enzyme Mix were then 
added to the RNA mixture, incubated 50 minutes at 42°C. The reaction was heat-inactivated 
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at 85°C for 5 minutes before being allowed to chill on ice for 1 minute. The concentration was 
measured by spectrophotometry and adjusted to 50 ng/ml. The cDNA was stored at -20°C. 
 
2.2.3.5. Polymerase chain reaction (PCR) 
Specific DNA sequences can be amplified in vitro using PCR, involving a temperature 
dependent DNA polymerase, a template DNA sequence and forward and reverse primers 
that bind specifically to the DNA template.The amplification of the DNA fragments used for 
cloning was performed using the Phusion polymerase. The reactions were set as follows: 
 
Buffer 5x : 4 µl 10 µl 
dNTPs 2 mM : 2 µl 5 µl 
Forward primer 5 µM : 0.5 µl 0.5 µl 
Forward primer 5 µM : 0.5 µl 0.5 µl 
DNA template : 1 µl 1 µl 
Phusion : 0.2 µl 0.5 µl 
H2O : 11.8 µl 32 µl 
Total volume : 20 µl 50 µl 
 
The thermocycler was programmed as followed: 
Initial denaturation : 95 °C 10 min 
} 
 
Denaturation : 95 °C 45 sec 
35 cycles Annealing : X °C 45 sec 
Elongation : 68 °C X sec 
Termination : 68 °C 10 min  
Maintaining : 4 °C ∞   
 
The amplification of the DNA fragments for colony screening was performed using the Taq 
polymerase. The reactions were set as follows: 
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Buffer 5x : 2.5 µl 
dNTPs 2 mM : 2.5 µl 
MgCl2 50 mM : 1.25 µl 
Forward primer 5 µM : 0.25 µl 
Forward primer 5 µM : 0.25 µl 
Taq : 0.25 µl 
H2O : 18 µl 
Total volume : 25 µl 
 
The primer pair was chosen to start amplifying in the plasmid and not in the ligated DNA 
fragment.  
 
The thermocycler was programmed as followed: 
Initial denaturation : 90 °C 5 min 
} 
 
Denaturation : 90 °C 45 sec 
30 cycles Annealing : X °C 45 sec 
Elongation : 68 °C X sec 
Termination : 68 °C 10 min  
Maintaining : 4 °C ∞   
 
2.2.3.6. Quantitative real-time PCR (qRT-PCR) 
Quantitative real-time PCR was performed using the LightCycler® 2.0 Instrument detection 
system and the LightCycler® FastStart DNA Master SYBR Green I kit. The samples were 
prepared in technical triplicates in the following manner: 
 
LightCycler FastStart Reaction Mix SYBR Green 
10x 
: 1 µl 
MgCl2 25 mM : 0.8 µl 
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Forward primer 0.5 µM : 0.25 µl 
Forward primer 0.5 µM : 0.25 µl 
cDNA : 2 µl (100 ng) 
H2O : 5.7 µl 
Total volume : 20 µl 
 
The thermocycler was programmed as followed: 
Denaturation : 95 °C 1 sec 
} 50 cycles Annealing : 50 °C 10 sec 
Elongation : 68 °C 10 sec 
 
 
Data were analyzed with LightCycler® Software 4.1. 
 
2.2.3.7. Agarose gel electrophoresis and nucleic acids 
Agarose is widely used for the separation of DNA and RNA molecules according to their size 
and charge. The resolution of the nucleic acid bands is dependent on the concentration of 
the agarose gel. The most common concentration used for DNA electrophoresis varies from 
0.8% (for large 4 to 10 kb fragments) to 2% (for small 0.1 to 1 kb fragments). 
DNA electrophoresis was performed by weighing an appropriate amount of agarose mixed 
with TAE buffer. The mixture was boiled in a microwave until complete dissolution of the 
agarose. The gel was subsequently cooled down to 55°C, supplemented with EtBr (1:10 000 
dilution) and poured in a gel cast. 6 x DNA loading buffer was added to the DNA samples for 
a final concentration of 1x, and samples were then loaded onto the gel. A 1 kb Plus DNA 
LadderTM was run alongside the samples as a size marker. Electrophoresis was carried out 
for 30 to 90 minutes at a constant voltage of 90 to a40 volts depending of the need.  Samples 
were photographed under UV illumination using a DC120 Zoom Digital camera (Kodak). 
As RNA shows a tendency to form secondary structures, formaldehyde was used for RNA 
electrophoresis to maintain the denaturated form of RNA. The gel was prepared by 
dissolving 0.28 grams of agarose (leading to a 0.7% gel) in 2 ml of 20 x RNA gel running 
buffer and 30 ml of water. The mixture was boiled in the microwave until complete dissolution 
of the agarose, then allowed to cool down to 55°C. 8 ml of formaldehyde and 0.5 µl of EtBR 
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were then added and the mixture was poured into a gel cast. Electrophoresis was carried out 
for 60 to 90 minutes at a constant voltage of 60 volts in RNA gel running buffer. The gel was 
then photographed under UV illumination using a DC120 Zoom Digital camera (Kodak). 
 
2.2.3.8. Agarose gel extraction and PCR product purification 
The purification of specific DNA fragment from agarose gel or the cleanup of digested DNA 
fragments from the digestion mixture was performed using the Qiagen gel extraction kit. 
Briefly, the specific agarose gel fragments were cut and solubilized in QG buffer (1:3 w/v 
ratio) at 50°C until complete dissolution. In the presence of isopropanol and high salt 
concentration, the DNA was separated and bound to a QIAquickTM membrane inside the 
column, while the contaminants flowed through. After washing with PE buffer, the DNA was 
eluted with an appropriated amount of water. For digested DNA fragments, the digestion 
mixture first mixed with PB buffer (1:3 ratio) and applied to the column without the first 
solubilization step at 50°C. The purified fragments were stored at -20°C. 
 
2.2.3.9. Photometric determination of DNA/RNA concentration 
Nucleic acid concentration was measured by spectrophotometry using the UVIKON 923 
photometer (Kontron instruments). The absorbance (OD) at 260 nm was analyzed for DNA 
and RNA, where and OD260 of 1 equals 50 µg/ml dsDNA, 30 µg/ml ssDNA and 40 µg/ml 
ssRNA. 
Dilutions were included using the following formula: 
OD260 x 50 (dsDNA) x dilution factor /1000 = X µg/µl 
OD260 x 30 (ssDNA) x dilution factor /1000 = X µg/µl 
OD260 x 40 (ssRNA) x dilution factor /1000 = X µg/µl 
 
2.2.3.10. Restriction digestion of DNA 
DNA can be enzymatically cleaved by restriction endonucleases, which recognize short, 
often palindromic sequences and catalyze a break in the backbone of DNA by hydrolysis. 
The DNA digestion reactions of plasmids and PCR products were set up as follows: 
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Digestion of vectors or 
inserts for cloning 
 Control digestion 
NEB buffer : 10 µl  NEB buffer : 1 µl 
DNA : 30 µg  DNA : 1 µg 
Enzymes : 1 µl of each  Enzymes : 0.4 µl of each 
H2O :  X µl  H2O : X µl 
Total volume : 100 µl  Total volume : 10 µl 
 
The control digestions were incubated for 90 min and the digestions of vectors and inserts for 
cloning for a minimum of 2 hours at the temperature for each enzyme recommended by 
NEB. 
 
2.2.3.11. Dephosphorylation of DNA with alkaline phosphatase 
Shrimp alkaline phosphatase (SAP) from Pandalus borealis catalyses the dephosphorylation 
of 5´phosphates from DNA, thus preventing the religation of plasmid vectors. Appropriate 
ligation is only possible with the insert which still has intact phosphate groups. SAP is 
completely and irreversibly inactivated by heat. All the vectors used for cloning were 
dephosphorylated prior to their use on ligation reactions. After restriction digestion, 1 µl of 
SAP enzyme (Promega) was added to the digestion mix as well as 1 µl of the 10X SAP 
Buffer, incubated at 37°C for 30 minutes and heat-inactivated for 15 minutes at 65°C. The 
vector was then purified using the QIAGEN PCR Purification kit and eluted in 30 μl of water. 
 
2.2.3.12. Ligation of digested DNA fragments  
T4 DNA ligation 
The vectors and DNA fragments ligated using the T4 DNA ligase were previously digested 
with the adapted restriction enzymes and purified using the QIAquick gel extraction kit. The 
ligation reaction was set in the following manner: 
 
Vector : 1 µg 
Insert : 3 -7 µg 
T4 DNA ligase buffer 10X : 1 µl 
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T4 DNA ligase : 1 µl 
H2O : X µl 
Total volume : 10 µl 
 
The reaction mixture was usually incubated at room temperature during 30 minutes to 1 hour 
before transformation. If the transformation was performed on the following day, the reaction 
was incubated over-night at 16°C. 
 
In Fusion 
The InFusion cloning technology was used to introduce the guide sequences into the pL6 
plasmids. The pL6 plasmid of interest was first digested with the enzyme BtgZI at 60°C for 3 
hours, dephosphorylated and purified with the QIAquick gel extraction kit. The primers 
containing the both guide sequences and the sequences for homology recombination were 
adjusted at 100 μM in water and 5 μl of each primer (forward and reverse) were mixed 
together with 1.1 μl of NEB buffer #2. The mixture was heated for 5 minutes at 94°C, allowed 
to cool down to 25°C in a step-wise manner and was kept on ice or frozen until use for the 
ligation reaction.  
The reaction ligation was set as follows: 
 
Vector : 0.5 µl (≈ 200 ng) 
Hybridized primers (1:10 dilution) : 3.5 µl 
Fusion enzyme mix : 1 µl 
Total volume : 5 µl 
 
The reaction mixture was incubated 15 minutes at 50°C and was kept on ice until its 
transformation into XL-10 Gold cells. 
 
Ligation into pJET1.2/blunt 
As an intermediate cloning step, some of the inserts used for this work were cloned into the 
pJET1.2/blunt plasmid. In this situation, the CloneJET PCR Cloning Kit (Fermentas) was 
used. The reaction was set in the following manner: 
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Reaction buffer 2X : 5 µl 
DNA bunting enzyme : 0.5 µl 
Insert : 3.5 µl (≈ 100 ng) 
Total volume : 5 µl 
 
The reaction mixture was incubated at 70°C for 5 minutes and chilled on ice. The following 
reagents were subsequently added: 
 
pJET1.2/blunt cloning vector : 0.5 µl 
T4 DNA ligase : 0.5 µl 
Total volume : 6 µl 
 
The ligation mixture was incubated at room temperature for 30 minutes and used directly to 
transform E. coli PMC 103 electrocompetent or XL-1-Blue chemocompetent cells. 
 
2.2.3.13. DNA sequencing 
DNA samples were sent to GATC (Konstanz) for sequencing. The Sanger dideoxynucleotide 
method [195] was used. The sent samples were prepared as follows: 
 
Plasmids : 30 µl, 30 – 100 ng/µl 
PCR products : 30 µl, 10 – 50 ng/µl 
Primers : 10 µl, 10 pmol/µl 
 
The GATC viewer software and the online platform ClustalW2 from EMBL were used to 
analyze the obtained sequences. 
 
2.2.3.14. Pyrosequencing 
The pyrosequencing technique is based on the quantification of a light-generating reaction, 
which depends on the amount of nucleotide that is incorporated at a specific base pair 
position. Consequently, this approach allows the determination of allele proportions in DNA 
mixtures. Briefly, the immobilized single stranded template DNA is hybridized with a 
sequencing primer binding in a directly adjacent manner to the polymorphic base pair. 
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Further, the enzymes DNA polymerase, ATP sulfurylase, luciferase and apyrase are added 
with the substrates adenosine 5’-Phosphosulfate (APS) as well as with luciferin. In a initial 
sequencing step, one of the four deoxynucleotide triphosphates (dNTPs) is added to the 
mixture. If the dNTP is complementary to the template, the DNA polymerase incorporates it 
into the newly synthesized strand, which releases pyrophosphate molecules (PPi) in a 
stoichiometric fashion. The ATP-sulfurylase then converts PPi into ATP in presence of APS. 
This freshly synthesized ATP subsequently fuels the luciferase-mediated conversion of 
luciferin into oxyluciferin, which in turn generates a visible light reaction proportional to the 
amount of previously generated ATP. This light reaction can be quantified and used to 
calculate the proportions of the two alleles in the mixture. 
A portion of the pfatp6 sequence was amplified by PCR using the biotinylated primers 
(primers [53]-for and [54]-rev). 37 µl of the resulting PCR product were mixed with 3 μl of 
Streptavidin Sepharose HP (GE Healthcare) and 40 μl of binding buffer, to a final volume of 
80 μl. The mixture was transferred to a 96 well-plate V-bottom and shaken for 10 minutes at 
1400 rpm. The strand separation was performed using the PyroMark Q96 vacuum 
workstation. Briefly, the filter probes were washed with 180 ml of water before being lowered 
into the 96 well-plate containing the samples to capture the beads. The beads were washed 
with 70% ethanol by flushing the filter probes for 5 seconds, denatured with the denaturation 
solution for 5 seconds and finally washed with wash buffer for 10 seconds. The filter probes 
were drained by raising the tool at 90° for 5 seconds and the beads were subsequently 
released into a PyroMark Q96 Plate Low containing 0.4 μM of the sequencing primer (primer 
[55]-for) in 40 μl of annealing buffer. The samples were heated at 80°C for 2 minutes and 
allowed to cool down to RT. The reagent cartridge was filled with the recommended volumes 
of PyroMark Gold Q96 Reagents provided by the software, according to the number of 
samples to analyze. The PyroMark Q96 Plate Low was placed on the heating block of the 
PyroMark Q96 ID and the cartridge on the dispensing unit. The set up and the run analysis 
were performed using the PyroMark Q96 Software v1.0. 
 
 Protein Biochemistry 2.2.4.
2.2.4.1. Preparation of P. falciparum protein extract 
P. falciparum cultures at a parasitemia in trophozoites of 3 to 5% were magnetically purified 
using the MACS system. After elution of the iRBC, the samples were centrifuged 2 minutes 
at 2100 rpm and the pellets were washed once with ice-cold PBS. The iRBCs were 
resuspended in approximately 1 ml of Protein Lysis Buffer, an appropriate volume for the 
amount of P. falciparum parasites obtained from such a culture, and subsequently incubated 
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on ice for 3 minutes. The samples were then centrifuged at 13 000 rpm for 1 minute at 4°C 
and the pellet of parasites was washed 2 times with ice-cold PBS and kept at -80°C or 
directly resuspended in an appropriate volume of Protein Loading Buffer. The samples were 
then sonicated (20% output) twice for 5 seconds, allowing a 30 seconds break on ice in 
between the two sonications. After centrifugation for 15 minutes at 4°C at 13 000 rpm, the 
supernatant was transferred in a fresh Eppendorf tube and kept at -20°C. 
 
2.2.4.2. SDS-PAGE electrophoresis 
Protein samples were analyzed by SDS-PAGE electrophoresis. Before being loaded on the 
SDS-PAGE gel, the samples were heated at 70°C for 5 minutes. The PageRuler Plus 
Prestained (Ambion) was used as a protein ladder. The gels were run at 40 mA and 150 V 
during approximately 90 min in SDS-PAGE running buffer. 
SDS-PAGE gels were prepared as follows: 
 
Resolving gel  Stacking gel 
  8% 10% 12%     
H2O : 4.68 ml 3.96 ml 3.35 ml  H2O : 3.46 ml 
1.5 M Tris pH 8.6 : 2.50 ml 2.50 ml 2.50 ml  1 M Tris pH 6.8 : 630 µl 
10% SDS : 100 µl 100 µl 100 µl  10% SDS : 50 µl 
30% Acrylamid : 2.66 ml 3.33 ml 4.00 ml  30% Acrylamid : 830 µl 
10% APS : 100 µl 100 µl 100 µl  10% APS (fresh) : 50 µl 
TEMED : 6 µl 6 µl 6 µl  TEMED : 5 µl 
Total volume 
: 
10 ml 10 ml 10 ml  Total volume : 5.025 ml 
 
 
2.2.4.3. Visualization of proteins by Coomassie staining 
To visualize the proteins in the whole extract after the SDS-PAGE electrophoresis, the gels 
were soaked in Coomassie Solution for 30 minutes under constant shaking and then washed 
with Coomassie Destaining Solution until the protein bands could be clearly distinguished.  
 
2.2.4.4. Western blotting 
The SDS-PAGE gels were transferred to an Immun-Blot® PVDF membrane (Bio-Rad) using 
a Trans-blot SD semi-dry transfer cell. The membrane was activated with methanol for 30 
seconds. Afterwards, 3 Whatman papers were soaked in transfer buffer and placed on the 
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device, followed by the membrane placed on top, the SDS-PAGE gel and finally 3 more 
soaked Whatman papers. The transfer was run for 1 hour at 230 mA and 30 V. The 
membrane was blocked over 1 hour with 5% (w/v) milk in PBS, and incubated overnight at 
4°C with the first antibody diluted in 3% (w/v) BSA in. The following day, three washes of 15 
minutes with PBST (0.1% (v/v) of Tween in PBS) were performed. The membrane was 
blocked again with 5% (w/v) milk in PBS for 1 hour. The incubation of the second antibody 
(diluted as well in 3% (w/v) BSA in PBS) was carried out for 30 minutes. Before 
development, the membrane was washed three times more during 15 minutes with PBST. 
The developing solution (BM chemiluminescence blotting substrate POD, Roche) was freshly 
prepared (2 ml of solution A + 20 μl of solution B) and the membrane was incubated with the 
solution for 5 minutes. The signal was captured with a blot scanner (C-DiGit from Li-Cor). 
The dilutions of the antibodies that were used for western blot are the following: 
 
Anti-α-tubulin monoclonal : 1:1000 
Anti-HA tag monoclonal : 1:1000 
Anti-mouse-POD monoclonal  : 1:10000 
 
2.2.4.5. Western blot striping 
In order to strip of the antibodies out of the western blot membrane, they were incubated for 
30 minutes with stripping buffer and then washed 3 times during 15 minutes with PBST 
(0.1% (v/v) of Tween in PBS). 
 
2.2.4.6.  [35S]-methionine incorporation assay during protein synthesis 
A [35S]-methionine incorporation assay was performed to investigate the possible effect of 
SC83288 on protein synthesis. The assay was performed at the Zentrum für Molekular 
Biologie (ZMBH) in Heidelberg, in Prof. Christine Clayton´s lab, together with Dr. Chaitali 
Chakraborty. Briefly, samples of approximately 3x106 iRBC were resuspended in 500 µl of 
prewarmed labeling medium (DMEM without methionine, ThermoFisher Scientific) and 
treated with various concentrations of SC83288 for 1 hour at 37°C. 1 µl of of 10 µCi/µl [35S]-
methionine stock solution (Hartmann Analytic) was added and the samples were further 
incubated for 30 minutes at 37°C. After 2 washes with PBS, the samples were resuspended 
in 10 µl of 2x Laemmli lysis buffer, and incubated 5 minutes at 95°C, before being loaded on 
a 10% SDS_PAGE gel for 2 hours. The gel was fixed for 30 minutes at room temperature in 
an aqueous solution containing 7.5% of acetic acid and 10% of methanol. It was 
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subsequently stained with Coomassie Blue for 1 hour and allowed to destain overnight 
before being imaged. The gel was then dried for 1 hour at 80°C, exposed over 2 days in a 
cassette and developed using a Fujifilm FLA-7000 detector. 
 
 Growth inhibition assay and determination of IC50 values 2.2.5.
The anti-malarial activity of a compound is generally assessed by measuring the growth 
inhibition of P. falciparum blood-stage parasites under drug treatment, and is expressed as 
50% inhibitory concentration (IC50 value). IC50 values indicate the concentration needed to 
inhibit the parasite´s multiplication by 50% over a chosen period of time. Growth inhibition 
assays were performed according to standard protocol based on the detection of parasitic 
DNA by fluorescent SYBRgreen staining [196]. Briefly, a synchronous culture of ring-stage P. 
falciparum blood-stage parasites was incubated for 72 hours in presence of decreasing drug 
concentrations in a black 96-well microtiter plate. The final conditions of the tests were 100 µl 
volume per well, 0.5% parasitemia, 2% final hematocrit and 72 hours incubation time at 
37°C. 
On the day of the assay a ring-stage culture, previously synchronized by sorbitol treatment, 
was established at 0.5% parasitemia and 4% hematocrit. A solution of niRBC at 4% 
hematocrit was used as a negative control. 
Drug solutions were prepared as working solutions (6x) in culture medium by diluting freshly 
thawed stock solution to 6x starting concentration (i.e. highest drug concentration to be 
tested). Per drugs, 60 µl of working solution was prepared. The starting concentration was 
chosen to allow the IC50 concentration to fall around the midpoint of a threefold serial dilution. 
This concentration was calculated based on IC50 values found in the literature or was tested 
in preceding growth-inhibition assays. The range of drug concentrations should cover 
parasite viability from 0 – 100% with sufficient data points all over this range in order to 
assure correct IC50 value calculation by the SigmaPlot Software.  
Growth inhibition assays were performed on black 96-well plates according to the following 
plate scheme (Figure 2.2). Firstly, 50 µl of culture medium was filled in each well. For 
preparation of serial drug dilutions, 25 µl of drug working solution (6x) was added in the first 
well and thoroughly mixed. A 10-points 1:3 serial dilution was obtained by transferring 25 µl 
from one row to the next row containing 50 µl of culture medium. The 25 µl drug solution from 
the final row was discarded. One line was reserved for non-infected erythrocytes (negative 
control) and another one for infected erythrocytes (positive control). Subsequently, 50 µl of 
prepared parasites culture was added to each well and 50 µl of niRBC solution were added 
to respective wells. Plates were covered with clear lids and incubated for 72 hours in the 
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usual incubator. After incubation period, plates were wrapped in aluminum foil and frozen at -
80°C until use in order to obtain complete lysis of erythrocytes, usually overnight. 
 
                        
  RBC RBC RBC RBC RBC RBC RBC RBC RBC RBC   
  iRBC iRBC iRBC iRBC iRBC iRBC iRBC iRBC iRBC iRBC   
Drug 
  1:3 dilution   
 
          
                      
Drug 
  1:3 dilution                   
                      
                        
 
Figure 2.2: Plate scheme of growth inhibition assay. Abbreviations: RBC, non-infected 
red blood cells; iRBC, infected red blood cells. 
 
Parasite multiplication was assessed by fluorescent SYBRgreen staining of the parasites of 
parasitic DNA. Measured fluorescence intensity stems from SYBRgreen binding to double 
stranded DNA and is associated to DNA replication by multiplying parasites 
On the day of the measurement, plates were thawed for at least 1 hour at room temperature. 
The plates were filled with 100 µl/well of a 1x SYBRGreen solution in Lysis Buffer, briefly 
shaken and incubated at room temperature for 1 hour protected from direct light exposure. 
Fluorescence was measured in a fluorescence plate reader (ext/em: 485/520 nm, gain 1380, 
10 flashes/well, top optic). 
IC50 values were calculated as followed. The fluorescence intensity of non-infected 
erythrocytes represents the background fluorescence of the cell solution; thus the calculated 
mean fluorescence intensity of non-infected erythrocytes was deducted from all infected 
erythrocytes measurements. The fluorescence intensity of untreated infected erythrocytes 
represents 100% parasite survival. Thus, the survival of treated infected erythrocytes was 
calculated based on the calculated mean fluorescence intensity of infected erythrocytes and 
expressed as percentage. These values, together with the respective drug concentrations, 
were plotted in form of a dose-response curve in SigmaPlot (x-axis = drug concentration [M], 
y-axis = parasite survival [%]). The IC50 values were calculated by SigmaPlot according to 
the Hill function (four parameters). 
 
 In vitro speed of action or “killing speed” experiments 2.2.6.
Three independent methods were used to determine the in vitro speed of action of the drugs 
used in this study. 
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2.2.6.1. Relative speed of action assay 
In order to obtain information on the speed of action of antimalarial drugs in a relatively fast 
manner, the approach developed by Le Manach et al. [197] was applied. Briefly, the growth 
of asynchronized parasites in the presence of antimalarial compounds was assessed using 
SYBRGreen staining, as described above, and expressed as IC50 values. For each 
compound, three incubation times were employed 72 (standard assay time), 48 and 24 
hours. Unless mentioned otherwise, the experimental conditions were similar to the ones 
used during the growth inhibition assay previously described. The IC50 ratios, normalized to 
the 72 hours assay were subsequently used to classify the compound as fast- or slow-acting. 
Here artemisinin and quinine were used as fast-acting reference, and atovaquone as slow-
acting reference. 
 
2.2.6.2. Recrudescence assay 
The so called “killing speed” experiment, based on the original protocol established by Sanz 
et al. [198], is founded on determination of parasite viability in response to drug treatment by 
assessing re-growth of treated parasites over time. The in vitro speed of action of SC81458, 
SC83288, artemisinin and atovaquone were assessed following this approach. Treatment 
was performed with concentrations corresponding to 10x IC50 value of each drug, previously 
established as described in Sanz et al [198].  
Briefly, an asynchronous culture of P. falciparum Dd2 blood-stage parasites, with a 
predominant ring-stage population was treated with a concentration corresponding to 10×IC50 
for a total duration of 7 days (168 h). Every 24 hours, a defined sample of parasites was 
taken from the treated culture, washed with drug-free medium and transferred to a 96-well 
plate, where 12-steps dilution was performed, 1:3 series in order to obtain a limiting dilution 
(i.e. one single parasite per well). Parasites were cultured for a total duration of 28 days to 
allow viable parasites to grow to higher parasitemia, further detected by SYBRgreen. The 
number of the last dilution step containing growing parasites was used to back-calculate the 
number of viable parasites present in the initial aliquot. Results are presented in graphical 
form as numbers of viable parasites over time of drug treatment. These results allow to 
obtain various parameters concerning the speed of action of the tested compounds, such as 
a potential lag phase (i.e. time needed to reach the maximal killing rate), the parasite 
reduction ratio (PRR) over one parasitic life cycle of 48 hours and the parasite clearance time 
(PCT) (i.e. time needed to kill 99.9% parasites).  
On the day of the assay, an asynchronous culture was established at 0.5% parasitemia and 
2% hematocrit, corresponding to 106 iRBC per ml, and distributed in small culture flasks (10 
ml per flask per drug treatment). An aliquot of 1 ml of the initial culture was kept separately in 
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order to establish the first serial dilution of untreated parasite (0 hour). Drug solutions for the 
complete experiment were prepared as 100× working solutions in culture medium by diluting 
a freshly thawed stock solution, aliquoted for each day and stored at -20 °C. Culture medium 
and drug were renewed daily over the entire treatment period.  
Drug treatment was started on day 0 by adding 100× working solution (10 µl per 1 ml of 
culture) into prepared culture flasks that were subsequently maintained under usual 
conditions in the incubator. At different time points (8, 24, 48, 72, 96, 120, 144 and 168 
hours), aliquots of treated parasites à 500 µl were taken from the treated culture. Before 
preparing the serial dilutions, treated parasites were thoroughly washed 3 times with fresh 
culture medium to wash out the drug. After the last washing step, it was important to restore 
the original volumes and thereby the original hematocrit (i.e. number of cells per µl).  
Serial dilutions (12 steps, 1:3 dilutions) of untreated or treated parasites were prepared in 
triplicates on 96-well plates (F-bottom). Therefore, a solution of non-infected red blood cells 
(niRBC) at 2% hematocrit was prepared. The plates were prepared as follows. The outer 
rows were omitted from use due to extensive evaporation and were filled with 200 µl of sterile 
water. Wells 2 to12 of the serial dilution (in triplicates) were filled with 100 µl of the prepared 
niRBC solution, leaving the first well empty for the treated parasite culture. These ones were 
then filled with the washed parasites (150 µl per well). A 1:3 serial dilution was obtained by 
transferring 50 µl each from one row to the next row containing 100 µl niRBC solution. One 
additional column of wells was filled with 100 µl niRBC solution as negative control for 
SYBR® green detection. At the end, another 50 µl of prewarmed culture medium was added 
to each well (final conditions: 150 µl volume, 1.33% hematocrit). Plates were maintained 
under usual conditions in the incubator for a total duration of 28 days. Medium was replaced 
twice a week (100 µl), once a week with addition of fresh erythrocytes (100 µl niRBC solution 
of 0.66% hematocrit). Detection of viable parasites was performed using SYBRGreen 
according to Smilkstein et al. [196], as previously described in section 2.2.5.  
 
Calculation of viable parasites, parasite reduction ratio and parasite clearance time: 
All parameters were calculated as described in the original protocol established by Sanz et 
al. [198]. The number of viable parasites was back-calculated by using the formula X(n-1), 
where X stands for the dilution factor (i.e. 3) and n the number of wells detected positive for 
viable parasites i.e., the number of the last dilution step containing growing parasites. When 
no well showed any parasite recovery (n=0), the number of viable parasites was estimated 
as zero. The numbers of viable parasites after drug treatment are presented in graphical 
form as “viable parasites +1” in logarithmic scale. This presentation was adopted from the 
original protocol [198] since only values greater than zero can be plotted on a logarithmic 
scale. A possible stagnation of parasite numbers during the first hours of treatment is 
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considered as lag phase, displaying a characteristic plateau. The parasite reduction ratio 
(PRR) was calculated as the decrease of viable parasite numbers over 48 h in the phase of 
maximal killing, therefore by excluding the period of lag phase. The parasite clearance time 
was determined using a linear regression of the time-response curve. The linear regression 
was calculated from time-point 0 h until the first time-point at which parasites were cleared 
(parasite number = 0) and included the possible lag phase.  
 
2.2.6.3. Dual-color flow cytometry assay 
Another faster method to measure the speed of action of antimalarial compounds, based on 
the approach described by Linares et al. [199] was used. This method uses the quantification 
of new infections to determine the parasite viability.  
Briefly, an asynchronous culture of P. falciparum Dd2 blood-stage parasites, with a 
predominant ring-stage population was treated with a concentration corresponding to 10×IC50 
for a total duration of up to 72 hours.  
On the day of the assay, an asynchronous culture was established at 0.5% parasitemia and 
4% hematocrit, and distributed at 50 µl per well in a 96-well V-shape bottom plate in 
triplicates. Drug treatment started on day 0 by adding 50 µl per well of 20×IC50 drug solution, 
resulting to a treatment corresponding to 10x the IC50. The drugs were freshly renewed every 
24 hours. At different time points (8, 14, 24, 48 and 72 hours), the parasites were washed-out 
the drug and resuspended in 100 µl of medium. 70 µl were then transferred into a fresh 96-
well V-shape bottom plate, containing 130 µl of CFDA-stained non-infected erythrocytes at 
2% hematocrit, resulting into a 1/3 dilution. After 48 hours of subsequent incubation at 37°C, 
the parasites were washed in PBS, and the DNA content was stained using Draq5 (1:500 
dilution in PBS) for 20 minutes at room temperature. The samples were washed once with 
PBS and fixed in PBS 0.05% glutaraldehyde for 20 minutes at room temperature. The fixed 
samples were kept in PBS at 4°C until flow cytometry analysis. 
Flow cytometry using a BD FACS Canto collecting fluorescence in the FITC and the PerCP-
Cy5 channels allowed defining the proportion of the doubly stained parasites, corresponding 
to the new infections. The total infections were calculated as followed:  
                 
 
 
                 
The parasite viability was then expressed as a percentage of the untreated parasites. 
 
 In vitro drug combination assays 2.2.7.
The fixed-ration isobologram method, established by Fivelman et al. [200] was used to 
investigate the in vitro interaction between two compounds. This approach relies on 
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determining the IC50 values of each individual drug on its own and the IC50 values of a 
mixture of both drugs at fixed concentration ratios. The shift of a drug´s IC50 value in 
combination with a second compound compared to the one determined for the drug on its 
own is indicative of the nature of the drug-drug interaction. Furthermore, arithmetical analysis 
allows obtaining the mean sum of fractional 50% inhibitory concentration (mean ∑     ), i.e. 
the unit of measurement. Both graphical, in the form of isobolograms and arithmetical 
analysis were used to establish the nature of the interaction between the two studied 
compounds. 
 
Assay 
The experimental set-up is similar to the growth inhibition assay (see 2.2.5). Briefly, a 
synchronous culture of ring-stage P. falciparum blood-stage parasites was incubated for 72 
hours in the presence of decreasing drug concentrations in a 96-well black microtiter plate. 
The final conditions of the tests were 100 µl volume per well, 0.5% parasitemia, 2% final 
hematocrit and 72 hours incubation time at 37°C. 
On the day of the assay a ring-stage culture, previously synchronized by sorbitol treatment, 
was established at 0.5% parasiteamia and 4% hematocrit. A solution of niRBC at 4% 
hematocrit was used as a negative control. Drugs were applied alone (A or B) and in 
combination at fixed concentration ratios (A:B) and analyzed in treefold serial dilutions. Drug 
mixtures were prepared from 2x working solution of each drug in the following fixed 
concentration ratios (v/v): ratio A:B = 4:1, 3:2, 2.5:2.5, 2:3, 1:4, directly in the 96-well plate. 
IC50 values of drugs A and B alone were determined on the same plate to ensure accurate 
calculation of drug interaction. 
The assays were performed according to the plate scheme showed below. The outer rows 
were omitted from used due to extensive evaporation and were filled with 200 µl of sterile 
water. Firstly, 50 µl of culture medium was filled in each well, leaving the first well empty for 
the drug solutions. For preparation of serial drug dilutions, 75 µl of 2x working solution 
(individual or as mix of drug A and drug B) was added in the first well and thoroughly mixed. 
A 10-points 1:3 serial dilution was obtained by transferring 25 µl from one row to the next row 
containing 50 µl of culture medium. The 25 µl drug solution from the final row was discarded. 
One line was reserved for non-infected erythrocytes (negative control) and another one for 
infected erythrocytes (positive control). Subsequently, 50 µl of prepared parasites culture 
was added to each well and 50 µl of niRBC solution were added to respective wells. Plates 
were covered with clear lids and incubated for 72 hours in the usual incubator. After 
incubation period, plates were wrapped in aluminum foil and frozen at -80°C until use in 
order to obtain complete lysis of erythrocytes, usually overnight. Parasite growth was 
assessed using SYBRGreen as described above. 
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Arithmetical analysis 
The fractional IC50 (FIC50) of each drug in a given concentration ratio was calculated 
according to the following definitions: 
FIC50(A) = IC50 in combination / IC50 of A alone 
FIC50(B) = IC50 in combination / IC50 of B alone 
 
The sum of FIC50(A) and FIC50(B) (∑     ) was established for each combination and the 
mean value of the four ∑     s was calculated. A mean ∑           was assumed to 
represent a synergistic interaction and a mean ∑           an antagonistic interaction 
between the tested drugs. Any value in between (0.7 – 1.3) was considered as an indifferent 
interaction.  
Graphical analysis was performed on isobolograms, obtained by plotting pairs of FIC50 values 
of drug A and drug B for each combination. The isobologram Figure 2.3 illustrates the 
characteristic isoboles for different drug-drug interaction. A straight line represents an 
indifferent interaction, i.e. a simple additive effect, a concave curve towards the origin of the 
axes indicates a synergy and a convex curve towards the opposite suggests antagonism. 
 
Figure 2.3: Theoretical example of isobologram illustrating the characteristic curves, 
or isoboles, for various types of in vitro drug-drug interactions. A straight diagonal line 
denotes an indifferent interaction (black), i.e. a simple additive effect, a concave curve 
towards the origin of the axes indicates a synergy (green) and a convex curve towards the 
opposite suggests antagonism (red). 
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 Ring Survival assay (RSA) 2.2.8.
The in vitro ring survival assay (RSA) rate was assessed as previously described by 
Mbengue et al. [161]. Briefly, tightly synchronized parasites were obtained by a double 
sorbitol treatment, 12 hours apart. Early ring parasites (0 to 3 hours p.i.) at a parasitemia of 
0.5 to 1% were exposed to various drugs at a concentration of 700 nM, or to PBS for 6 
hours. The parasites were subsequently washed four times with plain medium and returned 
in culture for 66 hours. The parasites were then harvested, washed once with PBS, 
resuspended in fixation solution and incubated either for 2 hours at room temperature or 
overnight at 4°C. The samples were then washed once with PBS, resuspended in 400 µl of 
PBS and kept at 4°C until further determination of the parasitemia by flow cytometry analysis. 
Parasites survival rates (%RSA) were expressed as a percentage by comparing the 
parasitemia between the drug-treated and the untreated control as followed: 
          ( )   
              ( )
             ( )
      
 
 Fitness assay 2.2.9.
The relative fitness of parasites was determined in a growth competition assay. For this 
purpose, P. falciparum 3D7 parasite lines, with isogenic background and differing pfatp6 
alleles were carefully counted, mixed 1:1 and seeded at an initial parasitemia of 3% of 
trophozoite stage, in triplicate. The parasitemia was maintained between 0.5 and 6% to 
assure optimal growing conditions of the cultures. The mixed parasites were kept in culture 
for 20 cycles, i.e. 40 days. In order to determine the ratio of both strains in the mixture 
overtime, saponin‐lysed parasite pellets of the mixed cultures were collected every 4 days 
and the genomic DNA was extracted from the pellets using the DNeasy Tissue Kit (Qiagen). 
The DNA was then used as a template for specific amplification and further ratiometric 
analysis by pyrosequencing (see Section 2.2.3.14). 
 
 Progression of P. falciparum through the life cycle 2.2.10.
In order to follow the parasites through their life cycle, cultures were tightly synchronized by a 
double sorbitol treatment, 12 hours apart. The parasites were then treated as late 
trophozoites/early schizonts with 50 U/ml of heparin to block further invasion. The growth of 
the parasites was monitored by Giemsa staining under light microscopy, and the heparin was 
washed-out at late schizont stage (42 to 48 hours p.i.). The point of invasion was considered 
4 hours after the washing steps. At around 10 hours post-invasion, the parasites were set in 
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culture at a parasitemia of 1%, and eventually exposed to drugs. Samples were collected 
every 2 to 4 hours from this point, until 52 hours post-invasion, washed once with PBS, 
resuspended in fixation solution and incubated either for 2 hours at room temperature or 
overnight at 4°C. The samples were then washed once with PBS, resuspended in 400 µl of 
PBS and kept at 4°C until further analysis.  
 
 Flow cytometry analysis 2.2.11.
DNA content analysis was performed by flow cytometry on SYBRGreen-stained parasites 
either to follow their evolution through the life cycle or to measure the precise parasitemia, 
using a BD FACS Canto. The staining procedure was performed as described by Ganter et 
al. [201]. Briefly, the fixed collected parasites were first transferred in a 96-well microtiter 
plate (V-shape bottom) and washed with 200 µl of PBS per well, by centrifugation for 2 
minutes at 2 100 rpm. The parasites were then permeabilized for 8 minutes at room 
temperature in 200 µl per well of permeabilization solution, before being washed two times 
with 200 µl of PBS as previously. The samples were subsequently subjected to a light RNase 
treatment, by incubation for 30 minutes at 37°C in 200 µl per well of RNase solution. The 
treated parasites were then washed two times as previously, and their DNA content was 
stained with SYBRGreen I by incubating them in 200 µl per well of SYBRGreen I solution for 
20 minutes at room temperature protected from direct light. After two PBS-washes, the 
parasites were transferred in tubes adapted for flow cytometry measurements. Fluorescence 
was collected in the green channel (FITC-H) of the FACS Canto. A minimum of 2 000 iRBCs 
were counted per measurement and plotted in the form of dot-plots using the software 
FlowingSoftware2.5.1. A region of interest excluding background fluorescence was 
determined and information such as the mean and gated events was collected for this 
selected area.  
 
 Microscopy techniques 2.2.12.
2.2.12.1. Live Fluorescence microscopy 
Live Calcium measurement  
Trophozoite-stage P. falciparum HB3 parasites were incubated with 10 µM of Fluo-4-AM in 
Ringer solution with Pluoronic F-127 (0,1% v/v) and 40 µM of probenecid and 0.1% of 
Pluoroninc acid for 40 minutes at 37°C, as previously described [202]. Dye-loaded parasites 
were washed two times before settling onto poly-L-lysine coated glass slides. Confocal laser 
scanning fluorescence microscopy was performed using a confocal Leica TCS SP5 (Leica 
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Microsystems CMS GmbH). Fluo-4-AM was excited at 488 nm (argon laser, 0.03 %) and the 
emitted fluorescence was collected from 505-520 nm. Single images were obtained using a 
63 x objective, with a 5-fold software zoom, 1024x1024 pixels, every 2 seconds over a time 
span of 120 seconds. The Ca2+ ATPase inhibitor CPA, the Na+/K+ ATPase inhibitor oubain, 
SC81458 and SC83288 were added to a final concentration of 10 µM at 45 seconds. The 
calcium signal was further analyzed using Fiji, and the mean fluorescence signals were 
compared using one-way ANOVA in SigmaPlot 13 (Systat Software Inc.). 
 
Calcium resting concentration measurement  
The ratiometric dye FuraRed shows a significant spectral shift with changes of free calcium 
Ca2+. Live cell confocal scanning imaging can be performed using excitation wavelengths of 
458 and 488 nm. The fluorescence emission is measured using a 570 nm long pass filter. 
Calibration of the FuraRed fluorescence was achieved using the Calcium Calibration Buffer 
Kit (ThermoFisher Scientific). Cells were permeabilized with 10 µM of the Ca2+ ionophore 
ionomycin, adjusted to varying free Ca2+ concentration and imaged. The fluorescent signal 
was also evaluated in the intact parasites, to obtain the calcium resting concentration. 
Trophozoite-stage P. falciparum 3D7 parasites were incubated with 9 µM of FuraRed-AM in 
Ringer solution with Pluoronic F-127 (0,1% v/v) and 40 µM of probenecid and 0.1% of 
Pluoroninc acid for 45 minutes at 37°C, as previously described [202]. Dye-loaded parasites 
were washed two times before settling onto poly-L-lysine 8 well chamber (ibidi). Confocal 
laser scanning fluorescence microscopy was performed using a confocal Leica TCS SP5 
(Leica Microsystems CMS GmbH). Single images were obtained using a 63x objective, 
1024x1024 pixels. Single cell fluorescent images were further analyzed using Fiji and regions 
of interest were defined to measure the mean fluorescent intensity. A region of interest was 
also defined in non-infected erythrocytes to allow for background subtraction. The mean 
fluorescence ratio (R458/488 nm) was then calculated. A calcium calibration curve was 
constructed as described in Rohrbach et al. [202] using a least square fit to a Hill function. 
The Hill coefficient was fixed to unity reflecting the 1:1 stoichiometry of the FuraRed binding 
to Ca2+ ions. A Grubbs test was performed to identify outliers (at the p = 0.01 level). These 
outliers were omitted for further analysis. The R458/488 nm ratio measured in resting parasites 
were then converted to the corresponding resting free [Ca2+] using the inverse Hill equation. 
The mean calcium resting concentrations between the wild-type and mutant parasites were 
compared using one-way ANOVA in SigmaPlot 13 (Systat Software Inc.). 
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2.2.12.2. Immunofluorescence analysis (IFA) 
In preparation for IFA, young trophozoite stage infected erythrocytes were purified using the 
MACS column. The samples were fixed in fixation solution for 30 minutes at room 
temperature. The cells were washed 3 times with PBS by centrifugation at 2 100 rpm for 1 
minute, permeabilized in permeabilization solution for 15 minutes and washed 3 times as 
described above. A 3% (w/v) BSA in PBS solution was used for the blocking as well as to 
dilute the antibodies. The samples were blocked for 2 hours at room temperature and further 
incubated with the first antibody for 90 minutes. The samples were washed 3 times and 
incubated with the secondary antibody, and if necessary along with 5 μM of Hoechst 33342 
for 45 min. The samples were then washed again 3 times and kept over-night in PBS at 4°C 
until they were analyzed using the confocal microscope Leica TCS SP5, equipped with an 
objective providing 63-fold magnification. Hoechst was excited at 364 nm and emission 
detected using a 385-470 filter, whereas 2nd antibody conjugated with Alexa 488 was 
excited using the 488 nm Argon laser and the emission was captured through a 505~550 
filter. 
 
Anti-HA tag monoclonal : 1:1000 
Anti-mouse Alexa Fluor 488  : 1:1000 
 
 Untargeted metabolomics analysis sample preparation 2.2.13.
Metabolites from the P. falciparum wild-type 3D7 or PfATP6 F972Y strains, in absence or 
presence of SC83288 were extracted for further quantitative analysis by mass spectrometry. 
Briefly, 6 culture plates of 35 ml at a parasitemia in trophozoites stages (10 to 12 hours p.i.) 
of 5% were treated with a concentration of SC83288 corresponding to 5xIC50 (i.e. 40 nM), or 
with the respective amount of DMSO as negative control, for 12 hours. Parasites were then 
magnetically purified using the MACS system. In order to avoid a long detainment of the 
parasites in the magnetic column, the culture plates were purified three by three, and the 
eluted iRBC were kept in medium at 37°C upon regular addition of glucose. Once pooled 
together, the iRBC were centrifuged for 2 minutes at 2 100 rpm and washed once in 10 ml of 
pre-warmed PBS. The parasites were allowed to recover from the magnetic purification in 5 
ml of RPMI at 37°C for 1 hour, with regular glucose addition. The metabolism was 
subsequently quenched by exchanging the medium with 2 ml of ice-cold RPMI and kept on 
ice. For each sample, 3.107 parasites were transferred into a fresh eppendorf tube, 
centrifuged at 2 100 rpm for 2 minutes at 4°C and washed one more time with ice-cold PBS. 
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The complete supernatant was removed, and the pellet was quickly resuspended in 150 µl of 
extraction buffer (Chloroform/Methanol/H2O at a 1:3:1 ratio, approximately 15:1 ration of 
extraction buffer to pellet size). The samples were incubated in a vortex for 1 hour at 4°C, 
and centrifuged for 10 minutes at 13 000 rpm at 4°C. 100 µl of each sample was transferred 
into a fresh eppendorf tube, sealed and kept at -80°C until further analysis. The remaining 20 
µl of each sample were pooled together and centrifuged for 10 minutes at 13 000 rpm at 4°C. 
The supernatant was transferred into a fresh eppendorf tube, sealed and kept at -80°C until 
further analysis. The samples were shipped to Glasgow Polyomics Center (College of 
Medical, Veterinary & Life Sciences, University of Glasgow, Research group of Prof. Michael 
Barrett) for quantitative mass spectrometry analysis. 
 
 Data and statistical analysis 2.2.14.
All the data analysis and display were performed using SigmaPlot 13.0. 
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3. Results 
3.1. Characterization of the in vitro antiplasmodial activity of 
SC81458 and SC83288 
 Susceptibility of P. falciparum to SC81458 and SC83288  3.1.1.
To assess the in vitro parasite susceptibility to both the SC-lead compounds, the half 
maximal growth inhibitory concentrations (IC50) and the maximal concentrations to inhibit the 
growth of the parasites by 90 and 99% (IC90 and IC99, respectively) were determined for the 
Dd2 strain of P. falciparum.  Both compounds exhibited inhibitory concentrations in the low 
nanomolar range (Table 3.1) and steep dose-response curves [189].  
Table 3.1: Relevant activity parameters of SC81458, SC83288, artemisinin and 
atovaquone. 
 
SC81458 SC83288 Artemisinin Atovaquone 
IC
50
, IC
90
, IC
99
 (nM) 8, 18, 50 3, 8, 20 2, 6, 50 0.6, 0.9, 2  
in vitro PCT
99.9% 
 (h) 
(1)
 37 ± 4 51 ± 6 21 ± 3 .87 ± 7.0 
in vitro logPRR   3.4 ± 0.4   3.0 ± 0.5   4.5 ± 0.5 2.1 ± 0.4 
in vitro lag phase (h)  < 5 < 5 0 < 24 
in vitro PCT
90% 
 (h) 
(2)
 n.d. 17 ± 3 .11 ± 0.8 < 80 
Mean ± SEM of at least 4 independent determinations; (1) values obtained using a 
recrudescence assay described by Sanz et al. [198], (2) values obtained using the method 
described by Linares et al. [199]. IC, inhibitory concentration; PCT, parasite clearance time; 
PRR, parasite reduction ratio; n.d., non-determined. Adapted from Pegoraro et al. [189]. 
 
Previous work showed that if SC81458 and SC83288 displayed their highest antiparasitic 
activity against trophozoite stages, a slightly lower activity was observed against schizont-
stages and only a moderate one on ring-stages [189]. 
SC81458 and SC83288 were also found to be active against a range of other P. falciparum 
lab strains, including multi-drug resistant strains other than Dd2, consistently displaying IC50 
values lower than 20 nM in vitro [189]. 
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 SC81458 and SC83288 in vitro speed of action in P. 3.1.2.
falciparum 
The efficiency of antimalarial compounds to decrease the parasite load in the blood and cure 
patients is partially mediated through their speed of action. In order to evaluate how quickly 
the SC-lead compounds were able to kill the parasites in vitro, various methods were used.  
First, an approach based on parasites recrudescence was employed [198]. The principle is 
based on the determination of the parasites viability following drug exposure at a 10-fold IC50 
concentration for various periods of time. Parasite viability was assessed by monitoring the 
re-growth of exposed parasites over time. This method enabled the extraction of different 
information regarding the speed of action, such as the potential lag phase in the action of the 
compound, the parasite reduction ratio (PRR), i.e. the decrease of viable parasites over one 
life cycle of 48 hours, and the parasite clearance time (PCT99.9%), corresponding to the time 
needed to kill 99.9% of the parasites. Those parameters are summed up in Table 3.1 [189]. 
For comparison purpose, two marketed antimalarial drugs were also evaluated, namely 
artemisinin and atovaquone, as fast- and slow-acting reference drugs, respectively (Figure 
3.1 and [189]). 
 
Figure 3.1: In vitro speed of action profiles of SC81458 and SC83288 in comparison to 
licensed antimalarial drugs. Number of Dd2 P. falciparum parasites in response to drug 
treatment at concentrations corresponding to 10 times the IC50 of SC81458 (80 nM), 
SC83288 (30 nM), artemisinin (20 nM) and atovaquone (10 nM). According to the original 
protocol, results are presented in logarithmic form (log10) as “viable parasites +1” (34). Mean 
± SEM of at least 3 independent experiments. Adapted from Pegoraro et al. [189]. 
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SC81458 and SC83288 were able to clear 99.9% of the initial parasite population (PCT99.9%) 
within 37 ± 4 hours and 51 ± 6 hours, respectively, corresponding to a PRR of 3.4 ± 0.4 and 
3.0 ± 0.5 log phases over 48h (Table 3.1, Figure 3.1 and [189]). This assay classified the SC-
lead compounds as fast acting compounds, with a short lag phase of less than 5 hours, 
acting significantly faster than atovaquone (PCT99.9% = 89 ± 7 hours, PRR = 2.1 ± 0.4, lag 
phase of more than 24 hours), although still not as fast as artemisinin (PCT99.9% = 21 ± 3 
hours, PRR = 4.5 ± 0.5, no lag phase) (Table 3.1, Figure 3.1 and [189]). 
To further confirm the SC-lead compounds as fast-acting, the approach developed by Le 
Manach et al. [197] was applied. The IC50 values of asynchronous P. falciparum cultures over 
24, 48 and 72 hours were determined, and the IC50 ratios, normalized to the 72 hours value, 
were calculated. It is worth mentioning that this approach allows only a rough classification of 
the antimalarial compounds, as fast- or slow-acting, but does not compare the speed of 
action of one compound to the other. This assay validated SC81458 and SC83288 as fast-
acting compounds. Indeed, the relative IC50 ratios were independent of exposure time for 
both SC81458 (0.96 ± 0.08, 1.21 ± 0.16 and 1.00 ± 0.08, respectively for 24, 48 and 72 hours 
of incubation, One-way ANOVA Holm-Sidak test, p > 0.05, n.s.) and SC83288 (1.28 ± 0.08, 
1.24 ± 0.05 and 1.00 ± 0.06, respectively for 24, 48 and 72 hours of incubation, One-way 
ANOVA Holm-Sidak test, p >0.05, n.s.) (Figure 3.2), indicating a fast mode of action. 
Similarly, exposure time did not affect the IC50 ratios of artemisinin (0.98 ± 0.07, 0.88 ± 0.01 
and 1.00 ± 0.01, respectively for 24, 48 and 72 hours of incubation, One-way ANOVA Holm-
Sidak test, p > 0.05, n.s.) and quinine (1.19 ± 0.06, 1.24 ± 0.06 and 1.00 ± 0.06, respectively 
for 24, 48 and 72 hours of incubation, One-way ANOVA Holm-Sidak test, p > 0.05, n.s.). In 
comparison, the IC50 ratios of atovaquone were significantly different (3.44 ± 0.11, 1.35 ± 
0.05 and 1.00 ± 0.04, respectively for 24, 48 and 72 hours of incubation, One-way ANOVA 
Holm-Sidak test, p < 0.001, ***), consistent with atovaquone being a slow acting antimalarial 
drug (Figure 3.2). 
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Figure 3.2: IC50-based relative speed of action profiles of SC81458, SC83288, 
artemisinin, quinine and atovaquone. The assay was performed as described previously 
[197], on unsynchronized cultures of P. falciparum Dd2. Mean ± SEM of at least 4 
independent determinations. 
 
Finally, a third approach was used to evaluate the speed of action of SC83288, alone as well 
as in combination with artesunate or atovaquone, in the prospect of a potential combination 
therapy. The method described by Linares et al. [199] quantifies the new infections to back-
calculate the parasite viability, using a two-color flow cytometry analysis. As it does not rely 
on parasite re-growth, this assay is considerably shorter than the recrudescence assay, and 
limits the risk of contamination compromising the experiments. The results of this assay were 
consistent with the previous ones, marking SC83288 as a potent antimalarial compound, with 
a 90% parasite clearance time (PCT90%) of 17 ± 3 hours. In comparison, the measured 
PCT90% of artesunate and atovaquone were 11 ± 0.8 hours and > 80 hours, respectively 
(Figure 3.3 and Table 3.1). Combining artesunate and SC83288 did not lead to a significant 
difference in the PCT90% compared with artesunate alone (9 ± 0.5 hours, Student’s t-test, p > 
0.05, n.s.) (Figure 3.3). Similarly, combining SC83288 with atovaquone did not significantly 
alter the PCT90% of SC83288 alone (17 ± 6 hours Student’s t-test, p > 0.05, n.s.) (Figure 3.3).   
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Figure 3.3: Killing rate profiles for artesunate, atovaquone, SC83288 and combinations 
of artesunate+SC83288 and atovaquone+SC83288. The assay was performed as 
described previously [199] on unsynchronized cultures of P. falciparum Dd2. Viability profiles 
of parasites treated with concentrations corresponding to 10x the IC50 values of artesunate, 
atovaquone, SC83288 alone or in combinations. The number of viable infected erythrocytes 
was normalized using the number of untreated parasites. Mean ± SEM of 4 independent 
experiments. 
 
 
 Progression of P. falciparum over its life cycle upon SC83288 3.1.3.
treatment  
Giemsa (Figure 3.4 A) and Hoechst (Figure 3.4 B) stained smears of Dd2 P. falciparum 
parasites over their 48 hours life cycle revealed that early treatment, i.e. before 24 hours p.i., 
with a concentration corresponding to 10x the IC50 value of SC83288 appeared to cause an 
arrest of the parasite at the early trophozoite stage, possibly inhibiting the necessary DNA 
replication to further progress in the cycle. 
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Figure 3.4: Progression of Dd2 P. falciparum parasites over their life cycle in presence 
or absence of SC83288. Parasites were treated with a concentration of SC83288 
corresponding to 10x the IC50 value (30 nM) as early ring-stages (6 to 12 hours p.i.). (A) Thin 
blood smears were performed every 4 hours, shortly fixed in methanol, stained with Giemsa 
and further analyzed by light microscopy. (B) Parasites were harvested every 4 hours and 
analyzed by fluorescent microscopy after fixation and staining with the Hoechst DNA marker. 
Representative images of at least 3 independent experiments. Scale bar 5 µm. 
 
These qualitative observations were corroborated using flow cytometry, where the DNA 
content of the parasites was stained with SYBRGreen. This quantitative analysis confirmed 
the absence of DNA replication in the parasites when treated early in their life-cycle (up to 24 
hours p.i.) (Figure 3.5).  
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Figure 3.5: SC83288 fully inhibits DNA replication of Dd2 P. falciparum only when 
applied on early stages. Parasites were treated with a concentration of SC83288 
corresponding to 10x the IC50 value (30 nM), or with 200 μM pyrimethamine, starting at 
different time points of their life cycle (arrowheads of respective colors) and harvested every 
4 hours, up to 52 hours p.i. After fixation, permeabilization and light RNase A treatment, the 
parasites were stained with SYBRGreen and submitted to flow cytometry analysis. The C-
value was obtained by normalization to the signal corresponding to the single infection by 
ring stages at 2 hours p.i. Mean ± SEM of at least 3 independent experiments. 
 
However, when treated later (after 24 hours p.i.), the parasites still underwent DNA 
replication, even though not to the full extent, and their DNA content never dropped back as 
it should if the parasites were invading new erythrocytes and starting a new cycle as rings 
(Figure 3.5). 
The interference of SC83288 with the DNA replication process was further confirmed by a 
quantitative metabolomics analysis. 3D7 P. falciparum parasites were treated with a 
concentration of SC83288 corresponding to 5x IC50 (i.e. 40 nM) as young trophozoites (10 to 
12 hours p.i.) for 12 hours. These conditions were pre-determined to achieve a killing of half 
of the parasite´s population. 15 of the 32 detected metabolites involved in nucleotide 
metabolism showed a clear, yet non-significant on a Student´s T-test, increase when the 
parasites were treated with SC83288 compared to the untreated control (Figure 3.6 A). The 
distinct profiles of the nucleotide metabolites under the treated and untreated conditions were 
validated by the principal component analysis (PCA), with Eigenvectors almost diametrically 
opposed (Figure 3.6 B). 
Time post-invasion (h ± 2)
0 10 20 30 40 50 60
C
-v
a
lu
e
0
2
4
6
8
10
12
14
16
Pyrimethamine 
untreated
SC83288 applied at 6h p.i. 
SC83288 applied at 24h p.i. 
SC83288 applied at 28h p.i.
SC83288 applied at 30h p.i.
SC83288 applied at 32h p.i.
SC83288 applied at 36h p.i.
Results 
82 
 
 
Figure 3.6: Nucleotide metabolism profile of P. falciparum 3D7 parasites untreated or 
treated with 5x IC50 of SC83288. (A) Relative concentration fold change of various 
metabolites involved in nucleotide metabolism when treated with SC83288, normalized to the 
untreated parasites. Mean ± SEM of at 4 independent experiments. (B) Principal component 
analysis (PCA) of the metabolites involved in nucleotide metabolism when untreated and 
treated with SC83288. The biplot of the first two principal components is shown (PC 1 and 
PC 2) and the percentage of the total variance explained by each principal component is 
displayed in parenthesis. The Eigenvectors are represented as arrows (red, untreated; blue, 
SC83288-treated), and their amplitude was multiplicated by 5 for visualization purposes.  
 
 Profiling the SC-lead compounds against artemisinins 3.1.4.
Although artemisinin and its derivatives are established treatments against malaria [203], 
their mode of action is still a highly controversial subject [119,120]. Over the last decades, 
PfATP6 was discussed as a potential target of artemisinin [55,204], or to be involved in a 
resistance mechanism [61]. However, these hypotheses are now questioned [46,60] and 
resistance seems to rather be associated with mutation in the kelch13 protein in P. 
falciparum [205].  
Since similar observations and hypotheses were issued concerning SC81458 and SC83288 
with regard to PfATP6 [189], we investigated the possibility of a similar mode of action, and 
therefore and interaction between the SC-lead compounds and artemisinin. 
 
3.1.4.1. The SC-lead compounds do not interact with artemisinin 
The interaction profiles were established on P. falciparum Dd2 using a fixed-ratio 
isobologram approach [200]. This method is based on determining the IC50 values of two 
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individual drugs alone and the IC50 values of the two drugs in combination at different 
concentration ratios. In principle, the shift of a drug´s IC50 value assessed in combination 
compared to the one determined for this drug alone is indicative of the nature of the 
interaction between the two drugs. It is commonly accepted that a mean sum of fractional 
50% inhibitory concentrations (mean ΣFIC50) lower than 0.5 corresponds to a synergistic 
interaction, and higher than 1.5 to an antagonistic one [206]. A mean ΣFIC50 between these 
two cut-off values represents an indifferent interaction between the two investigated drugs. 
The arithmetical analysis revealed mean ΣFIC50 values of 0.99 ± 0.09 and 0.97 ± 0.06, 
respectively for SC81458 and SC83288, suggesting an indifferent interaction between 
artemisinin and the SC-lead compounds. The graphical analysis, obtained by plotting the 
pairs of fractional IC50 (FIC50) values of artemisinin and SC81458 or SC83288 for each 
combination, agreed with the arithmetical observation, following almost perfectly the diagonal 
trend line (fit to a linear curve with R2 = 0.944 and 0.972, respectively for SC81458 and 
SC83288), thereby corroborating the conclusion that both drugs do not interact with each 
other (Figure 3.7).  
                  
Figure 3.7: Indifferent interaction between artemisinin and the SC-lead compounds. 
Isobolograms showing the interaction between artemisinin and SC81458 (A) or SC83288 (B) 
in P. falciparum Dd2 parasites. The diagonal line represents an indifferent interaction of the 
two drugs. Mean ± SEM of 7 independent experiments. 
 
3.1.4.2. The SC-lead compounds show no cross-resistance with 
artemisinins 
The matter of cross-resistance between artemisinin and the SC-lead compounds was 
assessed using two independent approaches. First, the susceptibility to SC81458 and 
SC83288 of artemisinin-resistant parasites was evaluated, using the P. falciparum NF54 
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strain bearing an artificially introduced mutation in the kelch protein 13 (K13C580Y), an 
established marker of artemisinin resistance [161]. A significant difference in the artemisinin 
responsiveness in the wild-type NF54 line and the PfK13C580Y lines was observed, with IC50 
values of 20 ± 0.6 nM and 3.5 ± 1.3 nM, respectively (Student’s t-test, p < 0.001, ***). In 
comparison none were observed concerning the sensitivity to SC81458 (3.4 ± 0.6 nM and 
5.3 ± 0.7 nM, respectively, Student’s t-test, p > 0.05, n.s.) or SC83288 (5.1 ± 0.7 nM and 4.9 
± 0.8 nM, respectively, Student’s t-test, p > 0.05, n.s.) (Table 3.2).  
Conversely, the susceptibility to artemisinin of P. falciparum lines resistant to the SC-lead 
compounds was evaluated. The Dd2 P. falciparum parasites, selected in vitro with the SC-
lead compounds, described in details in Section 3.2 (Table 3.3 and [189], namely Dd2 SC81458 
and Dd2 SC83288) and the 3D7 P. falciparum genetically engineered to be resistant to the SC-
lead compounds, described in Section 3.2.3.1 (Table 3.4 and Figure 3.15, namely 3D7 
PfATP6 F972Y), were used to this purpose. Dd2 SC81458, Dd2 SC83288 and their parental Dd2 
strain revealed comparable IC50 values to artemisinin (3.8 ± 1.0 nM, 4.9 ± 0.5 nM, and 3.3 ± 
0.3 nM, respectively, Student’s t-test, p > 0.05, n.s.) (Table 3.2). Similarly, the IC50 values to 
artemisinin of 3D7 ATP6 F972Y and its parental line 3D7 showed no significant difference (18 ± 
0.9 nM and 11 ± 1.0 nM, respectively, Student’s t-test, p > 0.05, n.s.) (Table 3.2). 
Table 3.2: Susceptibility, expressed as IC50 values, of the NF54 WT and NF54        
PfK13 C580Y, Dd2 WT, Dd2 SC81458, Dd2 SC83288, 3D7 WT and 3D7 ATP6 F972Y P. falciparum 
lines to SC81548, SC83288 and artemisinin. 
Line 
IC
50
 (nM) 
SC81458 SC83288 Artemisinin 
NF54 WT 003.4 ± 0.60*  005.1 ± 0.70*  .20 ± 0.6 * 
NF54 PfK13 
C580Y
 005.3 ± 0.70*  004.9 ± 0.80*  .35 ± 1.3 * 
Dd2 WT 008.1 ± 0.50* 003.1 ± 0.20*  3.3 ± 0.3 * 
Dd2 
SC81458
 .1200 ± 900.* .1000 ± 100.* 3.8 ± 1.0 * 
Dd2 
SC83288
 .6200 ± 700.* .1000 ± 200.* 4.9 ± 0.5 * 
3D7 WT 005.6 ± 0.60*  008.2 ± 2.00* .11 ± 1.0 * 
3D7 ATP6
 F972Y
 .3600 ± 300.* .5000 ± 300.* .18 ± 0.9 * 
Mean ± SEM of 6 to 13 independent determinations. *, p < 0.001 as compared with the 
parental strain. 
 
A ring survival assay (RSA) was further performed to take into account the activity of 
artemisinin against the ring stages of P. falciparum [161]. As expected, the NF54 PfK13 C580Y 
line showed a significant difference in its RSA score to dihydroartemisinin (DHA) compared 
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to its parental line (RSA score of 11.5 ± 1.51 % and 24.1 ± 1.87 %, respectively, Student’s t-
test, p < 0.001, ***). In comparison, various SC-resistant parasite lines displayed low and 
comparable RSA scores with respect to their parental lines (RSA scores of 9.94 ± 2.66 %, 
12.0 ± 0.99 % and 7.65 ± 0.31%, for the wild-type Dd2, Dd2SC81458 and Dd2SC83288, 
respectively, One-way ANOVA Holm-Sidak test, p > 0.05, n.s.; RSA scores of 11.6 ± 3.41 %, 
13.8 ± 2.12 %, for the wild-type 3D7 and 3D7 PfATP6 F972Y, respectively, One-way ANOVA 
Holm-Sidak test, p > 0.05, n.s.) (Figure 3.8). The data from these two independent assays 
strongly suggest against any kind of cross-resistance effects between artemisinins and the 
SC-lead compounds. 
                      
Figure 3.8: Ring survival rate to dihydroartemisinin (DHA). RSA scores of different P. 
falciparum strains: NF54, wild-type (WT) or bearing the PfK13 C580Y mutation; Dd2, wild-type 
(WT) or the in vitro-generated parasites resistant to 1 μM of either SC81458 or SC83288; 
3D7, wild-type (WT) or bearing the PfATP6 F972Y mutation, to DHA. Mean ± SEM of 3 to 6 
independent determinations; ***, p < 0.001. 
 
Considering the similar parasite clearance time of the artesunate + SC83288 combination, 
compared to artesunate alone (Figure 3.3), the indifferent interaction and the lack of cross-
resistance firmly point toward distinct modes of action and resistance between the SC-lead 
compounds and artemisinins. 
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3.2. Investigation of the role of PfTAP6 and calcium 
homeostasis with respect to the SC-lead compounds 
mode of action and resistance mechanism 
 
Preceding the work presented here, and in order to obtain insights into the mode of action of 
the SC-lead compounds and into the mechanisms by which the parasites could develop 
resistance, P. falciparum Dd2 parasites were selected under gradual increase of SC81458 or 
SC83288 concentration (from 50 nM up to 1 µM), during a period of approximately 240 days 
[189]. All selected lines, namely Dd2 SC81458 and Dd2 SC83288, showed a cross-resistance to the 
two SC-lead compounds, suggesting a shared mode of action and/or similar mechanism of 
resistance from the parasite [189]. Importantly, resistance to the SC-lead compounds did not 
decrease the susceptibility to various licensed antimalarial drugs (Table 3.3 and [189]). 
Table 3.3: Susceptibility, expressed as IC50 values, of the in vitro developed SC-lead 
compounds resistant Dd2 P. falciparum lines to various licensed drugs. 
Drug 
IC50 (nM) 
Dd2
SC81458
 Dd2
SC83288
 Dd2 WT 
Chloroquine .00150 ± 12.00 .00120 ± 25.00 .00135 ± 21.00 
Quinine .00160 ± 10.00 .00094 ± 9.000 .00100 ± 10.00 
Quinidine .00026 ± 1.000 .00009 ± 0.400 .00015 ± 1.000 
Mefloquine .00018 ± 1.000 .00006 ± 0.400 .00004 ± 0.100 
Pyrimethamine .31000 ± 2000. 22000 ± 2000 22000 ± 2000 
Amodiaquine .00008 ± 3.000 .00005 ± 1.000 .00007 ± 1.000 
Artemisinin .00004 ± 1.000 .00005 ± 0.500 .00003 ± 0.300 
Atovaquone 0000.3 ± 0.100 0000.8 ± 0.100 0000.6 ± 0.100 
Mean ± SEM of 5 independent determinations. Adapted from Pegoraro et al. [189]. 
 
All selected clones were submitted to ultra-deep sequencing analysis to identify genomic 
differences between the sensitive and the SC-lead compounds resistance parasites. A copy 
number variation (CNV) in chromosome 1, as well as several single nucleotide 
polymorphisms (SNPs) were consistently detected in the selected clones [189]. These SNPs 
led to mutations in the genes encoding the multi-drug resistance transporter 2 (PfMDR2, 
Pf3D7_1447900), a putative ATP-dependent RNA helicase DBP9 (Pf3D7_1241800), and the 
Ca2+ transporting PfATP6 (Pf3D7_0106300). The pfatp6 locus and its upstream flanking 
region on chromosome 1 were duplicated in the Dd2 SC83288 lines, and SNPs in the amplified 
pfatp6 sequence were identified, leading to the substitution of the two consecutive alanine 
residues at positions 108 and 109 into threonines within the second transmembrane domain 
of PfATP6 (Figure 3.9) [189]. Five others identified genes were also present in this amplified 
locus, three of those annotated to encode conserved Plasmodium proteins of unknown 
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function (Pf3D7_0105800, Pf3D7_0106000 and Pf3D7_0106200), a putative DNA binding 
protein (Pf3D7_0105900), and a putative V-type proton ATPase subunit C (Pf3D7_0106100) 
(http://PlasmoDB.org). Additionally, another polymorphism was identified in the Dd2 SC81458 
lines, leading to the substitution of a phenylalanine residue at position 972 into tyrosine within 
the fifth transmembrane domain of PfATP6 (Figure 3.9) [189]. The presence of both point 
mutations and gene amplification was striking and led us to investigate the role of PfATP6 in 
the development of resistance to SC81458 and SC83288, as well as their mode of action(s). 
 
Figure 3.9: Predicted topological model of PfATP6. Reconstruction using the open-source 
visualization tool Protter [49], based on the model described in [50]. This model highlights the 
mutations in the amino acid sequence caused by the single nucleotide polymorphisms 
identified in the in vitro developed SC-lead compounds resistant Dd2 P. falciparum clones: 
the double mutation A108T, A109T in the second transmembrane domain found in the 
Dd2SC83288 line, and the F972Y mutation in the fifth transmembrane domain found in the 
DD2SC81458 line. 
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 PfATP6 is not a direct molecular target of the SC-lead 3.2.1.
compounds 
To investigate PfATP6 as a potential biological target, dynamic changes in cytoplasmic free 
Ca2+ levels were monitored using the Ca2+ sensitive fluorochrome Fluo-4-AM in a live cell 
confocal setup. The cell-permeable, established and reversible inhibitor of PfATP6 
cyclopiazonic acid (CPA) [207] was used as a positive control, and the Na+/K+ ATPase 
inhibitor ouabain as a negative control.  
Under those conditions, treatment of the P. falciparum HB3 parasites with 10 μM of SC81458 
or SC83288 resulted in no significant increase in cytoplasmic free Ca2+ (mean F75/F0 ratio 
0.98 ± 0.10 and 0.99 ± 0.09, respectively), as opposed to the response induced by 10 μM of 
CPA (mean F75/F0 ratio 1.55 ± 0.15). The Na
+/K+ ATPase inhibitor ouabain (10 μM) had no 
effect on the cytoplasmic Ca2+ concentration in the parasite (mean F75/F0 ratio 0.99 ± 0. 04) 
(Figure 3.10).  
        
Figure 3.10: SC81458 and SC83388 induced cytoplasmic Ca2+ responses in P. 
falciparum. Trophozoite stages of HB3 P. falciparum strain were stained with Fluo-4-AM (10 
μM) and transient cytoplasmic Ca2+ levels were recorded in response to SC81458 (10 μM), 
SC83288 (10 μM), ouabain (10 μM), and CPA (10 μM), using a confocal live cell setup. (A) 
Representative Ca2+ traces in the parasite’s cytoplasm. The mean fluorescence intensity (F) 
was normalized to the fluorescence intensity at time point zero (F0). (B) Mean fluorescence 
intensity at time point 75 seconds (F75) normalized to the fluorescence intensity at time point 
zero (F0). Mean ± SEM of at least 4 independent experiments with at least four 
determinations in each replicate. One-way ANOVA, p < 0.001, ***. Adapted from Pegoraro et 
al. [189]. 
 
To confirm the live calcium observations, a different approach was used. SC81458 and 
SC83288 were sent to our collaborators at St George’s University of London (Prof. Sanjeev 
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Krishna´s group), to investigate PfATP6 as a direct target in a different experimental system. 
The compounds were tested in K667 Saccharomyces cerevisiae, lacking the endogenous 
vacuolar Ca2+ exchanger Vcx1, calcineurin regulatory subunit B cnb1 and the vacuolar 
calcium pump Pmc1 [70,208]. Only the heterologous expression of PfATP6 allows these 
yeasts to tolerate high calcium levels. Dose-response assays (experiments performed by 
Hatoon Abdullah Niyazi) showed no direct inhibition of PfATP6 by the SC-lead compounds 
(Figure 3.11). Indeed, concentrations of up to 10-2 M of SC83288 (Figure 3.11 B) or SC81458 
(Figure 3.11 C), did not interfere with S. cerevisiae growth, as opposed to a concentration 
higher than 10-5 M of CPA (Figure 3.11 A). 
Figure 3.11: Effect of CPA, SC83288 and SC81458 on high calcium concentration 
tolerance on knock-out S. cerevisiae. Dose-response assays using the S. cerevisiae 
knock-out of the endogenous vacuolar Ca2+ exchanger Vcx1, calcineurin regulatory subunit B 
cnb1 and the vacuolar calcium pump Pmc1, to CPA (A), SC83288 (B) and SC81458 (C) 
when transfected with PfATP6 or a control empty plasmid pUG. Mean ± SEM of 3 
independent experiments, performed by Hatoon Abdullah Niyazi (St George’s University of 
London, UK). 
 
These observations are not consistent with SC81458 and SC83288 directly targeting 
PfATP6, but rather tend to suggest an involvement of PfATP6 in a mechanism of resistance 
to those compounds. 
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 Use of the CRISPR/Cas9 system for genetically engineering 3.2.2.
PfATP6 
Even though it was ruled out as a direct target for SC81458 or SC83288, PfATP6 was kept 
under investigation for a possible role in the resistance mechanisms to those compounds. In 
order to properly correlate the identified SNPs in PfATP6 in the Dd2 SC81458 and Dd2 SC83288 
lines with SC-lead compounds resistance, the CRISPR-Cas9 system was used to introduce 
these mutations into the P. falciparum genome in a marker-free fashion [78] (Figure 3.12).  
 
Figure 3.12: General CRISPR-Cas9 strategy used to mutate PfATP6. The vector pUF1-
Cas9 (left) encodes the Cas9 endonuclease (light blue) flanked by nuclear localization 
signals (NLS, green). Its expression is regulated by the promoter region of the heat shock 
protein 86 (5’ hsp, orange) and the 3’UTR region of the P. berghei dhfr (3’ Pb dhfr, orange). 
The selection marker of the plasmid is the yeast dihydroorotate dehydrogenase gene 
(ydhodh, grey). The pL6 plasmid (right) contains the single-guide RNA (sgRNA)-expression 
cassette. The expression of the sgRNA is regulated by the promoter of the P. falciparum U6 
snRNA polymerase III (5’ U6, orange) and the 3’UTR region (orange). The homology region 
(dark blue) contains the desired mutation(s) (blue star) as well as the necessary shield 
mutation(s) (red star). The selection marker of the plasmid is the human dihydrofolate 
reductase gene (hdhfr, grey) and the negative selection marker is the bifunctional yeast 
cytosine deaminase and uridyl phosphoribosyl transferase (yfcu). Both plasmids are 
transfected together in P. falciparum parasites by electroporation. 
 
After several trials, the parasites transfected with the plasmid containing the mutations 
coding for the A108T, A109T substitutions never showed recombination events (Figure 3.13).  
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Figure 3.13: Attempted generation of the PfATP6 A108T, A109T mutant using the 
CRISPR/Cas9 system. (A) Target sequence recognized by sgRNAatp6:Cas9 highlighting the 
20-nucleotide guide sequence and the PAM motif (top). Modified locus showing the desired 
mutations (blue) to generate the A108T, A109T replacement. In this case, both the desired 
mutations play also the role of shield mutations, as they directly overlap with the sgRNA 
guide (bottom). (B) Chromatogram showing the sequence analysis of the resulting 
transfectants. The DNA sequence and consequently the amino acid sequence remained 
unchanged. Representative of 6 independent transfection rounds. 
 
A single control transfection with a plasmid encoding for synonymous mutations led to a 
successful recombination, demonstrating a proper activity of the designed RNA guide (Figure 
3.14). This observation suggests that the double mutation is probably not viable on its own, 
and the parasites must rely on other compensatory mutations to survive.  
This approach was however successful for introducing the mutation leading to the 
substitution of the phenylalanine at position 972 into tyrosine in the endogenous locus of 
pfatp6 (Figure 3.15). Two pure clones, namely #E4 and #H12, were obtained by limiting 
dilution and used for characterization and further experiments. 
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Figure 3.14: Generation of the PfATP6 A108A, A109A mutant using the CRISPR/Cas9 
system and sgRNA guide efficiency confirmation. (A) Target sequence recognized by 
sgRNAatp6:Cas9 highlighting the 20-nucleotide guide sequence and the PAM motif (top). 
Modified locus showing the desired silent-mutations (blue) to generate the A108A, A109A 
replacement. In this case, both the desired mutations play also the role of shield mutations, 
as they directly overlap with the sgRNA guide (bottom). (B) Chromatogram showing the 
sequence analysis of the resulting transfectants. The presence of the silent mutations 
demonstrated a successful recombination event, testifying for the sgRNA efficiency. 
 
 
Figure 3.15: Generation of the PfATP6 F972Y mutant using the CRISPR/Cas9 system. 
(A) Target sequence recognized by sgRNAatp6:Cas9 highlighting the 20-nucleotide guide 
sequence and the PAM motif (top). Modified locus showing the desired silent-mutations 
(blue) to generate the F972Y replacement and the necessary shield mutations (red) (bottom). 
(B) Chromatogram showing the sequence analysis of the resulting transfectants. The 
presence of the desired and silent mutations demonstrated a successful recombination 
event. The designed amino acid change is highlighted in bold. 
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 Characterization of the 3D7 PfATP6 F972Y mutant line 3.2.3.
3.2.3.1. P. falciparum 3D7 PfATP6 F972Y susceptibility to SC81458 and 
SC83288 
To assess the effect of the F972Y mutation in PfATP6 on the susceptibility of the parasite to 
the SC-lead compounds, the IC50 value was determined for both SC81458 and SC83288. 
The sensitivity to chloroquine was evaluated in parallel as a control. 
Table 3.4: Susceptibility, expressed as IC50 values, of the 3D7 WT and 3D7
PfATP6 F972Y to 
SC81548, SC83288 and chloroquine. 
Line 
IC
50
 (nM) 
SC81458 SC83288 Chloroquine 
3D7
WT
 005.6 ± 0.60 008.2 ± 2.00 8.6 ± 0.4 
3D7 ATP6
 F972Y
 .3600 ± 300. .5000 ± 300. 7.9 ± 0.5 
The values obtained for the #E4 and #H12 pure clones were combined. Mean ± SEM of 3 to 
6 independent determinations. 
 
The presence of the F972Y mutation led to a drastic effect, i.e. an increase of approximately 
three orders of magnitude on the IC50 values for SC83288 (8.2 ± 2.0 nM and 5.0 ± 0.3 µM, 
for the wild-type and the mutant, respectively, Student‘s t-test, p < 0.001, ***) (Figure 3.16  A 
and C, Table 3.4), and SC81458 (5.6 ± 0.6 nM and 3.6 ± 0.3 µM, for the wild-type and the 
mutant, respectively, Student‘s t-test, p < 0.001, ***) (Figure 3.16 B and C, Table 3.4). The 
susceptibility to chloroquine was not affected by the introduction of the F972Y mutation (IC50 
values of 86 ± 0.4 nM and 79 ± 0.4 nM, for the wild-type and the mutant, respectively, 
Student‘s t-test, p > 0.05, n.s.). 
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Figure 3.16: Susceptibility of the 3D7 wild-type and 3D7 PfATP6 F972Y P. falciparum 
parasites to SC81548, SC83288 and chloroquine. (A and B) Growth inhibition assay by 
SC83288 (A) or SC81458 (B) for the wild-type (WT) and both 3D7 PfATP6 F972Y clones (#E4 
and #H12). (C)  IC50 values obtained from the growth inhibition assays, by combining the 
results obtained by the two mutant clones for SC81458, SC83288 and chloroquine (CQ) as a 
control. Mean ± SEM of 3 to 6 independent determinations, One-way ANOVA, p < 0.001, ***. 
 
Additionally, the ring sensitivity of the mutant parasites to the SC-lead compounds was 
evaluated by performing a ring survival assay (RSA), as previously described [161]. No 
significant difference was observed in the ring-stage susceptibility of the wild-type or mutant 
parasites to SC81458 (RSA score of 94.5 ± 11.9 %, 109 ± 6.54 % and 109 ± 6.11 %, 
respectively for the wild-type and the two mutant clones, One-way ANOVA, p > 0.05, n.s.)  
(Figure 3.17 A) or SC83288 (RSA score of 90.5 ± 1.16 %, 111 ± 19.4 % and 94.3 ± 3.84 %, 
respectively for the wild-type and the two mutant clones, One-way ANOVA, p > 0.05, n.s.) 
(Figure 3.17 B). 
A B C 
SC83288 (M)
10-1010-910-810-710-610-510-410-3
P
a
ra
s
it
e
 G
ro
w
th
 (
%
)
0
20
40
60
80
100
120
3D7 WT
F 3D7 ATP6 F972Y #E4 3D7 ATP6 F972Y #H12
SC81458 (M)
10-1010-910-810-710-610-510-410-3
W
T
AT
P6
 
F9
72
Y
IC
5
0
 (
M
)
10-9
10-8
10-7
10-6
10-5
10-4
CQ 
SC81458 
SC83288 
***
***
Results 
95 
 
Time post-invasion (h ± 2)
0 10 20 30 40 50 60
C
-v
a
lu
e
0
5
10
15
20 WT untreated 
WT SC83288 
PfATP6 F972Y 
untreated 
PfATP6 F972Y 
SC83288
 
Figure 3.17: Ring survival rate of 3D7 wild-type and 3D7 PfATP6 F972Y P. falciparum 
parasites.  RSA score of wild-type (WT) and both 3D7 PfATP6 F972Y clones (#E4 and #H12) 
in response to a 6 hours pulse treatment of 700 nM of SC81458 (A) and SC83288 (B). Mean 
± SEM of 3 to 6 independent determinations. 
 
Finally, wild-type or mutant parasites were treated with a concentration of SC83288 
corresponding to 10x the IC50 value on the wild-type (i.e. 80 nM) as ring stages, and their 
DNA content was followed by flow cytometry over their life cycle. While the SC83288-treated 
wild-type P. falciparum parasites did not show DNA replication, the mutants, treated with or 
without SC83288, behaved similarly to the non-treated wild-type line, undergoing schizogony 
as suggested by the increase of their DNA content over time, and by the sudden drop around 
48 hours post-invasion corresponding to the beginning of a new cycle as ring stages (Figure 
3.18). 
Figure 3.18: Progression of 3D7 wild-type 
and 3D7 PfATP6 F972Y P. falciparum 
parasites over their life cycle in presence 
of absence of SC83288. Parasites were 
treated with a concentration of SC83288 
corresponding to 10x the IC50 value (80 nM) 
as ring-stages (approximately 20 hours p.i., 
arrowhead) and harvested every 4 hours, up 
to 60 hours p.i. After fixation, permeabilization 
and light RNase A treatment, the parasites 
were stained with SYBRGreen and submitted 
to flow cytometry analysis. The C-value was 
obtained by normalization to the signal 
corresponding to the single infection by ring 
stages at 20 hours p.i. Mean ± SD of 
technical duplicates of one experiment. 
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3.2.3.2. The PfATP6 F972Y mutation gives rise to a fitness cost related to 
calcium homeostasis 
To measure the extent to which the PfATP6 F972Y mutation influenced the relative growth rate 
of asexual blood stage parasites and serving as a partial proxy for assessing fitness costs, 
an in vitro co-culture competition assay was performed, as previously described [209,210]. 
Briefly, the wild-type 3D7 line was mixed with the 3D7 ATP6 F972Y clones at a 1:1 ratio and 
the proportions of the individual pfap6 alleles were quantified by pyrosequencing every 2 
cycles (i.e. every 4 days), over a period of 20 cycles. Results were fit to a linear function of 
the relative proportion of the wild-type or the mutated pfatp6 alleles over time (y = (55.5 ± 4) 
+ (1.6 ± 0.4) * x, with an R2 = 0.675; y = (43.7 ± 4) - (1.5 ± 0.4) * x, with an R2 = 0.658 for the 
wild-type and the mutated pfatp6 alleles respectively) (Figure 3.19). The PfATP6 F972Y 
mutations led to a growth deficiency compared to the wild-type line, which was predicted to 
completely take over the mutant line in approximately 29 cycles.  
              
Figure 3.19: Effect of the PfATP6 F972Y mutation on the parasite fitness. Mixed cultures at 
a 1:1 ratio between 3D7 wild-type (WT) and 3D7 PfATP6 F972Y were cultured over 20 cycles. 
The allelic proportions of pfatp6 were measured by pyrosequecning every 2 cycles. The 
proportion of 3D7 WT in the cultures overtime is represented in black (left y-axis) and the 
proportion of the 3D7 PfATP6 F972Y allele in dark blue (right y-axis). Results were fit to a linear 
function of the relative proportion of the wild-type or the mutated pfatp6 alleles over time. 
Mean ± SEM of 3 independent determinations. 
 
Considering the role of PfATP6 in the parasite calcium homeostasis, it was tempting to 
speculate on a possible alteration of the calcium resting concentration in the mutant 
parasites. 
In order to quantitatively measure the cytosolic calcium resting concentration in the wild-type 
and PfATP6 F972Y 3D7 P. falciparum parasites, the ratiometric dye Fura-Red-AM was used 
Cycles
0 4 8 12 16 20P
ro
p
o
rt
io
n
 o
f 
3
D
7
 W
T
 g
D
N
A
 (
%
)
0
20
40
60
80
100
P
ro
p
o
rt
io
n
 o
f 
3
D
7
 P
fA
T
P
6
 F
9
7
2
Y
 
g
D
N
A
 (
%
)
0
20
40
60
80
100
Results 
97 
 
[202].  The Ca2+ fluorophore Fura-Red can be excited using an argon laser at 458 and 488 
nm. Unlike most other Ca2+ indicators, Fura-Red fluorescence decreases upon binding to 
free Ca2+, and the fluorescence ratio (F458/488 nm) increases with rising free Ca
2+ 
concentrations. Parasites were stained with Fura-Red-AM and stable fluorescence intensities 
(F458 nm and F488 nm) were recorded in the cell cytoplasm (Figure 3.20). 
               
Figure 3.20: Confocal live cell Fura-Red-AM imaging of P. falciparum infected 
erythrocytes. Representative trophozoite stage 3D7 P. falciparum infected erythrocyte 
stained Fura-Red-AM, excited at 458 nm (0.15% laser intensity) and 488 nm (0.04% laser 
intensity). Scale bar 5 µm. 
 
First, this method was validated on Dd2 P. falciparum parasites. A calibration curve was 
established using free Ca2+ concentrations ranging from 0.6 nM to 1.2 mM (Figure 3.21 A), 
and was used to quantify the free calcium resting concentration in the cytosol of untreated 
parasites, or in presence of 30 µM of CPA (Figure 3.21 B and Table 3.5). The measurement 
of 97 cells allowed determining a calcium resting concentration in untreated Dd2 P. 
falciparum of 308 ± 82 nM, consistent with the value of 352 ± 42 nM previously reported 
[202]. As expected, short treatment with CPA led to a significant increase in the cytosolic free 
calcium concentration, to 840 ± 83 nM (for 43 cells measured) (Rank Sum test, p < 0.001, 
***) (Figure 3.21 B).  
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Figure 3.21: Calibration of Fura-Red-AM fluorescence and determination of apparent 
resting free Ca2+ concentration in the P. falciparum Dd2 cytoplasm. (A) Ca2+ 
equilibration curve for the steady-state Fura-Red-AM fluorescence ratio (458/488 nm) from 
the cytoplasm of Dd2 P. falciparum parasites at the young-trophozoite stage. Cells were 
permeabilized with the Ca2+ ionophore ionomycin and adjusted to the indicated free-Ca2+ 
concentrations. N corresponds to the total number of measured cells. (B) Mean apparent 
cytoplasmic resting Ca2+ ([Ca2+]) concentrations in absence or presence of the PfATP6 
inhibitor CPA. Mean ± SEM of respectively 97 and 43 independent determinations. Rank 
Sum test, p < 0.001, ***. 
 
These preliminary experiments confirmed the use of FuraRed as a reliable method to 
measure cytosolic calcium concentration in a quantitative manner.  
This approach was then used on the P. falciparum 3D7 wild-type and PfATP6 F972Y parasites, 
in presence or absence of SC83288. Preliminary experiments were first conducted to 
determine the appropriate SC83288 concentration and time of treatment that would affect the 
parasite viability on the long term, i.e. one cycle, but not within the experimental measuring 
time. From both the recrudescence and the direct speed of action assays, we knew that a 
concentration corresponding to 10 times the IC50 value was already sufficient to obtain a 
PCT99.9% of approximately 50 hours. To ensure a similar effect even after a short treatment 
time, a concentration corresponding to 50 times the IC50 concentration (i.e. 400 nM in the 
3D7 strain) for 1 hour was used. Such a treatment resulted in the death of the SC83288-
sensitive parasites on the next day, as demonstrated by the absence of ring stages (Figure 
3.22 A), without affecting the PfATP6 F972Y line (Figure 3.22 B). 
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Figure 3.22: Morphological appearance of P. falciparum 3D7 wild-type and PfATP6 F972Y 
mutant after a SC83288 pulse treatment. P. falciparum 3D7 wild-type (WT) (A) or 
PfATP6F972Y mutant (B) parasites were treated with 50x IC50 concentration of SC83288 (400 
nM) for 1 hour before removal of the compound. Parasites were further incubated for 24 
hours and Giemsa-stained smears were produced. WT parasites appeared as arrested 
trophozoites, whereas the PfATP6 F972Y mutants progressed into a new life cycle as ring 
stages. 
 
However, after 1 hour of treatment, both the wild-type and the PfATP6 F972Y mutant were 
alive, with intact membranes, as confirmed by cFDA-SE (Figure 3.23 A and B) and 
MitoTracker (Figure 3.23 C and D) staining, and were metabolically active, as shown by ATP 
level measurements (Figure 3.24).  
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Figure 3.23: Integrity of P. falciparum 3D7 wild-type and PfATP6 F972Y mutant after a 
SC83288 pulse treatment. P. falciparum 3D7 wild-type (WT) (A and C) and PfATP6 F972Y 
mutant (B and D) parasites were treated with 50x IC50 concentration of SC83288 (400 nM) 
for 1 hour. Parasites were fixed and permeabilized and further stained either with cFDA (10 
µM) (A and B) for membrane integrity or with Mitotracker (80 nM) (C and D) fluorescent dyes 
for 1 hour before imaging. No differences in staining pattern or intensity are noteworthy 
between the WT and the PfATP6 F972Y mutant. Scale bar 5 µm.  
                             
Figure 3.24: Variation in ATP levels in P. 
falciparum 3D7 wild-type and PfATP6 F972Y 
mutant after a SC83288 pulse treatment. 
P. falciparum 3D7 wild-type (WT) or PfATP6 
F972Y mutant parasites were treated with 50x 
IC50 concentration of SC83288 (400 nM) for 1 
hour. Parasites were magnetically enriched 
for trophozoite stages and their ATP content 
was determined using a luminescence-based 
approach (ATP Bioluminescence Assay Kit 
CLS II, Roche). Mean ± SD of technical 
duplicates. 
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A treatment with a concentration corresponding to 50x IC50 of SC83288 for 1 hour was then 
considered appropriate for cytosolic calcium measurement. In a similar manner as for the 
Dd2 strain, a calibration curve was established using free Ca2+ concentrations ranging from 
0.6 nM to 1.2 mM in 3D7 P. falciparum parasites (Figure 3.25 A). A significantly lower free 
cytosolic calcium concentration was observed in the PfATP6 F972Y line compared to the wild-
type (299 ± 35 nM versus 550 ± 31 nM, for the PfATP6 F972Y and the wild-type respectively, 
measured on 310 and 361 cells, Rank Sum test, p <0.001, ***) (Figure 3.25 B and Table 3.5). 
If the wild-type parasites displayed no difference in their calcium level when treated with 
SC83288 (441 ± 37 nM, measured on 310 cells, Rank Sum test, p > 0.05, n.s.), the PfATP6 
F972Y mutants showed a significant increase in their calcium concentration upon SC83288 
treatment (610 ± 27 nM, measured on 369 cells, Rank Sum test, p < 0.001, ***) (Figure 3.25 
B and Table 3.5), reaching back the basal level. 
       
Figure 3.25: Calibration of Fura-Red-AM fluorescence and determination of apparent 
resting free Ca2+ concentration in the P. falciparum 3D7 wild-type and PfATP6 F972Y 
mutant cytoplasm. (A) Ca2+ equilibration curve for the steady-state Fura-Red-AM 
fluorescence ratio (458/488 nm) from the cytoplasm of 3D7 P. falciparum parasites at the 
young-trophozoite stage. Cells were permeabilized with the Ca2+ ionophore ionomycin and 
adjusted to the indicated free-Ca2+ concentrations. N corresponds to the number of 
independent experiments, and n to the total number of measured cells. (B) Mean apparent 
cytoplasmic resting Ca2+ ([Ca2+]) concentrations in untreated or SC83288-treated parasites. 
Mean ± SEM of respectively 361, 310, 349 and 369 independent determinations. Rank Sum 
test, p < 0.001, ***. 
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Finally, all lines, untreated or pre-treated with SC83288, showed the expected significant 
increase in their cytosolic free calcium concentration in response to brief CPA exposure 
(Figure 3.25 and Table 3.5). 
Table 3.5: Measured free cytosolic calcium concentration ([Ca2+)free] in P. falciparum 
Dd2, 3D7 wild-type and PfATP6 F972Y mutant. 
Strain/Line 
[Ca
2+
]
free
 (nM) 
Untreated SC83288 (400 nM) CPA (30 µM) SC83288 + CPA 
3D7 WT 550 ± 31 (361) 441 ± 37 (310) 1311 ± 219 (113) 1279 ± 215 (101) 
3D7 PfATP6 
F972Y
 299 ± 35 (349) 610 ± 27 (369) 901 ± 151 (98) 1863 ± 316 (83)0 
Dd2 WT 308 ± 82 (97)0 - 840 ± 83 (43)0 - 
 
Mean ± SEM of (n) measured cells. 
 
The lower cytoplasmic Ca2+ concentration in the PfATP6 F972Y mutant suggests a higher 
ATPase activity of the mutated PfATP6 compared to its wild-type variant. This hypothesis 
further awaits confirmation in the S. cerevisiae complementation model. 
 
 Overexpression of the PfATP6 T108, T109 variant in P. 3.2.4.
falciparum is altering the susceptibility to SC83288 
Episomal transfection was used to overexpress the wild-type variant of PfATP6 (ATP6 WT) 
(Figure 3.26 A) in the Dd2 P. falciparum parasite, and the PfATP6 A108T, A109T variant 
(ATP6 A108T, A109T) (Figure 3.26 B) as an alternative to CRISPR-Cas9 genome editing. 
The respective coding sequences of PfATP6 were C-terminally fused to a hemagglutinin 
(HA) tag, and episomaly expressed under the control of the PFC0005w promoter [211].  
 
Figure 3.26: PfATP6 variants overexpression strategy. The plasmid pHBIRH encodes the 
S. cerevisiae codon-optimized pfatp6 sequence (purple), wild-type (A) or bearing the 
mutations coding for the A108T, A109T (B), fused with a hemagglutinin tag (HA, red) on the 
C-terminal end. The selection marker of the plasmid is the blasticidin-S-deaminase gene 
(BSD, grey). Their expression is regulated by a bi-directional P. falciparum promoter (intron 
of PFC0005w). Both plasmids are transfected in Dd2 P. falciparum parasites by 
electroporation. 
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After transfection by electroporation, the parasites were selected with concentrations of 2.5 
µg/ml (mild selection) or 15 µg/ml (high selection) of blasticidin. The overexpression of 
PfATP6 was confirmed both on the transcript level by RT-qPCT (relative transcript levels to 
wild-type 1.01 ± 0.003, 3.51 ± 0.20 and 1.60 ± 0.19 for P. falciparum Dd2 wild-type (WT) or 
transfected with the pHBIRH-ATP(WT)-HA or pHBIRH-ATP6(A108T, A109T)-HA plasmids, 
respectively) (Figure 3.27 A) and on the protein level by western blot analysis, by detecting 
the C-terminal HA-tag (Figure 3.27 B). 
                             
Figure 3.27: Episomal overexpression of PfATP6 variants in Dd2 P. falciparum 
parasites. (A) Transcript levels of pfatp6. Levels of pfatp6 transcripts measured by RT-
qPCR in wild-type (WT) parasites or transfected with the pHBIRH-ATP6(A108T, A109T)-HA 
or pHBIRH-ATP(WT)-HA plasmids. Mean ± SEM of 3 independent determinations (3 
independent mRNA isolations on late-stage parasites), normalized to the wild-type (WT). 
Tubulin was used as a housekeeping gene for calibration. (B) Western blot analysis of the 
Dd2 wild-type and Dd2 ATP6-overexpressing parasites. Lysates corresponding to the Dd2 
parasites wild-type (WT, lane 1), or transfected with the pHBIRH-ATP6(A108T, A109T)-HA 
(lane 2) or pHBIRH-ATP6(WT)-HA (lane 3) plasmids. The signal at 140 KDa corresponds to 
the PfATP6 variant, and the one at 55 KDa to the α-tubulin, used as a loading control. 
 
The Dd2 pHBIRH-ATP6(A108T, A109T)-HA parasites showed a decrease in their 
susceptibility to SC83288, displaying a four-fold increase in their IC50 value compared to the 
wild-type parasites (3.1 ± 0.2 nM and 12.5 ± 1.0 nM, respectively for parental and the 
overexpressing parasite lines, Student´s t-test, p < 0.001, ***) (Figure 3.28 A and Table 3.6). 
The overexpression of the wild-type PfATP6 did not lead to such an increase (3.1 ± 0.2 nM 
and 3.2 ± 0.2 nM, respectively for the parental and the overexpressing parasite lines, 
Student´s t-test, p > 0.05, n.s.) (Figure 3.28 B and Table 3.6). 
W
T
pH
BI
R
H
-A
TP
6
(A
10
8T
, A
10
9T
)-
H
A
   
   
   
   
   
   
pH
BI
R
H
-
AT
P6
(W
T)
-H
A
R
e
la
ti
v
e
 t
ra
n
s
c
ri
p
t 
le
v
e
l
0
2
4
6
*** 
* 
A B 
Results 
104 
 
  
Figure 3.28: Susceptibility of the Dd2 wild-type and PfATP6-overexpressing Dd2 P. 
falciparum parasites to SC83288. Growth inhibition assay by SC83288 for the wild-type 
(WT) and Dd2 P. falciparum parasites overexpressing the T108, T109 variant of PfATP6 (A) 
or the wild-type variant (B). Mean ± SEM of 11 to 13 independent determinations. 
 
The susceptibility to chloroquine was not affected by overexpression of PfATP6 (IC50 values 
of 96 ± 2.0 nM, 110 ± 1.0 nM and 99.0 ± 0.5 nM, for the wild-type and the mutants, 
respectively, Student‘s t-test, p > 0.05, n.s.) (Table 3.6). 
Table 3.6: Susceptibility, expressed as IC50 values, of the Dd2 WT, Dd2 pHBIRH-
ATP6(WT)-HA and Dd2 pHBIRH-ATP6(A108T,A109T)-HA parasites to SC83288 and 
chloroquine. 
Line 
IC
50
 (nM) 
SC83288 Chloroquine 
Dd2 WT 03.1 ± 0.2  096 ± 2.0  
Dd2 pHBIRH-ATP6(WT)-HA  03.2 ± 0.2  110 ± 1.0  
Dd2 pHBIRH-ATP6(A108T,A109T)-HA  12.5 ± 1.0  099 ± 0.5  
Mean ± SEM of 11 to 13 independent determinations. 
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 The pfatp6 amplified locus in Dd2SC83288 P. falciparum does 3.2.5.
not carry genes coding for proteins involved in the resistance 
mechanism to the SC-lead compounds  
The parasites selected for SC83288 resistance consistently showed an amplification on 
chromosome 1. Even though the duplications were of different nature, the four 
sequenced clones duplicated the same six genes [189]. Three of those are annotated to 
encode for conserved Plasmodium proteins of unknown function (Pf3D7_0105800, 
Pf3D7_0106000 and Pf3D7_0106200), one for a putative DNA binding protein 
(Pf3D7_0105900), another one for a putative V-type proton ATPase subunit C 
(Pf3D7_0106100), and the last one for PfATP6 (Pf3D7_0106300). The increase in 
transcript levels of these six genes in the SC83288 selected clones was assessed by 
qPCR (Figure 3.29 and Table 3.7). 
 
Figure 3.29: Transcript levels of the genes in the amplified DNA locus identified in the 
SC83288-resistant in vitro generated Dd2 P. falciparum as graphical (A) or numerical 
(B) form. Levels of Pf3D7_0105800, Pf3D7_0105900, Pf3D7_0106000, Pf3D7_0106100, 
Pf3D7_0106200 and Pf3D7_0106300 transcripts, measured by RT-qPCR in P. falciparum 
Dd2SC83288. Mean ± SEM of 4 independent determinations (3 independent mRNA isolations 
on late-stage parasites), normalized to the parental Dd2 line (WT). Tubulin was used as a 
housekeeping gene for calibration. 
           
The coding sequences of Pf3D7_0105800, Pf3D7_0105900, Pf3D7_0106000, 
Pf3D7_0106100 and Pf3D7_0106200 were amplified from a wild-type P. falciparum Dd2 
strain, and cloned in the pARL vector for overexpression and fused with an HA-tag, each 
protein encoded by these genes being investigated as potential target or their involvement in 
a resistance mechanism. After confirmation of the overexpression of the proteins by Western 
blot (Figure 3.30 A), the susceptibility to SC81458 and SC83288 was assessed (Figure 3.30 
Gene 
Relative transcript level 
Dd2 WT Dd2
SC83288
 
Pf3D7_0105800 1.09 ± 0.06 12.3 ± 2.3 
Pf3D7_0105900 1.00 ± 0.01 7.49 ± 1.5 
Pf3D7_0106000 1.05 ± 0.02 12.7 ± 3.9 
Pf3D7_0106100 1.05 ± 0.02 1.35 ± 0.5 
Pf3D7_0106200 1.03 ± 0.01 12.2 ± 0.3 
Pf3D7_0106300 1.04 ± 0.01 17.3 ± 3.7 
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B). No significant difference in their SC-lead compounds responsiveness was observed upon 
the episomal overexpression of the various proteins (F-test, p > 0.05, n.s.). 
 
Figure 3.30: The overexpression of the amplified genes did not affect the 
responsiveness to the SC-lead compounds. (A) Overexpression confirmation by western 
blot analysis of the Dd2 wild-type and Dd2 pARL-gene-HA P. falciparum parasites. Lysates 
corresponding to the Dd2 parasites wild-type (WT, lane 1), Dd2 pARL-0105800-HA (lane 2, ≈ 
103 KDa), Dd2 pARL-0105900-HA (lane 3, ≈ 57 KDa), Dd2 pARL-0106000-HA (lane 4, ≈ 113 
KDa), Dd2 pARL-0106100-HA (lane 5, ≈ 49 KDa), Dd2 pARL-0106200-HA (lane 6, ≈ 30 
KDa). The signal at 55 KDa corresponds to the α-tubulin, used as a loading control. (B) 
Susceptibility of the Dd2 wild-type and Dd2 pARL-gene-HA P. falciparum parasites to 
SC81548, SC83288 and chloroquine. IC50 values obtained from the growth inhibition assays 
by SC83288, SC81458 or chloroquine (CQ) for the wild-type (WT) and the parasites 
overexpressing the Pf3D7_0105800, Pf3D7_0105900, Pf3D7_0106000, Pf3D7_0106100 
and Pf3D7_0106200 genes. Mean ± SEM of 6 independent determinations, F-test, p > 0.05, 
n.s. 
 
The susceptibility to chloroquine was not affected by overexpression of any of these genes 
(Figure 3.30 B) (F-test, p > 0.05, n.s.). 
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4. Discussion 
4.1. Characterization of SC83288 in vitro antiplasmodial 
activity as a candidate for clinical development 
  
Despite the substantial progress regarding the decrease of case incidence over the last two 
decades, malaria continues to impose a heavy burden upon mankind. Not only the death toll 
remains concerning, but the loss of development potential for malaria-endemic countries and 
the impact on their economic growth and health-care systems are to be taken into account 
[212]. Fortunately, the past decade has seen a renaissance on the research and 
development for antimalarial medicine, with a particular focus on finding new chemotypes.  
As a result, the antimalarial drug portfolio rapidly transformed, and now contains more than a 
dozen of new chemical entities in (pre)clinical development. Nonetheless, however optimistic 
this pipeline appears, there is still a dire need for new antimalarial chemical agents, 
particularly regarding the alarming development of resistance to marketed therapies. 
Here the in vitro antiplasmodial activity of two lead compounds arising from a medicinal 
chemistry program [189] was characterized, specifically the second lead compound 
SC83288, considered as a clinical development candidate for the treatment of severe 
malaria. 
Both SC81458 and SC83288 displayed advantageous parasitological properties, according 
to the MMV´s Target Compound Profiles [213], such as their steep growth inhibition curves 
[189] and low nanomolar IC50, IC90 and IC99 values. They fall in the range of both the old and 
current gold standards, i.e. respectively quinine and chloroquine (with in vitro IC50 values in 
the moderate nanomolar range, depending of the sensitive lab strains) and artemisinin. Even 
though a low in vitro IC50 value does not directly translate into a low in vivo effective dose, it 
is already a first discriminative step towards the selection of a compound for preclinical 
development.  
A previous study reported a stage specificity of SC81458 and SC83288 on asexual blood 
stages [189]. In a 6 hours exposure assay, the SC-lead compounds showed their higher 
activity against trophozoites stages, with IC50 values in the moderate nanomolar range. A 
slightly lower activity was observed in schizonts, with two-fold increased IC50 values 
compared to trophozoite stages, and the activity on ring stages was limited, with IC50 values 
in the micromolar range [189]. These observations were confirmed by following the 
morphology and the DNA content of the parasites when treated with SC83288 over their life 
cycle. Ring stage parasites did not appear to be affected by SC83288, and were able to 
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develop into morphologically healthy young trophozoites. These ones were however not able 
to progress further into schizogony, underlining the potent action of SC83288 against P. 
falciparum trophozoite stages. When SC83288 was applied on young trophozoites (i.e. about 
24 hours p.i.), the parasites were still able to enter schizogony, but to a limited extend as 
they appeared to be able to undergo only one round of DNA replication. This delayed 
antiplasmodial effect reflects the 5 hours lag-phase of the SC-lead compounds observed 
during the recrudescence assay. Similarly, the later in their life cycle the parasites were 
exposed to SC83288, the more DNA replication cycles they were able to undertake before 
arresting. Indeed, whether partially or fully formed, the SC83288-treated schizonts did not 
appear to be able to burst and release merozoites, suggesting a toxic activity of SC83288 
even on late P. falciparum stages. 
While the SC-lead compounds are primarily active against asexual blood stages, they also 
have been shown to target early stage gametocytes (stages I to III), showing IC50 values in 
the moderate nanomolar range. They were however proven to be devoid of activity against 
late stage gametocytes (stages IV and V), suggesting no potential for the blocking of the 
parasite´s transmission [189]. The SC-lead compounds could therefore only be considered 
as chemotherapeutic agents, and not in a prophylactic prospect. Such a goal could however 
be achieved by combining SC83288 with a gametocidal activity, such as the 8-
aminoquinoline primaquine [92].  
 
A quality feature emphasized by the MMV for an antimalarial compound is the PRR after a 
single dose, i.e. the speed of action of a molecule [213]. The speed of action takes a 
particular importance in the context of severe malaria, where the rapid clearance of 
sequestered parasites from the patient´s microvasculature can make the difference between 
survival and death. Furthermore, fast-acting antimalarial drugs are now favored for their 
ability to reduce the risk of resistant parasites arising within the patient. Here, the speed of 
action profile of SC832288 was characterized using three different approaches: a 
recrudescence assay [198], a relative speed assay [197] and a re-invasion assay [199]. The 
recrudescence assay revealed a profile for the SC-lead compounds closer to the fast-acting 
artemisinin than to the slow-acting atovaquone, although they showed a slightly longer 
clearance time and a lower PRR than artemisinin. Nonetheless a logPRR ≥ 3, obtained for 
both SC81458 and SC83288, is considered a favorable property of an antimalarial drug 
candidate [214]. The results of the somewhat controversial recrudescence assay [198,199] 
were confirmed by relative speed and re-invasion assays, consistently marking SC81458 and 
SC83288 as fast-acting antimalarial compounds. These in vitro observations were confirmed 
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in vivo by our collaborators, in a humanized SCID/NSG mouse model system, where a 
similar logPRR was measured and an intraperitoneal injection of a minimum dose of 2.5 
mg/kg of SC83288  was sufficient to reduce the parasite load by more than 99.9% in 48 
hours [189]. 
 
The in vitro or in vivo pharmacokinetic parameters are obviously not the only crucial aspects 
to be considered when developing an antimalarial compound. As for any exogenous 
molecule, the beneficial versus detrimental effects have to be carefully weighed. For 
instance, the two standards of care for severe malaria, artesunate and quinine, are 
associated with various side-effects, such as injection-site pathology [86] and cinchonism 
[87,88] in the case of intravenous quinine treatment, or a delayed hemolysis after artesunate 
treatment [215–217]. Preliminary results of the SC83288 safety and toxicological studies on 
mice and dogs, in the frame of the Non-Clinical Assessment for First-in-Human Study, are 
promising in this regard (unpublished data). Profiling the side-effects on human early-on 
during the drug development process would be ideal; unfortunately, possible adverse effects 
are usually reported during the phase IV of clinical trials and during the post-marketing 
surveillance studies. Developing compounds with independent mode(s) of action from the 
drugs with known side-effects might decrease this risk. In line with this, this study revealed 
no interaction between artemisinin and SC81458 or SC83288, suggesting distinct modes of 
action. This observation was supported by both the graphical and arithmetical analysis of an 
isobolomic assay, with an isobologram following a linear trend, and a mean sum of fractional 
50% inhibitory concentration (∑FIC50) falling into the commonly admitted range of an 
indifferent interaction [206]. Such an assay may however overlook possible similar modes of 
action, particularly if the two tested compounds are either competitive inhibitors or mutually 
exclusive non-competitive inhibitors. A competition of both compounds for the same binding 
site, independently of an interference with the binding site of the endogenous substrate, 
would not be noticed during an isobolomic assay. However, in the case of artemisinin and 
SC81458 or SC83288, such a competition is considered highly unlikely. Both the chemical 
and structural differences between the SC-lead compounds and artemisinin (Figure 4.1), and 
the wide range of proposed modes of action and molecular targets proposed for artemisinin 
[116] strongly argue against this possibility. 
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Figure 4.1: Chemical structures of artemisinin (A), and the SC-lead compounds 
SC81458 (B) and SC83288 (C) for comparison purpose. 
 
The distinct mode of action of the SC-lead compounds and artemisinin and its derivatives 
was further confirmed when combining SC83288 with artesunate, which did not alter the 
artesunate clearance time in the re-invasion assay. 
 
Drug resistance is another critical aspect of the MMV´s antimalarial candidate profiles [213]. 
Resistance to all past and current marketed antimalarial drugs has been identified to various 
degrees [218]. Therefore, novel drugs need to be able to overcome these existing resistance 
mechanisms. Along this line, resistance to either SC81458 or SC83288 did not affect the 
susceptibility of P. falciparum to other antimalarial drugs, including artemisinins, chloroquine, 
mefloquine and the folate antagonists. It is important to mention that the case of sensitivity to 
artemisinin required both a growth inhibition assay, as well as a ring survival assay. The RSA 
takes into account the antiplasmodial activity of artemisinins against the early blood stages 
[116,161], that can easily be overlooked in the standardized 72 hours growth inhibition 
assay. In both these assays, the SC-lead compound resistant parasite strains proved to be 
fully sensitive to artemisinins. Conversely, the activity of SC81458 and SC83288 against 
various P. falciparum lab strains was previously established, including parasites strains 
resistant to quinoline, quinoline-like and antifolate antimalarials [189]. This analysis was 
further extended in this study to include the in vitro engineered P. falciparum that carry the 
C580Y mutation in the kelch 13 protein associated with reduced artemisinin responsiveness. 
These experiments profiling the SC-lead compounds against artemisinins suggest that both 
SC8148 and SC83288 were able to break established resistance in P. falciparum and 
maintain their full activity independently of the parasite´s resistance status.  
 
A 
SC83288 Artemisinin 
B C 
SC81458 
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In light of these preclinical observations, and in the context of a dire need for artemisinins 
alternatives in areas where artemisinin-resistance is becoming a growing concern, the SC-
lead compounds, in particular SC83288, might be considered as apotential alternative 
chemotherapeutic option for severe malaria. However, such a conclusion is a bit premature 
and still awaits the results of clinical studies demonstrating the safety and efficacy of 
SC83288 in humans. 
 
4.2. PfTAP6 is a component of resistance to SC83288 
 
Novel antimalarial compounds identified by whole cell-based assays, such as SC81458 and 
SC83288, inherently have poorly defined modes of action. While understanding the mode of 
action or the mechanisms of resistance of new potential antimalarial drugs is not critical for 
their development, it can for instance become a paramount concern in case of failure during 
clinical trials. In this instance, knowledge of the mode of action and possibly of the molecular 
target(s) may help guide further development of the compounds. Similarly, understanding the 
mechanisms underlying the resistance to the compounds, some of those possibly involving 
their molecular targets, could on the one hand allow tracking the selection and spread of 
resistance by monitoring patients for the emergence of drug-resistant parasites and on the 
other hand help the design of more potent antimalarials.  
Previously, proteins involved in drug resistance could be identified by mating drug-sensitive 
and drug-resistant parasites and mapping the sensitivity in their recombinant progeny. 
Although this approach successfully allowed identifying PfCRT as a principal actor of CQ 
resistance [219], it remains an extremely intensive and time consuming process, and 
nowadays made obsolete due to the rapidity of whole genome sequencing. Over the last 
decades, this method has been replaced with the in vitro selection of resistant parasites. The 
selected resultant clones can then be submitted to either genome scanning or whole genome 
sequencing to identify mutations, i.e. SNPs, copy number variations and small insertions or 
deletions, conferring resistance [220]. This method successfully identified nonsynonymous 
SNPs resulting in resistance in genes coding for the molecular targets of various marketed 
antimalarial drugs, particularly in the drug-binding pockets of PfDHFR [138], PfDHPS [221] 
and PfCyt b1 [222,223]. It is however crucial to bear in mind that the detected change in the 
genomes of the resistant parasites directly reveals only the mechanisms of resistance. Some 
of these acquired genetic changes, as illustrated by the role or PfCRT in resistance to CQ 
[144–148], or of PfMDR1 in the resistance to QN, CQ and halofantrine [164], are not involved 
in the mode of action of the drugs, but rather in biological processes to reduce the 
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concentration of the compounds at their site of action. The role of the selected proteins of 
interest must therefore be further confirmed as targets or components of resistance by other 
molecular, chemical and/or modeling approaches. Recently, PfATP4 was confirmed as the 
molecular target of the promising new antimalarial class spiroindolones [181,224], after its 
identification in such a comparative genomic approach [179]. Similar successes in directly 
identifying the molecular target of antimalarial compounds can further be illustrated by the 
benzoxaborole AN3661 targeting the pre-mRNA processing factor (PfCPSF3) [225] or the 
aminopyridine MMV390048 as an inhibitor of the phosphatidylinositol 4-kinase PfI4K [226]. 
In the case of SC83288, the identification of the molecular target is not as straightforward. 
Comparative genomics of the SC-lead compounds selected Dd2 P. falciparum parasites with 
their parental line identified the Ca2+ ATPase pump PfATP6 as a protein of interest regarding 
their mode of action [189]. The finding of both nonsynonymous SNPs and duplications of the 
pfatp6 gene locus led us to consider PfATP6 as a direct molecular target of the SC-lead 
compounds. The cell permeable Ca2+ indicator Fluo-4-AM used in a live confocal laser-
scanning microscopy set-up allows to directly follow the fluctuation in the intracytosolic 
calcium concentration. However, the P. falciparum strain loaded with Fluo-4-AM has to be 
carefully considered for this assay, as certain polymorphisms in the multi-drug resistance 
protein 1 (PfMDR1) modulate its affinity to Fluo-4-AM, leading to an accumulation of the dye 
in the parasite’s DV [162]. Such strains, i.e. Dd2, K1 and FCB, cannot reliably be used to 
quantitively measure intracytosolic Ca2+ variations. The HB3 strain however, shows a uniform 
distribution of Fluo-4-AM between the parasite’s cytosol and it’s DV, and was therefore used 
for this assay. Under these experimental conditions, no relative increase in the intracellular 
calcium level was observed upon addition of the SC-lead compounds, as it is clearly 
observed when the parasites are treated with established PfATP6 inhibitors such as 
thapsigargin or CPA [202]. The absence of direct PfATP6 inhibition by the SC-lead 
compounds was further confirmed using a yeast complementation assay. Yeast 
complementation studies are simple approaches to assess the in vitro inhibition potential of 
chemical compounds on proteins otherwise difficult to express in heterologous systems. This 
generally implies replacing a yeast’s gene with the Plasmodium homologous gene either by 
allelic exchange or by episomal overexpression [220]. The S. cerevisiae model recently 
developed by Pulcini et al. is knocked-out of various genes encoding proteins essential to 
Ca2+ homeostasis. The yeasts are therefore not able to grow when stressed with high 
ambient calcium concentrations. As growth rescue relies on episomal overexpression of 
PfATP6, the yeasts growth directly correlates with PfATP6 inhibition and therefore represents 
and ideal system to study the effect of small molecules on PfATP6 activity [70]. The growth 
of these complemented S. cerevisiae was however proven to be unaffected by the addition of 
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either SC81458 or SC83288, while CPA induced the expected concentration-dependent 
growth inhibition. Both these assays strongly argue against the rapid and direct inhibition of 
PfATP6 by the SC-lead compounds, excluding PfATP6 as a primary molecular target.  
 
PfATP6 was nonetheless kept under investigation as a protein involved in a resistance 
mechanism, if not as a molecular target. Genome editing using the CRISPR/Cas9 approach 
[78] and episomal overexpression allowed the genomic variations observed in the Dd2 SC81458 
and Dd2 SC83288 parasites to be introduced into either their parental line or the 3D7 wild-type 
parasites. The CRIPSR/Cas9-mediated genome editing was carried out in the 3D7 strain. 
Indeed, the design of the sgRNA was based on this strain’s genome and all our transfections 
in the Dd2 strain were unsuccessful, suggesting off-target effects of the RNA guide in Dd2 
that were not predicted from the 3D7 genome. The F972Y substitution in PfATP6, previously 
identified in the Dd2 SC81458 line, was successfully introduced in 3D7 and led to an 
approximate 1000-fold decrease in the sensitivity to the SC-lead compounds. The 
overexpression of the T108, T109 PfATP6 variant, identified in the Dd2 SC83288 line, similarly 
induced a decrease in the parasite’s susceptibility to SC83288, moderate yet significantly 
marked. However, the overexpression of the wild-type PfATP6 was insufficient to affect the 
susceptibility of the parasites. It is worth to note that the multiple attempts to introduce the 
SNPs leading to the A108T, A109T substitutions on PfATP6 using the CRISPR/Cas9 system 
were unsuccessful. This further confirmed the vital role of PfATP6 in Ca2+ homeostasis, as 
this double substitution might alter the PfATP6 essential function in a detrimental fashion for 
the parasite. This damaging effect was not observed in the Dd2 SC83288 line, as the SNPs 
were identified on the extra copy of pfatp6, leaving a residual regular activity of the non-
mutated PfATP6. The hypothesized abnormal activity of the mutant PfATP6 might 
furthermore have been compensated by other mutations, either on pfatp6 specifically or on 
other genomic loci, that might not have been consistently detected in the comparative 
genomic analysis. These hypotheses are further supported by the fact that the selection of 
parasites with high pHBIRH-ATP(WT)-HA plasmid copy number was straightforward, hence 
non-detrimental, whereas it was only possible to select parasites with low copy number of the 
pHBIRH-ATP6(A108T, A109T)-HA plasmid, suggesting a toxic effect of a too important 
overexpression of this variant relative to the wild-type one. 
These various genomic modifications confirmed the correlation between PfATP6 and the 
resistance to the SC-lead compounds. To further understand the molecular details of the role 
of PfATP6 in a resistance mechanism to the SC-lead compounds, we used the genetically 
engineered 3D7 PfATP6 F972Y line generated using the CRISPR/Cas9 approach.  Compared 
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to the Dd2 line overexpressing the T108, T109 PfATP6 variant, it had the advantage to be 
stable and did not require a constant selection.   
Drug-resistance conferring mutations are generally associated with fitness costs, leading to 
the attrition of the mutant parasites upon drug pressure removal, allowing the reemergence 
of the fitter wild-type ones [227]. This general observation was confirmed in the case of the 
3D7 PfATP6 F972Y mutants during an in vitro co-culture competition assay with its parental 
3D7 wild-type strain. The proportions of the wild-type and mutated PfATP6 alleles were 
determined by pyrosequencing. Pyrosequencing is a fast technique based on sequencing-
by-synthesis with real-time read-out and is highly suitable for sequencing short stretches of 
DNA [228]. Its high reliability, particularly for SNP genotyping [209,229], is based on a 
combination of four enzymes eventually leading to the quantitative detection of 
pyrophosphate (PPi) release during DNA synthesis [230]. The four deoxynucleotide 
triphosphates (dNTPs) are sequentially added to the reaction mixture containing the desired 
DNA locus previously amplified by PCR. Each nucleotide incorporation by the DNA 
polymerase is directly followed by the release of PPi in a quantity equimolar to the amount of 
incorporated nucleotides. The PPi is subsequently quantitatively converted into ATP by the 
ATP sulfurylase. The luciferase, driven by the generated ATP, catalyzes the conversion of 
luciferin into the visible light-producing oxyluciferin. The detected light signal is proportional 
to the amount of ATP. The last enzyme, the apyrase, continuously degrades ATP and the 
non-incorporated dNTPs from the reaction mixture, preventing signal overlaps and allowing a 
precise quantification of the proportion of each allele present in the amplified DNA locus. This 
approach clearly revealed a fitness cost of the 3D7 PfATP6 F972Y mutant, as its proportion 
gradually decreased over the 20 analyzed life cycles of the parasites, suggesting a growth 
deficiency compared to parental line. Extrapolation predicted the complete attrition of the 
mutants after approximately 29 cycles. It is difficult to estimate whether these in vitro 
observations could directly be translated to the field, as they were obtained in absence of 
drug pressure. Indeed, a prolonged drug exposure can provide the resistant parasite the 
opportunity to acquire additional mutations, either within the primary resistance factor or 
within secondary factors. The new mutations can potentially compensate for the initial fitness 
cost, and these new mutants can further compete with and eventually take over the wild-type 
ones, even in a drug-free environment [210]. 
Considering the crucial role of PfATP6 in Ca2+ homeostasis, a link between the observed 
fitness cost in the 3D7 PfATP6 F972Y mutants and abnormal intracellular Ca2+ levels was 
speculated. In order to measure the intracellular Ca2+ concentration in a quantitative manner, 
the Fura-Red-AM indicator was used. Fura-Red is a ratiometric dye widely used for absolute 
calcium quantification, and offers several advantages over other Ca2+-sensitive 
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fluorochromes such as Fluo-4 [202]. Unlike Fluo-4, Fura-Red can be used for ratiometric 
measurement and therefore the intensity of the measured signal does not depend on dye 
loading efficiency and/or partitioning, which would not allow a direct absolute quantification of 
Ca2+ concentration [202]. After a calibration including both the ionophore ionomycin and the 
calcium chelator EGTA to control the free Ca2+ concentrations, it was possible to 
quantitatively determine the intracytosolic free Ca2+ concentrations in various parasites lines 
under different conditions. As previously measured in a relative manner, the treatment of 3D7 
P. falciparum parasites with SC83288 did not lead to a notable change in their free Ca2+ 
concentrations, refuting again a direct inhibition of PfATP6 by SC83288. Interestingly, the 
3D7 PfATP6F972Y mutant showed a significantly lower cytosolic free Ca2+ concentration, 
almost diminished by half compared to the parental line. This would suggest a higher activity 
of PfATP6 F972Y, pumping Ca2+ into the ER more efficiently than the wild-type variant. Such a 
drastic change in the ATPase activity could be explained by the introduction of a tyrosine 
residue at the position 972 and/or its potential phosphorylation, although this remains to be 
properly demonstrated by mass spectrometric analysis. It is however difficult to affirm that 
the lower intracellular Ca2+ concentration in the mutant is exclusively caused by the abnormal 
activity of the PfATP6 F972Y variant. Preliminary metabolomics analysis of the mutant line 
revealed a not significant yet marked decrease in the concentration of several precursors of 
inositol-1,4,5-triphosphate (IP3). In eukaryotic cells, and presumably in the P. falciparum wild 
type parasite, Ca2+ effluxes from the ER mainly through the opening of IP3-gated Ca
2+ 
channels. These channels are activated upon binding of the IP3 produced by the dissociation 
of the phosphatidylinositol-4,5-bisphosphate (PIP2) into IP3 and diacylglycerol (DAG) 
catalyzed by the phosphoinositide phospholipase C (PLC) (Figure 4.2 A). In the 3D7 
PfATP6F972Y mutant, the possible decrease in IP3 concentration compared to the parental 
strain may contribute to the low cytosolic Ca2+ concentration, as the reduced amount of IP3 
may not be sufficient to trigger the opening of enough IP3-gated Ca
2+ channels to allow a 
proper efflux of Ca2+ into the cytosol (Figure 4.2 B). This hypothesis is however to be taken 
with caution, as pharmacological approaches have suggested the presence of a IP3 
canonical pathway in P. falciparum [21], although it still remains unidentified in its genome. 
Moreover, it is impossible to exclude regulatory processes involving the release of Ca2+ from 
the other storage compartments, such the mitochondrion, the acidocalcisomes or the 
parasitophorous vacuole. The difficulty mainly relies in our present lack of a full 
understanding of the mechanisms of Ca2+ homeostasis in P. falciparum and the involved 
proteins [21].  
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Figure 4.2: Hypothetical partial model of Ca2+ regulation in wild-type P. falciparum and 
the PfATP6 F972Y mutant. (A) In the wild type parasite, IP3, along with DAG, is produced by 
the dissociation of PIP2 catalyzed by PLC. The opening of the Ca
2+ channels localized in the 
ER membrane is triggered by the binding of IP3 allowing the efflux of Ca
2+ from the ER into 
the cytosol. The PfATP6 actively pumps the cytosolic Ca2+ into the ER for storage. (B) In the 
PfATP6 F972Y mutant, the decreased amount of IP3 does not allow the opening of enough ER 
Ca2+ channels for an efficient release of Ca2+ into the cytosol. This low intracytosolic Ca2+ 
concentration is accentuated by the higher activity of the mutant PfATP6 F972Y. ER, 
endoplasmic reticulum; PLC, phospholipase C; IP3, inositol-1,4,5-triphosphate; PIP2, 
phosphatidylinositol-4,5-bisphosphate; DAG, diacylglycerol.   
 
The analysis of the PfATP6 F972Y variant in the S. cerevisiae complementation model will 
confirm the hypothesis of a higher ATPase activity (Figure 4.2 B) by placing PfATP6F972Y out 
of its biological context and excluding other actors of Ca2+ homeostasis that could possibly 
act downstream or in parallel of PfATP6, and influence the Ca2+ resting concentration.  
Surprisingly, the treatment of the 3D7 PfATP6 F972Y mutant with SC83288 restored the resting 
free Ca2+ concentration to its basal level, i.e. to a concentration similar as the one measured 
in the parental strain, even though the concentration of SC83288 used on the mutant 
parasites was shown not to affect the growth in the standard 72 hours growth inhibition 
assay. Here again, our lack of defined Ca2+ influx and efflux processes make it difficult to 
speculate on the molecular mechanisms taking place in the mutant in presence of SC83288, 
and deeper calcium signaling studies would be necessary.  
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All our observations confirmed the role of PfATP6 as a component of resistance. Whether it 
is a primary factor or a secondary one is a more complex issue and remains an unanswered 
question. Up to date, efforts to determine the precise localization of the SC-lead compounds 
in the parasites have been unsuccessful. Indeed, covalently tagging the SC-lead compounds 
with flurophores led to compounds with a drastically reduced antiplasmodial activity. 
Furthermore, click-chemistry experiments [231–233] were performed in vain, as the 
interaction between SC83288 and its molecular target appears to be non-covalent and a 
milder approach used to a localization purpose only led to highly unspecific signals. 
Consequently, this lack of knowledge both concerning the cellular localization of the SC-lead 
compounds and their direct molecular target does not allow to speculate on a potential role of 
the mutated PfATP6 pumping SC83288 into the ER where the damage for the parasite could 
be minimized. We rather favor a compensatory role of PfATP6 in the resistance to the SC-
lead compounds, instead of being a primary factor related to the mode of action of the 
compounds. This hypothesis is further supported by the recurrence of PfATP6 in the 
investigation of the mechanisms to other antimalarial drugs, particularly artemisinins. The 
inconsistency of the appearance of PfATP6 in the artemisinins resistance studies [50,62–
66,68,149] tends to confirm the role of PfATP6 as a secondary compensatory mechanism of 
resistance. Furthermore, PfATP6, despite its essentiality, has been shown to be prone to 
acquired spontaneous mutations in the field, therefore displaying an already important 
geographic diversity, even in a drug-free environment [234–236].  
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5. Conclusion and outlooks  
 
SC83288, an amicarbalide-based compound issued from a medicinal chemistry optimization 
program, is a potent blood schizonticide. Its fast antiplasmodial activity has been 
demonstrated both in vitro using different blood culture-based approaches during this study 
and in vivo in a humanized mice model by our collaborators [189]. No cross-resistance to 
artemisinins, nor any similar mode of action were detected, marking SC83288 as a possible 
candidate for complementing artemsinins in geographic areas where artemisinin-resistance 
is becoming a growing concern, providing a positive and secure evaluation of SC83288 
during human clinical trials.  
This study further aimed to gain insight into the mode of action of SC83288, as well as on the 
mechanisms by which the P. falciparum parasite could develop resistance against it. The 
Ca2+ ATPase PfATP6 has been ruled out as a direct molecular target of SC83288, but was 
confirmed as a component of an assumed compensatory resistance mechanism. Even 
though a disruption of Ca2+ homeostasis in the PfATP6 F972Y mutant was clearly observed, 
the molecular details of resistance to SC83288 remain to be unraveled. Similarly, if the 
treatment of the PfATP6 F972Y mutant with SC83288 brought back the possibility of a more 
pleiotropic mode of action through disturbed calcium signaling, consistent with the toxic 
activity of SC83288 on both the trophozoite and schizonts stages, the mode of action of the 
SC-lead compounds remains far from understood.  
The role of extracellular calcium in the antiplasmodial action of SC83288 could be further 
investigated using either higher, yet non-toxic, calcium concentrations, or known Ca2+ 
chelators, such as EGTA [237]. The SC83288 responsiveness in a standard growth inhibition 
assay could be measured under these conditions, to determine if the antiplasmodial action is 
dependent of extracellular calcium. 
An untargeted metabolomics approach, as previously used to determine the mode of action 
of some antibiotics [238] or antiprotozoal drugs [239], has up to now not been successful to 
that regard. However, the treatment conditions as well as the exposure time could be 
adjusted to obtain more precise results. The progress in the quantitative mass spectrometry 
analysis field opened other doors of the “omics” approaches, such a proteomics as a mean 
of target identification [240]. Even if preliminary results did not mark SC83288 as a de novo 
protein synthesis inhibitor in P. falciparum (See Appendix III, Figure 9.1), a full proteomics 
analysis, particularly a comparison between the PfATP6 F972Y mutant and its parental line, 
could give helpful insights to determine a more precise mechanism of resistance.  
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Finally, the other two proteins identified with nonsynonymous SNPs in the Dd2SC814158 and 
Dd2SC83288 parasites could be further investigated. PfMDR2 (PF3D7_1447900) could also be 
contemplated as a component of a secondary resistance mechanism expelling SC83288 out 
of the parasite. This hypothesis of PfMDR2 acting as an export system is supported by its 
localization at the plasma membrane of the parasite [241,242] and its implication in heavy 
metal tolerance [243] and contribution to a decreased responsiveness to several antimalarial 
drugs such as atovaquone, chloroquine, quinine or mefloquine [241,244]. It should however 
be confirmed using genetic engineering and uptake assays with radiolabeled SC83288. The 
role of the putative ATP-dependent RNA helicase (PF3D7_1241800) is more difficult to 
predict and a confirmation of its role in resistance to SC83288, and possibly its mode of 
action, is deserved. RNA helicases have not yet been considered as druggable targets in 
Plasmodium, although they are considered suitable drug targets for antiviral and anticancer 
therapies and are suggested to have a crucial role in various protozoic, bacterial or fungal 
infections [245]. 
Independently of the identifications of a direct molecular target for the SC-lead compounds or 
of the components of their resistance mechanisms, SC83288 will hopefully prove to be 
successful in the clinical trials and contribute to the eradication of malaria.  
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7. Appendix I: DNA and proteins sequences 
All the sequences displayed here were obtained from PlasmoDB, and processed on 
http://www.bioinformatics.org/sms2/ or http://www.ebi.ac.uk/Tools/msa/clustalo/ for display. 
 
7.1. PF3D7_0106300 calcium-transporting ATPase (PfATP6) 
  Genomic DNA sequence 7.1.1.
In lower case, non-coding DNA sequences; in red, A108 and A109 mutations loci; in green, 
F972 mutation locus; simply underlined, homology region A (HRA); doubly underlined, 
homology region B (HRB); in bold, guide 6 and guide 7. 
       1 ATGGAAGAGG TTATTAAGAA TGCTCATACA TACGATGTTG AGGATGTACT  
      51 AAAATTTTTG GATGTAAACA AAGATAATGG TTTAAAGAAT GAGGAATTGG  
     101 ATGATAGAAG ATTAAAATAT GGTTTGAATG AATTAGAAGT AGAAAAGAAG  
     151 AAAAGTATTT TTGAATTGAT ATTAAATCAA TTTGATGATT TATTAGTAAA  
     201 GATATTATTA CTAGCTGCAT TCATTAGTTT CGTGTTAACT TTATTAGATA  
     251 TGAAACATAA AAAAATAGAA ATATGTGATT TTATTGAACC ATTAGTTATA  
     301 GTATTAATAT TAATATTAAA TGCTGCCGTA GGTGTATGGC AAGAATGTAA  
     351 TGCTGAAAAA TCTTTAGAAG CTTTAAAAGA ATTACAACCT ACCAAAGCTA  
     401 AAGTATTACG AGATGGGAAG TGGGAAATTA TTGATAGTAA ATATTTATAT  
     451 GTTGGTGATA TTATTGAATT GAGTGTTGGT AATAAAACTC CCGCTGATGC  
     501 AAGAATAATT AAAATATATT CAACAAGTTT AAAAGTTGAA CAGAGTATGT  
     551 TAACAGGAGA ATCCTGTTCA GTTGACAAAT ATGCTGAAAA AATGGAAGAT  
     601 AGTTATAAAA ATTGTGAAAT ACAGTTGAAA AAAAATATTT TATTTTCATC  
     651 TACCGCTATT GTATGTGGTA GATGTATAGC TGTTGTAATC AACATAGGTA  
     701 TGAAGACTGA AATAGGTCAT ATTCAGCATG CTGTTATAGA ATCAAATAGT  
     751 GAAGATACTC AAACACCTTT ACAAATAAAA ATCGATTTAT TTGGTCAACA  
     801 ATTATCAAAA ATCATTTTTG TAATATGTGT AACTGTATGG ATTATTAATT  
     851 TTAAACATTT CTCAGATCCA ATTCATGGTT CATTTTTATA TGGTTGTTTA  
     901 TATTATTTTA AAATTAGTGT TGCTTTAGCT GTTGCTGCTA TACCAGAAGG  
     951 ATTGCCAGCA GTCATAACAA CTTGTTTAGC TTTAGGAACA AGAAGAATGG  
    1001 TAAAAAAAAA TGCTATAGTA AGAAAATTAC AAAGTGTTGA GACGTTAGGA  
    1051 TGTACAACGG TTATATGTTC TGATAAAACA GGTACCCTTA CAACAAATCA  
    1101 AATGACAACA ACCGTGTTTC ATTTGTTTAG AGAATCTGAT TCTTTAACAG  
    1151 AATACCAACT ATGTCAAAAA GGGGATACCT ATTACTTTTA TGAAAGTTCA  
    1201 AACTTAACAA ATGATATATA TGCAGGTGAA TCATCTTTTT TTAATAAATT  
    1251 AAAAGATGAA GGAAATGTTG AAGCTTTAAC GGATGATGGA GAAGAAGGAT  
    1301 CAATTGATGA AGCTGATCCA TATAGTGATT ATTTTTCTAG TGATAGTAAG  
    1351 AAAATGAAAA ATGATTTAAA CAACAACAAT AATAATAATA ATAATAGTAG  
    1401 TAGGAGTGGT GCTAAGAGGA ATATTCCTTT AAAAGAAATG AAATCAAATG  
    1451 AAAATACAAT AATAAGTAGA GGTAGTAAAA TATTAGAAGA TAAAATTAAT  
    1501 AAATATTGTT ATTCAGAATA TGATTATAAT TTTTATATGT GTTTAGTAAA  
    1551 TTGTAATGAA GCAAATATTT TCTGTAACGA TAATAGTCAA ATAGTAAAAA  
    1601 AATTTGGAGA CAGTACCGAA TTAGCTTTAT TACATTTTGT ACATAATTTT  
    1651 GATATATTAC CAACATTCTC TAAAAATAAT AAAATGCCAG CAGAATATGA  
    1701 AAAAAATACA ACACCTGTAC AATCATCAAA TAAGAAGGAT AAATCACCAA  
    1751 GGGGTATCAA CAAATTCTTT AGTTCAAAAA ATGATAACAG TCATATTACC  
    1801 AGTACATTGA ATGAAAATGA TAAGAATTTA AAGAATGCTA ACCATTCTAA  
    1851 TTATACTACA GCTCAGGCAA CAACAAATGG ATATGAAGCT ATAGGAGAAA  
    1901 ATACATTTGA GCATGGCACA AGTTTTGAAA ATTGTTTCCA CTCAAAATTG  
    1951 GGTAATAAAA TAAATACCAC ATCAACACAT AATAATAATA ACAACAATAA  
    2001 TAATAATAGT AATAGTGTTC CAAGTGAATG TATTTCTTCT TGGAGAAATG  
    2051 AATGTAAACA AATAAAAATT ATTGAATTCA CTAGAGAAAG GAAACTTATG  
    2101 AGTGTTATTG TTGAAAATAA AAAAAAAGAA ATAATATTGT ATTGTAAAGG  
    2151 TGCACCTGAG AATATAATAA AAAATTGTAA ATATTATTTA ACGAAAAATG  
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    2201 ATATACGTCC ATTAAATGAA ACTTTAAAAA ATGAAATTCA TAATAAGATT  
    2251 CAAAATATGG GAAAAAGAGC ATTAAGAACA CTTAGCTTTG CTTATAAAAA  
    2301 ATTAAGTAGT AAAGATTTAA ATATTAAGAA TACAGATGAT TATTATAAAT  
    2351 TAGAACAAGA TTTAATTTAT TTAGGTGGAT TAGGTATTAT TGATCCACCA  
    2401 CGTAAATATG TAGGAAGAGC AATTAGATTA TGCCATATGG CTGGTATACG  
    2451 TGTATTTATG ATTACAGGTG ATAATATTAA TACGGCCAGA GCTATAGCTA  
    2501 AAGAAATTAA TATATTAAAT AAAAATGAAG GAGATGATGA AAAGGATAAT  
    2551 TATACAAATA ATAAAAATAC ACAAATATGT TGTTATAATG GAAGAGAATT  
    2601 TGAAGATTTT TCATTAGAAA AGCAAAAACA TATTTTAAAA AATACACCAA  
    2651 GAATTGTTTT CTGTAGAACT GAACCTAAAC ATAAAAAACA AATTGTAAAA  
    2701 GTATTAAAAG ACTTAGGAGA AACAGTTGCT ATGACAGGTG ATGGTGTAAA  
    2751 TGATGCACCA GCATTGAAAT CAGCTGACAT AGGAATAGCT ATGGGTATTA  
    2801 ATGGAACGGA GGTAGCTAAA GAAGCATCAG ATATTGTTTT AGCTGATGAT  
    2851 AATTTTAATA CTATAGTTGA AGCAATTAAA GAAGGAAGAT GTATATATAA  
    2901 TAATATGAAA GCATTTATCC GTTATCTAAT TAGTAGTAAT ATAGGAGAAG  
    2951 TTGCATCCAT TTTTATAACA GCCTTATTGG GTATACCTGA CAGTTTAGCT  
    3001 CCCGTTCAAT TATTGTGGGT AAATTTGGTT ACTGACGGAT TACCAGCAAC  
    3051 AGCACTAGgt aataacaata aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa  
    3101 tatattatat attatatatt atatatatat atatgtatgt gtgttaattg  
    3151 tttgtcttat acatcctatt catcaattat cttttttttt aattttttta  
    3201 gGGTTCAATC CACCAGAACA TGACGTAATG AAGTGCAAGC CGAGACACAA  
    3251 AAACGACAAT TTAATAAACG GTCTAACTTT ATTAAGATAT ATAATTATTG  
    3301 GAACATATGT AGGAATAGCT ACAGTCTCAA TATTTGTGTA CTGGTTTTTA  
    3351 TTTTATCCAG ATTCAGATAT GCACACGTTG ATAAACTTTT ATCAATTATC  
    3401 ACATTATAAC CAATGTAAAG CATGGAATAA CTTCCGTGTA AATAAGGTTT  
    3451 ATGATATGTC TGAGGATCAC TGTTCATATT TTTCAGCAGG AAAAATTAAG  
    3501 gtaataaata tagtgcacac acacaaacat acacacacac atatatatat  
    3551 atatatatat atatatatat gtatatttac gtatatatgt atatatttat  
    3601 atatattcat ttatttatat atttttttat ttttagGCAA GCACCTTATC  
    3651 TTTATCCGTT TTAGTTTTAA TAGAAATGTT TAATGCTTTG AATGCCTTGA  
    3701 GTGAGTATAA TTCCTTATTT GAAATACCAC CATGGAGAAA TATGTACCTA  
    3751 GTATTAGCTA CTATAGGTTC CTTACTTTTA CATGTCTTAA TACTTTACAT  
    3801 TCCACCCTTA GCTCGTATTT TTGGTGTTGT TCCATTAAGT GCATATGACT  
    3851 GGTTCTTAGT ATTCTTGTGG TCCTTCCCAG TTATTATACT TGACGAAATT  
    3901 ATTAAATTCT ATGCAAAGAG GAAATTAAAG GAAGAGCAAA GAACCAAGAA  
    3951 AATTAAAATT GATTAA  
 
  Aminoacid sequence 7.1.2.
In red, A108 and A109; in green, F972  
       1 MEEVIKNAHT YDVEDVLKFL DVNKDNGLKN EELDDRRLKY GLNELEVEKK  
      51 KSIFELILNQ FDDLLVKILL LAAFISFVLT LLDMKHKKIE ICDFIEPLVI  
     101 VLILILNAAV GVWQECNAEK SLEALKELQP TKAKVLRDGK WEIIDSKYLY  
     151 VGDIIELSVG NKTPADARII KIYSTSLKVE QSMLTGESCS VDKYAEKMED  
     201 SYKNCEIQLK KNILFSSTAI VCGRCIAVVI NIGMKTEIGH IQHAVIESNS  
     251 EDTQTPLQIK IDLFGQQLSK IIFVICVTVW IINFKHFSDP IHGSFLYGCL  
     301 YYFKISVALA VAAIPEGLPA VITTCLALGT RRMVKKNAIV RKLQSVETLG  
     351 CTTVICSDKT GTLTTNQMTT TVFHLFRESD SLTEYQLCQK GDTYYFYESS  
     401 NLTNDIYAGE SSFFNKLKDE GNVEALTDDG EEGSIDEADP YSDYFSSDSK  
     451 KMKNDLNNNN NNNNNSSRSG AKRNIPLKEM KSNENTIISR GSKILEDKIN  
     501 KYCYSEYDYN FYMCLVNCNE ANIFCNDNSQ IVKKFGDSTE LALLHFVHNF  
     551 DILPTFSKNN KMPAEYEKNT TPVQSSNKKD KSPRGINKFF SSKNDNSHIT  
     601 STLNENDKNL KNANHSNYTT AQATTNGYEA IGENTFEHGT SFENCFHSKL  
     651 GNKINTTSTH NNNNNNNNNS NSVPSECISS WRNECKQIKI IEFTRERKLM  
     701 SVIVENKKKE IILYCKGAPE NIIKNCKYYL TKNDIRPLNE TLKNEIHNKI  
     751 QNMGKRALRT LSFAYKKLSS KDLNIKNTDD YYKLEQDLIY LGGLGIIDPP  
     801 RKYVGRAIRL CHMAGIRVFM ITGDNINTAR AIAKEINILN KNEGDDEKDN  
     851 YTNNKNTQIC CYNGREFEDF SLEKQKHILK NTPRIVFCRT EPKHKKQIVK  
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     901 VLKDLGETVA MTGDGVNDAP ALKSADIGIA MGINGTEVAK EASDIVLADD  
     951 NFNTIVEAIK EGRCIYNNMK AFIRYLISSN IGEVASIFIT ALLGIPDSLA  
    1001 PVQLLWVNLV TDGLPATALG FNPPEHDVMK CKPRHKNDNL INGLTLLRYI  
    1051 IIGTYVGIAT VSIFVYWFLF YPDSDMHTLI NFYQLSHYNQ CKAWNNFRVN  
    1101 KVYDMSEDHC SYFSAGKIKA STLSLSVLVL IEMFNALNAL SEYNSLFEIP  
    1151 PWRNMYLVLA TIGSLLLHVL ILYIPPLARI FGVVPLSAYD WFLVFLWSFP  
    1201 VIILDEIIKF YAKRKLKEEQ RTKKIKID  
 
 
 
  Alignment of pfatp6 coding sequence and the S. 7.1.3.
cervisiae codon optimized atp6 sequence 
In green, 3xHA tag coding sequence. 
78% identity between the sequences 
pfatp6           ATGGAAGAGGTTATTAAGAATGCTCATACATACGATGTTGAGGATGTACTAAAATTTTTG 
opt_atp6_HA      ATGGAAGAAGTTATTAAGAACGCCCACACCTACGATGTTGAAGATGTTTTGAAGTTCTTG 
                 ******** *********** ** ** ** *********** *****  * ** ** *** 
 
pfatp6           GATGTAAACAAAGATAATGGTTTAAAGAATGAGGAATTGGATGATAGAAGATTAAAATAT 
opt_atp6_HA      GACGTCAACAAGGATAACGGTTTGAAGAACGAAGAATTGGATGATAGAAGATTGAAGTAT 
                 ** ** ***** ***** ***** ***** ** ******************** ** *** 
 
pfatp6           GGTTTGAATGAATTAGAAGTAGAAAAGAAGAAAAGTATTTTTGAATTGATATTAAATCAA 
opt_atp6_HA      GGTTTGAACGAATTGGAAGTCGAAAAGAAGAAGTCCATCTTCGAATTGATCTTGAATCAA 
                 ******** ***** ***** ***********    ** ** ******** ** ****** 
 
pfatp6           TTTGATGATTTATTAGTAAAGATATTATTACTAGCTGCATTCATTAGTTTCGTGTTAACT 
opt_atp6_HA      TTTGACGACTTGTTGGTTAAGATCTTGTTGTTGGCTGCCTTCATCTCTTTCGTTTTGACT 
                 ***** ** ** ** ** ***** ** **  * ***** *****   ****** ** *** 
 
pfatp6           TTATTAGATATGAAACATAAAAAAATAGAAATATGTGATTTTATTGAACCATTAGTTATA 
opt_atp6_HA      TTGTTGGATATGAAGCACAAAAAGATCGAAATCTGCGACTTCATCGAACCATTGGTTATC 
                 ** ** ******** ** ***** ** ***** ** ** ** ** ******** *****  
 
pfatp6           GTATTAATATTAATATTAAATGCTGCCGTAGGTGTATGGCAAGAATGTAATGCTGAAAAA 
opt_atp6_HA      GTCTTGATCTTAATTTTGAACGCTGCTGTTGGTGTTTGGCAAGAATGTAATGCTGAAAAG 
                 ** ** ** ***** ** ** ***** ** ***** ***********************  
 
pfatp6           TCTTTAGAAGCTTTAAAAGAATTACAACCTACCAAAGCTAAAGTATTACGAGATGGGAAG 
opt_atp6_HA      TCTTTGGAAGCCTTGAAAGAATTGCAACCTACTAAGGCTAAGGTCTTGAGAGATGGTAAA 
                 ***** ***** ** ******** ******** ** ***** ** **  ******* **  
 
pfatp6           TGGGAAATTATTGATAGTAAATATTTATATGTTGGTGATATTATTGAATTGAGTGTTGGT 
opt_atp6_HA      TGGGAAATCATCGACTCTAAGTACTTGTACGTTGGTGACATCATCGAATTGTCTGTTGGT 
                 ******** ** **   *** ** ** ** ******** ** ** ******  ******* 
 
pfatp6           AATAAAACTCCCGCTGATGCAAGAATAATTAAAATATATTCAACAAGTTTAAAAGTTGAA 
opt_atp6_HA      AACAAAACTCCAGCTGATGCCAGAATTATCAAGATCTACTCTACCTCCTTGAAGGTTGAA 
                 ** ******** ******** ***** ** ** ** ** ** **    ** ** ****** 
 
pfatp6           CAGAGTATGTTAACAGGAGAATCCTGTTCAGTTGACAAATATGCTGAAAAAATGGAAGAT 
opt_atp6_HA      CAATCTATGTTGACTGGTGAATCTTGCTCCGTTGATAAGTACGCTGAAAAGATGGAAGAT 
                 **   ****** ** ** ***** ** ** ***** ** ** ******** ********* 
 
pfatp6           AGTTATAAAAATTGTGAAATACAGTTGAAAAAAAATATTTTATTTTCATCTACCGCTATT 
opt_atp6_HA      TCCTACAAGAACTGCGAAATCCAATTGAAGAAGAACATCTTGTTCTCTTCCACCGCTATC 
                    ** ** ** ** ***** ** ***** ** ** ** ** ** ** ** ********  
 
pfatp6           GTATGTGGTAGATGTATAGCTGTTGTAATCAACATAGGTATGAAGACTGAAATAGGTCAT 
opt_atp6_HA      GTTTGTGGTAGATGTATTGCTGTTGTTATCAACATCGGTATGAAGACCGAAATTGGTCAT 
                 ** ************** ******** ******** *********** ***** ****** 
 
pfatp6           ATTCAGCATGCTGTTATAGAATCAAATAGTGAAGATACTCAAACACCTTTACAAATAAAA 
opt_atp6_HA      ATTCAACATGCCGTCATCGAATCCAATTCCGAAGATACTCAAACTCCATTGCAAATCAAG 
                 ***** ***** ** ** ***** ***   ************** ** ** ***** **  
 
pfatp6           ATCGATTTATTTGGTCAACAATTATCAAAAATCATTTTTGTAATATGTGTAACTGTATGG 
opt_atp6_HA      ATCGACTTGTTCGGTCAACAATTGTCCAAGATCATTTTCGTTATCTGCGTTACCGTTTGG 
                 ***** ** ** *********** ** ** ******** ** ** ** ** ** ** *** 
 
pfatp6           ATTATTAATTTTAAACATTTCTCAGATCCAATTCATGGTTCATTTTTATATGGTTGTTTA 
opt_atp6_HA      ATCATCAATTTCAAGCACTTCTCCGATCCAATCCATGGTTCTTTCTTGTATGGTTGCTTG 
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                 ** ** ***** ** ** ***** ******** ******** ** ** ******** **  
 
pfatp6           TATTATTTTAAAATTAGTGTTGCTTTAGCTGTTGCTGCTATACCAGAAGGATTGCCAGCA 
opt_atp6_HA      TACTACTTCAAGATCTCTGTTGCTTTAGCTGTTGCTGCTATTCCAGAAGGTTTGCCAGCT 
                 ** ** ** ** **   ************************ ******** ********  
 
pfatp6           GTCATAACAACTTGTTTAGCTTTAGGAACAAGAAGAATGGTAAAAAAAAATGCTATAGTA 
opt_atp6_HA      GTTATTACTACTTGTTTGGCTTTGGGTACTAGAAGAATGGTTAAGAAGAACGCCATCGTC 
                 ** ** ** ******** ***** ** ** *********** ** ** ** ** ** **  
 
pfatp6           AGAAAATTACAAAGTGTTGAGACGTTAGGATGTACAACGGTTATATGTTCTGATAAAACA 
opt_atp6_HA      AGAAAGTTGCAATCTGTTGAAACTTTGGGTTGCACCACCGTTATTTGTTCTGATAAGACT 
                 ***** ** ***  ****** ** ** ** ** ** ** ***** *********** **  
 
pfatp6           GGTACCCTTACAACAAATCAAATGACAACAACCGTGTTTCATTTGTTTAGAGAATCTGAT 
opt_atp6_HA      GGTACTTTGACCACCAATCAAATGACTACTACCGTTTTCCACTTGTTCAGAGAATCTGAT 
                 *****  * ** ** *********** ** ***** ** ** ***** ************ 
 
pfatp6           TCTTTAACAGAATACCAACTATGTCAAAAAGGGGATACCTATTACTTTTATGAAAGTTCA 
opt_atp6_HA      TCTTTGACCGAATACCAATTGTGCCAAAAGGGTGATACTTACTACTTCTACGAATCCTCT 
                 ***** ** ********* * ** ***** ** ***** ** ***** ** ***   **  
 
pfatp6           AACTTAACAAATGATATATATGCAGGTGAATCATCTTTTTTTAATAAATTAAAAGATGAA 
opt_atp6_HA      AACTTGACCAACGATATCTATGCTGGTGAAAGTTCCTTCTTCAACAAATTGAAAGACGAA 
                 ***** ** ** ***** ***** ******   ** ** ** ** ***** ***** *** 
 
pfatp6           GGAAATGTTGAAGCTTTAACGGATGATGGAGAAGAAGGATCAATTGATGAAGCTGATCCA 
opt_atp6_HA      GGTAACGTCGAAGCTTTGACTGATGATGGTGAAGAAGGTTCTATTGACGAAGCTGATCCA 
                 ** ** ** ******** ** ******** ******** ** ***** ************ 
 
pfatp6           TATAGTGATTATTTTTCTAGTGATAGTAAGAAAATGAAAAATGATTTAAACAACAACAAT 
opt_atp6_HA      TACTCTGATTACTTCTCATCCGACTCCAAAAAGATGAAGAATGACTTGAACAATAACAAC 
                 **   ****** ** **    **    ** ** ***** ***** ** ***** *****  
 
pfatp6           AATAATAATAATAATAGTAGTAGGAGTGGTGCTAAGAGGAATATTCCTTTAAAAGAAATG 
opt_atp6_HA      AACAACAATAACAACTCCTCCAGATCCGGTGCTAAGAGAAATATTCCATTGAAAGAAATG 
                 ** ** ***** **       **    *********** ******** ** ********* 
 
pfatp6           AAATCAAATGAAAATACAATAATAAGTAGAGGTAGTAAAATATTAGAAGATAAAATTAAT 
opt_atp6_HA      AAGTCCAACGAAAACACCATTATCTCCAGAGGTTCCAAGATTTTGGAAGATAAGATCAAC 
                 ** ** ** ***** ** ** **    ******   ** ** ** ******** ** **  
 
pfatp6           AAATATTGTTATTCAGAATATGATTATAATTTTTATATGTGTTTAGTAAATTGTAATGAA 
opt_atp6_HA      AAGTACTGCTACTCCGAATACGACTACAACTTCTACATGTGTTTGGTCAACTGTAACGAA 
                 ** ** ** ** ** ***** ** ** ** ** ** ******** ** ** ***** *** 
 
pfatp6           GCAAATATTTTCTGTAACGATAATAGTCAAATAGTAAAAAAATTTGGAGACAGTACCGAA 
opt_atp6_HA      GCCAACATTTTCTGCAACGACAACTCTCAAATCGTCAAGAAATTCGGTGACTCTACTGAA 
                 ** ** ******** ***** **   ****** ** ** ***** ** ***  *** *** 
 
pfatp6           TTAGCTTTATTACATTTTGTACATAATTTTGATATATTACCAACATTCTCTAAAAATAAT 
opt_atp6_HA      TTGGCTTTGTTGCATTTCGTTCACAACTTCGATATTTTGCCAACCTTCTCCAAGAACAAC 
                 ** ***** ** ***** ** ** ** ** ***** ** ***** ***** ** ** **  
 
pfatp6           AAAATGCCAGCAGAATATGAAAAAAATACAACACCTGTACAATCATCAAATAAGAAGGAT 
opt_atp6_HA      AAAATGCCAGCAGAATACGAAAAGAACACTACCCCAGTTCAATCCTCCAACAAAAAAGAT 
                 ***************** ***** ** ** ** ** ** ***** ** ** ** ** *** 
 
pfatp6           AAATCACCAAGGGGTATCAACAAATTCTTTAGTTCAAAAAATGATAACAGTCATATTACC 
opt_atp6_HA      AAGTCTCCAAGAGGTATTAACAAGTTCTTCTCCTCCAAAAACGACAACAGTCATATTACC 
                 ** ** ***** ***** ***** *****    ** ***** ** *************** 
 
pfatp6           AGTACATTGAATGAAAATGATAAGAATTTAAAGAATGCTAACCATTCTAATTATACTACA 
opt_atp6_HA      TCTACCTTGAACGAAAACGATAAGAACTTGAAGAATGCCAACCACTCTAACTACACTACT 
                   *** ***** ***** ******** ** ******** ***** ***** ** *****  
 
pfatp6           GCTCAGGCAACAACAAATGGATATGAAGCTATAGGAGAAAATACATTTGAGCATGGCACA 
opt_atp6_HA      GCTCAAGCTACTACTAATGGTTACGAAGCTATTGGTGAAAACACCTTCGAACATGGTACA 
                 ***** ** ** ** ***** ** ******** ** ***** ** ** ** ***** *** 
 
pfatp6           AGTTTTGAAAATTGTTTCCACTCAAAATTGGGTAATAAAATAAATACCACATCAACACAT 
opt_atp6_HA      TCTTTCGAAAACTGTTTCCACTCTAAGTTGGGTAACAAGATTAACACCACTTCCACCCAC 
                   *** ***** *********** ** ******** ** ** ** ***** ** ** **  
 
 
pfatp6           AATAATAATAACAACAATAATAATAATAGTAATAGTGTTCCAAGTGAATGTATTTCTTCT 
opt_atp6_HA      AACAATAACAATAACAACAACAACAACAGTAACTCCGTCCCTTCTGAATGTATTTCTAGT 
                 ** ***** ** ***** ** ** ** *****    ** **   *************  * 
 
pfatp6           TGGAGAAATGAATGTAAACAAATAAAAATTATTGAATTCACTAGAGAAAGGAAACTTATG 
opt_atp6_HA      TGGAGAAACGAATGCAAGCAAATCAAAATTATCGAATTCACCAGAGAAAGAAAGTTGATG 
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                 ******** ***** ** ***** ******** ******** ******** **  * *** 
 
pfatp6           AGTGTTATTGTTGAAAATAAAAAAAAAGAAATAATATTGTATTGTAAAGGTGCACCTGAG 
opt_atp6_HA      TCCGTTATCGTTGAAAACAAGAAGAAAGAAATCATCTTGTACTGCAAGGGTGCCCCAGAA 
                    ***** ******** ** ** ******** ** ***** ** ** ***** ** **  
 
pfatp6           AATATAATAAAAAATTGTAAATATTATTTAACGAAAAATGATATACGTCCATTAAATGAA 
opt_atp6_HA      AACATTATCAAAAATTGCAAGTACTACTTGACTAAGAACGACATCAGACCTTTAAACGAA 
                 ** ** ** ******** ** ** ** ** ** ** ** ** **  * ** ***** *** 
 
pfatp6           ACTTTAAAAAATGAAATTCATAATAAGATTCAAAATATGGGAAAAAGAGCATTAAGAACA 
opt_atp6_HA      ACCTTGAAAAACGAAATCCATAACAAGATCCAAAACATGGGTAAGAGAGCTTTGAGAACT 
                 ** ** ***** ***** ***** ***** ***** ***** ** ***** ** *****  
 
pfatp6           CTTAGCTTTGCTTATAAAAAATTAAGTAGTAAAGATTTAAATATTAAGAATACAGATGAT 
opt_atp6_HA      TTGTCTTTCGCTTACAAGAAGTTGTCCTCCAAGGATTTGAACATCAAGAACACCGATGAT 
                  *    ** ***** ** ** **       ** ***** ** ** ***** ** ****** 
 
pfatp6           TATTATAAATTAGAACAAGATTTAATTTATTTAGGTGGATTAGGTATTATTGATCCACCA 
opt_atp6_HA      TACTACAAGTTGGAACAAGACTTGATCTACTTGGGTGGTTTGGGTATTATTGATCCACCA 
                 ** ** ** ** ******** ** ** ** ** ***** ** ****************** 
 
pfatp6           CGTAAATATGTAGGAAGAGCAATTAGATTATGCCATATGGCTGGTATACGTGTATTTATG 
opt_atp6_HA      AGAAAGTATGTTGGTAGAGCCATTAGATTGTGTCATATGGCTGGTATCAGAGTTTTCATG 
                  * ** ***** ** ***** ******** ** **************  * ** ** *** 
 
pfatp6           ATTACAGGTGATAATATTAATACGGCCAGAGCTATAGCTAAAGAAATTAATATATTAAAT 
opt_atp6_HA      ATTACCGGTGATAACATTAACACCGCTAGAGCTATTGCCAAAGAAATCAACATCTTGAAC 
                 ***** ******** ***** ** ** ******** ** ******** ** ** ** **  
 
pfatp6           AAAAATGAAGGAGATGATGAAAAGGATAATTATACAAATAATAAAAATACACAAATATGT 
opt_atp6_HA      AAGAACGAAGGTGATGACGAAAAGGATAACTACACAAACAACAAGAATACCCAAATCTGC 
                 ** ** ***** ***** *********** ** ***** ** ** ***** ***** **  
 
pfatp6           TGTTATAATGGAAGAGAATTTGAAGATTTTTCATTAGAAAAGCAAAAACATATTTTAAAA 
opt_atp6_HA      TGCTACAACGGTAGAGAATTTGAAGATTTCTCCTTGGAAAAACAAAAGCACATTTTGAAA 
                 ** ** ** ** ***************** ** ** ***** ***** ** ***** *** 
 
pfatp6           AATACACCAAGAATTGTTTTCTGTAGAACTGAACCTAAACATAAAAAACAAATTGTAAAA 
opt_atp6_HA      AACACCCCAAGAATCGTTTTCTGTAGAACTGAACCTAAGCACAAGAAGCAAATTGTCAAG 
                 ** ** ******** *********************** ** ** ** ******** **  
 
pfatp6           GTATTAAAAGACTTAGGAGAAACAGTTGCTATGACAGGTGATGGTGTAAATGATGCACCA 
opt_atp6_HA      GTTTTGAAGGATTTGGGTGAAACTGTTGCTATGACAGGTGATGGTGTTAACGATGCTCCA 
                 ** ** ** ** ** ** ***** *********************** ** ***** *** 
 
pfatp6           GCATTGAAATCAGCTGACATAGGAATAGCTATGGGTATTAATGGAACGGAGGTAGCTAAA 
opt_atp6_HA      GCTTTGAAGTCTGCTGATATTGGTATTGCTATGGGTATCAACGGTACTGAAGTTGCTAAA 
                 ** ***** ** ***** ** ** ** *********** ** ** ** ** ** ****** 
 
pfatp6           GAAGCATCAGATATTGTTTTAGCTGATGATAATTTTAATACTATAGTTGAAGCAATTAAA 
opt_atp6_HA      GAAGCTTCCGATATAGTTTTGGCCGATGATAACTTCAACACCATCGTTGAAGCTATCAAA 
                 ***** ** ***** ***** ** ******** ** ** ** ** ******** ** *** 
 
pfatp6           GAAGGAAGATGTATATATAATAATATGAAAGCATTTATCCGTTATCTAATTAGTAGTAAT 
opt_atp6_HA      GAAGGTAGATGCATATACAACAACATGAAGGCTTTCATCAGATACTTGATCTCCAGTAAC 
                 ***** ***** ***** ** ** ***** ** ** *** * **  * **    *****  
 
pfatp6           ATAGGAGAAGTTGCATCCATTTTTATAACAGCCTTATTGGGTATACCTGACAGTTTAGCT 
opt_atp6_HA      ATTGGTGAAGTTGCCTCTATTTTCATTACCGCCTTGTTAGGTATTCCAGATTCTTTGGCT 
                 ** ** ******** ** ***** ** ** ***** ** ***** ** **   *** *** 
 
pfatp6           CCCGTTCAATTATTGTGGGTAAATTTGGTTACTGACGGATTACCAGCAACAGCACTAGGG 
opt_atp6_HA      CCTGTCCAATTATTGTGGGTTAACTTGGTTACTGATGGTTTACCAGCTACTGCTTTGGGT 
                 ** ** ************** ** *********** ** ******** ** **  * **  
 
pfatp6           TTCAATCCACCAGAACATGACGTAATGAAGTGCAAGCCGAGACACAAAAACGACAATTTA 
opt_atp6_HA      TTTAATCCACCAGAACATGATGTTATGAAGTGCAAGCCAAGACACAAGAATGACAACTTG 
                 ** ***************** ** ************** ******** ** ***** **  
 
pfatp6           ATAAACGGTCTAACTTTATTAAGATATATAATTATTGGAACATATGTAGGAATAGCTACA 
opt_atp6_HA      ATCAATGGTTTGACCTTGTTAAGATATATCATTATCGGTACTTACGTCGGTATTGCCACC 
                 ** ** *** * ** ** *********** ***** ** ** ** ** ** ** ** **  
 
 
 
pfatp6           GTCTCAATATTTGTGTACTGGTTTTTATTTTATCCAGATTCAGATATGCACACGTTGATA 
opt_atp6_HA      GTTTCTATTTTTGTTTACTGGTTTTTGTTCTACCCAGACTCCGATATGCATACCTTGATT 
                 ** ** ** ***** *********** ** ** ***** ** ******** ** *****  
 
pfatp6           AACTTTTATCAATTATCACATTATAACCAATGTAAAGCATGGAATAACTTCCGTGTAAAT 
opt_atp6_HA      AACTTCTACCAATTGAGTCACTACAATCAATGCAAGGCTTGGAACAACTTCAGAGTAAAC 
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                 ***** ** *****    ** ** ** ***** ** ** ***** ****** * *****  
 
pfatp6           AAGGTTTATGATATGTCTGAGGATCACTGTTCATATTTTTCAGCAGGAAAAATTAAGGCA 
opt_atp6_HA      AAGGTTTACGATATGTCCGAAGATCACTGCTCTTATTTTTCCGCTGGTAAGATTAAGGCT 
                 ******** ******** ** ******** ** ******** ** ** ** ********  
 
pfatp6           AGCACCTTATCTTTATCCGTTTTAGTTTTAATAGAAATGTTTAATGCTTTGAATGCCTTG 
opt_atp6_HA      TCTACCTTGTCTTTGTCCGTTTTGGTTTTGATCGAAATGTTCAATGCTTTGAACGCCTTG 
                    ***** ***** ******** ***** ** ******** *********** ****** 
 
pfatp6           AGTGAGTATAATTCCTTATTTGAAATACCACCATGGAGAAATATGTACCTAGTATTAGCT 
opt_atp6_HA      TCCGAATACAACTCCTTGTTTGAAATTCCACCTTGGAGAAATATGTACTTGGTTTTGGCT 
                    ** ** ** ***** ******** ***** *************** * ** ** *** 
 
pfatp6           ACTATAGGTTCCTTACTTTTACATGTCTTAATACTTTACATTCCACCCTTAGCTCGTATT 
opt_atp6_HA      ACTATCGGTTCTTTGTTGTTGCACGTTTTGATCTTGTACATTCCACCATTGGCTAGAATC 
                 ***** ***** **  * ** ** ** ** **  * *********** ** *** * **  
 
pfatp6           TTTGGTGTTGTTCCATTAAGTGCATATGACTGGTTCTTAGTATTCTTGTGGTCCTTCCCA 
opt_atp6_HA      TTTGGTGTTGTTCCATTGTCTGCTTACGATTGGTTCTTGGTTTTTTTGTGGTCTTTCCCA 
                 *****************   *** ** ** ******** ** ** ******** ****** 
 
pfatp6           GTTATTATACTTGACGAAATTATTAAATTCTATGCAAAGAGGAAATTAAAGGAAGAGCAA 
opt_atp6_HA      GTCATCATCTTGGACGAAATCATTAAGTTCTACGCCAAGAGAAAGTTGAAAGAAGAACAA 
                 ** ** **  * ******** ***** ***** ** ***** ** ** ** ***** *** 
 
pfatp6           AGAACCAAGAAAATTAAAATTGATTAA--------------------------------- 
opt_atp6_HA      AGAACTAAGAAAATCAAGATTGACGGTGGTGGTTACCCATATGATGTTCCAGATTATGCT 
                 ***** ******** ** *****                                      
 
pfatp6           ------------------------------------------------------------ 
opt_atp6_HA      TACCCTTACGATGTACCTGATTACGCATATCCATACGATGTCCCAGACTACGCTCATGGT 
                                                                              
 
pfatp6           ---------------- 
opt_atp6_HA      GTTTAACCCGGGCGAT 
 
 Alignment of pfatp6 aminoacid sequence and the S. cervisiae 7.1.4.
codon optimized atp6 sequence 
In green, 3xHA tag coding sequence. 
PfATP6      MEEVIKNAHTYDVEDVLKFLDVNKDNGLKNEELDDRRLKYGLNELEVEKKKSIFELILNQ 
opt         MEEVIKNAHTYDVEDVLKFLDVNKDNGLKNEELDDRRLKYGLNELEVEKKKSIFELILNQ 
            ************************************************************ 
 
PfATP6      FDDLLVKILLLAAFISFVLTLLDMKHKKIEICDFIEPLVIVLILILNAAVGVWQECNAEK 
opt         FDDLLVKILLLAAFISFVLTLLDMKHKKIEICDFIEPLVIVLILILNAAVGVWQECNAEK 
            ************************************************************ 
 
PfATP6      SLEALKELQPTKAKVLRDGKWEIIDSKYLYVGDIIELSVGNKTPADARIIKIYSTSLKVE 
opt         SLEALKELQPTKAKVLRDGKWEIIDSKYLYVGDIIELSVGNKTPADARIIKIYSTSLKVE 
            ************************************************************ 
 
PfATP6      QSMLTGESCSVDKYAEKMEDSYKNCEIQLKKNILFSSTAIVCGRCIAVVINIGMKTEIGH 
opt         QSMLTGESCSVDKYAEKMEDSYKNCEIQLKKNILFSSTAIVCGRCIAVVINIGMKTEIGH 
            ************************************************************ 
 
PfATP6      IQHAVIESNSEDTQTPLQIKIDLFGQQLSKIIFVICVTVWIINFKHFSDPIHGSFLYGCL 
opt         IQHAVIESNSEDTQTPLQIKIDLFGQQLSKIIFVICVTVWIINFKHFSDPIHGSFLYGCL 
            ************************************************************ 
 
 
 
PfATP6      YYFKISVALAVAAIPEGLPAVITTCLALGTRRMVKKNAIVRKLQSVETLGCTTVICSDKT 
opt         YYFKISVALAVAAIPEGLPAVITTCLALGTRRMVKKNAIVRKLQSVETLGCTTVICSDKT 
            ************************************************************ 
 
PfATP6      GTLTTNQMTTTVFHLFRESDSLTEYQLCQKGDTYYFYESSNLTNDIYAGESSFFNKLKDE 
opt         GTLTTNQMTTTVFHLFRESDSLTEYQLCQKGDTYYFYESSNLTNDIYAGESSFFNKLKDE 
            ************************************************************ 
 
PfATP6      GNVEALTDDGEEGSIDEADPYSDYFSSDSKKMKNDLNNNNNNNNNSSRSGAKRNIPLKEM 
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opt         GNVEALTDDGEEGSIDEADPYSDYFSSDSKKMKNDLNNNNNNNNNSSRSGAKRNIPLKEM 
            ************************************************************ 
 
PfATP6      KSNENTIISRGSKILEDKINKYCYSEYDYNFYMCLVNCNEANIFCNDNSQIVKKFGDSTE 
opt         KSNENTIISRGSKILEDKINKYCYSEYDYNFYMCLVNCNEANIFCNDNSQIVKKFGDSTE 
            ************************************************************ 
 
PfATP6      LALLHFVHNFDILPTFSKNNKMPAEYEKNTTPVQSSNKKDKSPRGINKFFSSKNDNSHIT 
opt         LALLHFVHNFDILPTFSKNNKMPAEYEKNTTPVQSSNKKDKSPRGINKFFSSKNDNSHIT 
            ************************************************************ 
 
PfATP6      STLNENDKNLKNANHSNYTTAQATTNGYEAIGENTFEHGTSFENCFHSKLGNKINTTSTH 
opt         STLNENDKNLKNANHSNYTTAQATTNGYEAIGENTFEHGTSFENCFHSKLGNKINTTSTH 
            ************************************************************ 
 
PfATP6      NNNNNNNNNSNSVPSECISSWRNECKQIKIIEFTRERKLMSVIVENKKKEIILYCKGAPE 
opt         NNNNNNNNNSNSVPSECISSWRNECKQIKIIEFTRERKLMSVIVENKKKEIILYCKGAPE 
            ************************************************************ 
 
PfATP6      NIIKNCKYYLTKNDIRPLNETLKNEIHNKIQNMGKRALRTLSFAYKKLSSKDLNIKNTDD 
opt         NIIKNCKYYLTKNDIRPLNETLKNEIHNKIQNMGKRALRTLSFAYKKLSSKDLNIKNTDD 
            ************************************************************ 
 
PfATP6      YYKLEQDLIYLGGLGIIDPPRKYVGRAIRLCHMAGIRVFMITGDNINTARAIAKEINILN 
opt         YYKLEQDLIYLGGLGIIDPPRKYVGRAIRLCHMAGIRVFMITGDNINTARAIAKEINILN 
            ************************************************************ 
 
PfATP6      KNEGDDEKDNYTNNKNTQICCYNGREFEDFSLEKQKHILKNTPRIVFCRTEPKHKKQIVK 
opt         KNEGDDEKDNYTNNKNTQICCYNGREFEDFSLEKQKHILKNTPRIVFCRTEPKHKKQIVK 
            ************************************************************ 
 
PfATP6      VLKDLGETVAMTGDGVNDAPALKSADIGIAMGINGTEVAKEASDIVLADDNFNTIVEAIK 
opt         VLKDLGETVAMTGDGVNDAPALKSADIGIAMGINGTEVAKEASDIVLADDNFNTIVEAIK 
            ************************************************************ 
 
PfATP6      EGRCIYNNMKAFIRYLISSNIGEVASIFITALLGIPDSLAPVQLLWVNLVTDGLPATALG 
opt         EGRCIYNNMKAFIRYLISSNIGEVASIFITALLGIPDSLAPVQLLWVNLVTDGLPATALG 
            ************************************************************ 
 
PfATP6      FNPPEHDVMKCKPRHKNDNLINGLTLLRYIIIGTYVGIATVSIFVYWFLFYPDSDMHTLI 
opt         FNPPEHDVMKCKPRHKNDNLINGLTLLRYIIIGTYVGIATVSIFVYWFLFYPDSDMHTLI 
            ************************************************************ 
 
PfATP6      NFYQLSHYNQCKAWNNFRVNKVYDMSEDHCSYFSAGKIKASTLSLSVLVLIEMFNALNAL 
opt         NFYQLSHYNQCKAWNNFRVNKVYDMSEDHCSYFSAGKIKASTLSLSVLVLIEMFNALNAL 
            ************************************************************ 
 
PfATP6      SEYNSLFEIPPWRNMYLVLATIGSLLLHVLILYIPPLARIFGVVPLSAYDWFLVFLWSFP 
opt         SEYNSLFEIPPWRNMYLVLATIGSLLLHVLILYIPPLARIFGVVPLSAYDWFLVFLWSFP 
            ************************************************************ 
 
PfATP6      VIILDEIIKFYAKRKLKEEQRTKKIKID-------------------------------- 
opt         VIILDEIIKFYAKRKLKEEQRTKKIKIDGGGYPYDVPDYAYPYDVPDYAYPYDVPDYAHG 
            ****************************                                 
 
PfATP6      -- 
opt         V* 
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7.2. PF3D7_0105800 conserved Plasmodium protein, 
unknown function 
  Genomic DNA sequence 7.2.1.
In lower case, non-coding DNA sequences. 
       1 ATGGCTACAA ATAGTAATAA TAACAACAGT AGTAATAATA ATAACAATTT  
      51 AGAGAACATA AATTTGAGCC TACACAAAAT ATTTAATTGT CGTCATAGTG  
     101 TTCCTAGTAA ATTTATTGAA GATGAAAAAG AAAATATAAG GAAACGTAGA  
     151 TGCACAGTGG CTCATATGTA TGAGAAGAAT ATAAATTCAA AGAATACTAA  
     201 TTATGATTAT TTAACCTATA ATTTTAATAA CTCGATAAGA AAGAGAAGAA  
     251 AATATTCTCC TACTATTCAA ACCCAATTAT ATAAAAAATA TTCTCCTTTA  
     301 AAAAGTAGAA TAGGATTAAG AAATAGTGTA GATGAGAGTA TTAAAAAAAG  
     351 TGCATGTATA AGATCTATTG TTAATAATAC GATAAAGAAT AAAACTAGGG  
     401 ATAGTAGTTA TATTCGAAAT GAAAATAAAA GTTGTTATAT TGGTGATAAA  
     451 AATAATAAAA TAATATATGA AGGCTCTAAA TATAATGAAA AAAATAATTA  
     501 TATAGATGAA AATATGAATG ATAGAAAAAT GTATATAAAT AAAAATTTAC  
     551 ATGATACATA TATTATGAGT AATACTACAC AAAGCGATAA TTTTTTTAGA  
     601 AGTAAAAATA TTAATAGAAT AAATAGTTTA ATAACGAATA GAGAAACGGC  
     651 ACCTATATAT ATGAATTCTG AATCTACACT TTCAAGTTTT AATTTTGAAC  
     701 CCAATGTAGA ACAAAAACAT TCTAAATTAA CATTAGATAT GAAAAGTACA  
     751 ATTTATATAC CATCAGATAT GTCTTTATTT AATAAGAATA AATATTCTTT  
     801 TATTTCAAAT ATGTCCTTAG AAGATTTAAA AAAAATGAAT AATGAATATA  
     851 CATCTAAAAA TAATTACAAT GTAGAAATTA CAAATAAAAT AAATGAACAT  
     901 TTACCTTTAA AAAGAAGACA CAGCACACAT GTGAGTAGTG AATATGATAA  
     951 ATATAATAAT TCTCAATCAT TTCTTATGAA TAAGAGATTA AAAGACGATC  
    1001 AAAATTTATC TAAAAATAAT GTTCGTAGGT ATAGCGATAC ATTAGAATTA  
    1051 AATATGTTAA ATAATAATAT GGGACCTAAT GAAAAGAATA ATGAATATAT  
    1101 TTCGAAAATG AATAAAGATC ATTATATATT AAATCCCAAC AATTATAATA  
    1151 AATATAATAA TAACAACAAT TGTTTCAATA ATATGAAGAA CTCTTCCGTT  
    1201 TTATATGAAT ATAACAAAAA AAATCTTTCA CATATGAAAC AAAATGATAA  
    1251 TCATCTCAAT AAATCGGTCG CTTCACATTA TGAAGAAAAC AATCACCCTT  
    1301 TACTTCATAC CTGTTTTTTT AAAAATGCGG AAGATTTTGA GAACAACGAT  
    1351 ATTAAAAGGA AAGgtaacca ccacacacaa ataaatatat acatatatat  
    1401 aatatatata tatatatata tgtgtgtgtg tgtgtgtaca tgtttgtgtt  
    1451 tttatttgtg tttatatttt tgttatatgt gtaattattt atattattgt  
    1501 acaaaagtgg tatccacaaa atgaataatc cattaatatt atcttttatt  
    1551 ttattttatt ttattttatt tcattttatt ttattttatt ttattttatt  
    1601 tcattttaat ttaatttaat tttattattt tttttttttt ttagAAAAAG  
    1651 TCGAATCCAA CGAAGAAGAC GAATTTGTCA TGAAAAAGGA CGCGGAATAT  
    1701 GTGTTTAGTC AAAAGTTTTT TCAAGATATT TATTCTAATA TTAAGAGCAA  
    1751 AGGGGAATTA AATTTTATAG ACGAGTTGCT ACAATTAGAT GAAGAGAATT  
    1801 ATATTAGTAA AAGTAAGTTG AATAAAATTG TTGAGAATGC AAAGAATAAA  
    1851 GAAATGAAGT ATCATTATAT TGATAGGATG TTTTTATATC GACATGCAAA  
    1901 AAATGTTATA GATGATGCTG ATTATGAAAA TTACAAAAAT AAATGTAGAA  
    1951 GTGAATATAA ATATTTAGAT GTACCATTCC CAAATTTGTG TGATATTATG  
    2001 AATCTTAAAC GTATTAGTAA CGATGACGAA ATTGATGACA CAGACGAATT  
    2051 TTATGATGCA GAAGTTGCAT TATTAGAGGA ATATTATTCA AGATGTAATA  
    2101 GACAAAAACA AGGTAAAGGT AATGATATTT TCTTAGATAA CAAAAAACAC  
    2151 AAAAAAAATA TAGAAAAGCA AAAAGATAAA AAAGGAAAGG AAAAAATAAA  
    2201 AAAAAATCAA CAAGAATTAA ATGATGATCA TAATAATAAA ATTATTTTAA  
    2251 AAAATAATAA GCTACATTTC AATAAAAATA ATGTAACAGA AGATTTATCT  
    2301 TTATTAGAAA AAAGAGATAA ATTAATGCAT TTTATGAATA AAATGAAAAG  
    2351 ACAAAAAGAT TCCTTTTATG AATCTATTAT AGATGCTCCA GACTTTTCTA  
    2401 AATTACTAGA ACCTGTTTTC TCATTAAACG AAAGCTTCTT ATTATCACAT  
    2451 CAATTATTTA ATGTACAATA TGCAGCACAA TTAGGACCTG TTGTATATCT  
    2501 TACAAAAACG GAGGATGAAA ATTATATATA TAGAGCTATT GAGGTAAGTA  
    2551 GACTCTTTGA AGAAAAAGTG AAATCTATTC TTGATAATCA AAAAAATCAT  
    2601 TCGGGTATGA AAAATAAAAG TGATTCATAT GATTGTTTTA CAAATGAAAA  
    2651 AAATCCATTC TTACATGAAC TAGATGTCAA ATATTATCTT CGTATCCCAA  
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    2701 TGAGTACTGG ATGGAATCAT TTCGGTTATT TAAAAAATCA AAATAATGTC  
    2751 CTATTTTTTA GACGACCTAA AAATAATTAA  
 
 
 Aminoacid sequence 7.2.2.
       1 MATNSNNNNS SNNNNNLENI NLSLHKIFNC RHSVPSKFIE DEKENIRKRR  
      51 CTVAHMYEKN INSKNTNYDY LTYNFNNSIR KRRKYSPTIQ TQLYKKYSPL  
     101 KSRIGLRNSV DESIKKSACI RSIVNNTIKN KTRDSSYIRN ENKSCYIGDK  
     151 NNKIIYEGSK YNEKNNYIDE NMNDRKMYIN KNLHDTYIMS NTTQSDNFFR  
     201 SKNINRINSL ITNRETAPIY MNSESTLSSF NFEPNVEQKH SKLTLDMKST  
     251 IYIPSDMSLF NKNKYSFISN MSLEDLKKMN NEYTSKNNYN VEITNKINEH  
     301 LPLKRRHSTH VSSEYDKYNN SQSFLMNKRL KDDQNLSKNN VRRYSDTLEL  
     351 NMLNNNMGPN EKNNEYISKM NKDHYILNPN NYNKYNNNNN CFNNMKNSSV  
     401 LYEYNKKNLS HMKQNDNHLN KSVASHYEEN NHPLLHTCFF KNAEDFENND  
     451 IKRKEKVESN EEDEFVMKKD AEYVFSQKFF QDIYSNIKSK GELNFIDELL  
     501 QLDEENYISK SKLNKIVENA KNKEMKYHYI DRMFLYRHAK NVIDDADYEN  
     551 YKNKCRSEYK YLDVPFPNLC DIMNLKRISN DDEIDDTDEF YDAEVALLEE  
     601 YYSRCNRQKQ GKGNDIFLDN KKHKKNIEKQ KDKKGKEKIK KNQQELNDDH  
     651 NNKIILKNNK LHFNKNNVTE DLSLLEKRDK LMHFMNKMKR QKDSFYESII  
     701 DAPDFSKLLE PVFSLNESFL LSHQLFNVQY AAQLGPVVYL TKTEDENYIY  
     751 RAIEVSRLFE EKVKSILDNQ KNHSGMKNKS DSYDCFTNEK NPFLHELDVK  
     801 YYLRIPMSTG WNHFGYLKNQ NNVLFFRRPK NN  
 
 
7.3. PF3D7_0105900 DNA binding protein, putative 
  Genomic DNA sequence 7.3.1.
       1 ATGCTGAAAG GATTTAAGCA TATTTTAAAC ACATCACATA TTCTTTCATT  
      51 AGATTTTTCT TTTGGCGCAC GTTTTTATAA ATCATGTTTT TCTTCGCGTA  
     101 CAACATATGA AAATAATACA TATGAACAAT TGGAGGCTCT AAAATTTCCT  
     151 GGGCTTGTTA TATATGTTAA TAAAGATAAT ATAGAAAAAT ATCAAGAGAA  
     201 CATTTTGAAG TATTTCAATA CAAATGTTAT TGGATTCGAC ACGGAATTTA  
     251 TTATTGATAT AAATGAAAAA GAGAATAATA ATGAGAACAG ATCAATAAGT  
     301 TGTTATATTA AAAATGGAAA GGATAATAAT TATATAAATT CACAATTAAT  
     351 AAATATATTT AAAAAAAAAA AAAAAAATTA TGCATATAAC TTATGTAATA  
     401 ATGAAAAGAA TAAAATTTTA TGTTTAATTC AATTATGCTC TTCTGATTTA  
     451 TGTTTTGTAT TTAATATTCA CAAATTAAAT GGACATATCC CTATAAGCGT  
     501 AAAAAATATT CTAGAGAACG AAGAAATTAT AAAAGTTGCT CATGATATTA  
     551 AAAATGAAAA GGATATGTTT CTATCAAATA ATATACAAAT AAAAAATGTT  
     601 TTTGATTTAT ATAATTATGC CATTGATAAT TTTATATATC CTCCTTCATT  
     651 ACAATCTTTA GTTAAAATAT ATCTTAACAA ATTCTTAGAT AAAAAATTTA  
     701 GACTATCCAA CTGGTTAAAT TATTCCTTAT TACAAGAACA AATACTCTAT  
     751 GCAGCAGTCG ATGCATATGC ATCTAGACAA ATATATTTTC ATTTGGACGA  
     801 AAACAAAAAA AAAAGTCAAT CTTATATTCT TAATTATATC CTACAAGAAA  
     851 ACCAAATAAA ATCATGTTAT CAAAAGTTTA ATAAATATAC ATATAAAAAA  
     901 AAGGACCTCA ATAATGAAAA TATCATAAAA ATAGAAGAAA AAAACATACA  
     951 AAATATCGAA TCTATCAATA ATACTATACA CAATCAAAAA AAAAAAAATA  
    1001 ATATAAACAA TCAACATCAA AATGAATATG ATTCAAATAT TAAACAATTA  
    1051 CAATCTTTCT ATACACATAG TAATCAAAAC AAGAAAAATT ATGAATTTGT  
    1101 AGAAAAATAC AAACTTCAAT TAATAAACAG TTTAAAAAAT GAAATTCATA  
    1151 ACAAGTGTAC TAATATGACT AATATCTCAT TTGTCCAAGA AATGACTTTC  
    1201 ACAAATAATA CTTATAAAAA TATTTTGTCC TTAAAACATA ATCAAAATAA  
    1251 TTATAATTTC ATAAAGTTCT CTTCGGTCAA TTATGATGAG GAAATAAATT  
    1301 CATGCTACCA AATTTTAACA TACCTTGATC ACACGCTCTG CACATAA  
 
 Aminoacid sequence 7.3.2.
       1 MLKGFKHILN TSHILSLDFS FGARFYKSCF SSRTTYENNT YEQLEALKFP  
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      51 GLVIYVNKDN IEKYQENILK YFNTNVIGFD TEFIIDINEK ENNNENRSIS  
     101 CYIKNGKDNN YINSQLINIF KKKKKNYAYN LCNNEKNKIL CLIQLCSSDL  
     151 CFVFNIHKLN GHIPISVKNI LENEEIIKVA HDIKNEKDMF LSNNIQIKNV  
     201 FDLYNYAIDN FIYPPSLQSL VKIYLNKFLD KKFRLSNWLN YSLLQEQILY  
     251 AAVDAYASRQ IYFHLDENKK KSQSYILNYI LQENQIKSCY QKFNKYTYKK  
     301 KDLNNENIIK IEEKNIQNIE SINNTIHNQK KKNNINNQHQ NEYDSNIKQL  
     351 QSFYTHSNQN KKNYEFVEKY KLQLINSLKN EIHNKCTNMT NISFVQEMTF  
     401 TNNTYKNILS LKHNQNNYNF IKFSSVNYDE EINSCYQILT YLDHTLCT 
 
 
 
7.4. PF3D7_0106000 conserved Plasmodium protein, 
unknown function 
  Genomic DNA sequence 7.4.1.
       1 ATGCGATCCA AATATTACAA GGAAGAAGAA AATAAAGGTT TTATAAAAAC  
      51 GCATTATTTT CGTAAAATCG ATACAGAGAA AATCGACAAG AAATTAATAA  
     101 GCCTTGAGAA TAATTTTAAT GGTGATGATG TATATTTAGA CATTGTAATA  
     151 CATGATAAGG AACGAAATAA TTTTGATTTT TTCCTTATGA GAATAACAGA  
     201 AAGTTCAAGT GTTAATAATA GTTTAGATGC ATGGAATCAT ATCGATATAA  
     251 CTAATATATA TAATTATATA TTATATGATA ATAAATATTG TAGTGATATA  
     301 ATAAATGAAA AAAAAGGATA TTTAATATTG AAATTAAAAT ATACGAATGA  
     351 AAATAATATT ATTACATCTT ATTTTAAAGT TCATTGTAGA AATACAAAAT  
     401 GGGAAAATGA TAAGAAAGTA TGGCATATAC CTTTATTTTA TATATTTGAA  
     451 ATGTCTAAAC TTACCTTGTT TTTAGGGGGT ACCGTTAGTG ATACCGTTCT  
     501 TTATTATTTA TGTAAATTAT TTCATCATTT TTCTAGTATC AAAAATGTAA  
     551 ATAGCAATGT TAAAATGAAT GAATTATCTA AGGATCAGCT TATAAAAACG  
     601 GATGAAATAT GTGACACTAC CCATAAGGAA AAAAAGAACA ACGATGATGA  
     651 TAATACAGAT AATTATCACA ACAATAAAAA TAATAGTAAT AATAATAATA  
     701 ATAATAATAA TAATAATCAA AACAACAACA ATAATAATAA TATTGCTGTT  
     751 CAGGTTAATT GCAGGAAACA AGATAAATTT TATCCCAGTA ATAATGATGT  
     801 AATAAGAAAT TCAAGTCCAA AAATTATTTT AGAAAACAAA AATGAAGAAA  
     851 TAAATGTTAT AGAAAAGGAT TTAACCTTAA AGGATAACGG TGATGTATTA  
     901 TACAAGGAGA AAAAAATAAG AAATGATGAT GACAGGAATT ACAACACCGA  
     951 TGAGGACACA CATTATGGCA ATAATGATGA TACTTATTAT GATGATGAAA  
    1001 GTTGTGATAA TAAAAATGAT GATTCTGTTA ATAAAAATAA TATATGTGTT  
    1051 AATAAAAGTG ACGATTCTGT TAATAAAAGT AATGATTGTG ATAATAAAAA  
    1101 TGATGATGGT GTTAATAAAA ATGATCATTG TGATAATAAA AATGATCATT  
    1151 GTGATAATAA GAATGACCAT TGTGATAATA TAAATGACCA TTGTGATAAT  
    1201 AAGAATGACC ATTGTGATAA TAAAAATGAC CATTGTGATA ATAAAAATGA  
    1251 CCATTGTGAT AATAAGAATG ACCATTGTGA TAATAAGAAT GACCATTGTG  
    1301 ATAATAAGAA TGACCATTGT GATAATAAGA ATGACCATTG TGATAATATA  
    1351 AATGATCGTC ATACTAACCA AGAGAATAAT GTTTCGAAAG ACTGTAATAA  
    1401 GAATACAACA AATGAAATAA GTTTCAACTT GGATATTTTT ATAAAGGAAA  
    1451 ATAAATTAAA TTTTATAGAA TATATTAAGA ATGTAAGAAT GTTCAGGATT  
    1501 GAACACATCA TTATAAATAA TATTGTAAAA GGTGATACCA TGTATATAAA  
    1551 GATAATACCA TATAATGAAG ATATCGTTAC AAAAATAAAG CAAACAAATT  
    1601 TTATACAATG GAATAGAACG GAAAATATAT TATTAATAAA AAAAAGTAAT  
    1651 TTTAAAAATT TTTATATAAA TATAATAAAA GGTTTTAATT TCAAGTTATG  
    1701 TTCTTATTAT GATTATTTTA AATTATTTAG ACAAAAAATT ATGGAAAATG  
    1751 ATTCTAAATC GTTAAAAGGA AATTTTAGTG TCACAACAAA TATAACAATA  
    1801 AATACCGAAT ATTTAAGTAA GAAATTTAAT AAAAGAAAAA TGGATTTTCA  
    1851 TAATATAGAA GAAGAAATAA CCGATAAAGG AAATGTTCTA AAACATTCCA  
    1901 AAAAAAAGAA AAAATATAAA AATGAGTTTG GTTATGAGAG TACAGATTCA  
    1951 TGTAATTCAG ATGAATTATC GAATAATGTG GATTCAAGTT ATTATGAAGG  
    2001 TAGAGAATTA GTAAATAAAA TAAAATTAGT TGGTGCGGCA AATAATTATT  
    2051 ATAAAGAAGT TATATATAAT AAATTACATA AAATAAAACA TTTACGTCCA  
    2101 CCTAATTATA CATATGACCC TAAAGGATTA ATTACGAAAA ATGGAGCAGG  
    2151 TACCAAAGGT ATTGAAATTT TTGATATGCC TAGTGATATT AATGAATGGA  
    2201 ATAAAATAAG TTTTTGTATT GTACCTAATG AGAAAAAGGA TATCGATTTA  
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    2251 TATGATCCAA AAATTTTATG TAGTTTAGTT AGTGATGTTT ATTTACTTAA  
    2301 AGAAAAAGCA TTAGATATAA TATTGAAAAA TTATAAAAAA TGGCCTGAAT  
    2351 ATACTGATGT GTTTTGGAAT ACGGTATGCT CCGAAAATGA ATTTATTGTA  
    2401 TGTAATAAAA ACTTTAATAC AAGACAAAAA TTAGCTCATG ATAGATTATT  
    2451 TAATAAACAA TACTTTTATA TTTTTAATAT GGAAAGTATT AAACATTCAA  
    2501 ATTATTATAA TCCATTATTT TTATGTAAAG TTTTAATTAC CTTAGGTGAA  
    2551 GGAATCCTTG TTCAACATCC ATATGATGCA GAGTATATCA TTATCTCAAA  
    2601 TTCTAATGAT TTTAATGCTA TACAATTCTA TAATTATCTT CATGAAAAAA  
    2651 AAAAAAAAAA AAAAAAATTA CCCTTATTTG TAACTCCAAA GTTTATATAT  
    2701 GATTGTATTT TAAACTATTC TATTTCTTAT CCTTCAAAAA ATAAAAACCA  
    2751 CTTTGCCTTC TCCTCCTAA  
 
 Aminoacid sequence 7.4.2.
       1 MRSKYYKEEE NKGFIKTHYF RKIDTEKIDK KLISLENNFN GDDVYLDIVI  
      51 HDKERNNFDF FLMRITESSS VNNSLDAWNH IDITNIYNYI LYDNKYCSDI  
     101 INEKKGYLIL KLKYTNENNI ITSYFKVHCR NTKWENDKKV WHIPLFYIFE  
     151 MSKLTLFLGG TVSDTVLYYL CKLFHHFSSI KNVNSNVKMN ELSKDQLIKT  
     201 DEICDTTHKE KKNNDDDNTD NYHNNKNNSN NNNNNNNNNQ NNNNNNNIAV  
     251 QVNCRKQDKF YPSNNDVIRN SSPKIILENK NEEINVIEKD LTLKDNGDVL  
     301 YKEKKIRNDD DRNYNTDEDT HYGNNDDTYY DDESCDNKND DSVNKNNICV  
     351 NKSDDSVNKS NDCDNKNDDG VNKNDHCDNK NDHCDNKNDH CDNINDHCDN  
     401 KNDHCDNKND HCDNKNDHCD NKNDHCDNKN DHCDNKNDHC DNKNDHCDNI  
     451 NDRHTNQENN VSKDCNKNTT NEISFNLDIF IKENKLNFIE YIKNVRMFRI  
     501 EHIIINNIVK GDTMYIKIIP YNEDIVTKIK QTNFIQWNRT ENILLIKKSN  
     551 FKNFYINIIK GFNFKLCSYY DYFKLFRQKI MENDSKSLKG NFSVTTNITI  
     601 NTEYLSKKFN KRKMDFHNIE EEITDKGNVL KHSKKKKKYK NEFGYESTDS  
     651 CNSDELSNNV DSSYYEGREL VNKIKLVGAA NNYYKEVIYN KLHKIKHLRP  
     701 PNYTYDPKGL ITKNGAGTKG IEIFDMPSDI NEWNKISFCI VPNEKKDIDL  
     751 YDPKILCSLV SDVYLLKEKA LDIILKNYKK WPEYTDVFWN TVCSENEFIV  
     801 CNKNFNTRQK LAHDRLFNKQ YFYIFNMESI KHSNYYNPLF LCKVLITLGE  
     851 GILVQHPYDA EYIIISNSND FNAIQFYNYL HEKKKKKKKL PLFVTPKFIY  
     901 DCILNYSISY PSKNKNHFAF SS  
 
 
7.5. PF3D7_0106100 V-type proton ATPase subunit C, 
putative 
  Genomic DNA sequence 7.5.1.
       1 ATGAGTGAAA TTCCCATGTG TTTGTTCATA GCTTGTTCAA CACGAGATAA  
      51 TACAAGCCGT GAATATATTT ATACTATATT GAAGAATCGT CTTTTAGGTA  
     101 GTCATATATG TATAGATACG AATATATTGG ATGTGCCTAC GAATATAAAA  
     151 TTTTGTTCAT TTGATGATTT ATTAAAGTGT GCTGATGATT TACAGAAATA  
     201 TGATAGTTAC GCATATGGTT GTTTAAAAAA GATAGAAAAA ATAGCAAAAG  
     251 AATATGATGA AAATATTGAA TTGAAAATAA TATATCAACG TCAACATATA  
     301 AATATAGATC AATATATAAG AAGATTTACT TGGGATGATG CAAAATATCC  
     351 AAGGAGTAGA TCTTTAACGG ATACTATTGA TGTTATGATA AATAATATTA  
     401 CAAAATTATC TGATGAAATT CAAATAAAGT CAAGTATGTT AAATGATTTA  
     451 AAAGAAAAGA AAAAAAAAGA AGTACCAAAA AATGATTCCA ATAATTTCTT  
     501 TTTAAGAAAT TTGAATGAAA TATTAACTCC ACAAACTGTT AGCGAAACCG  
     551 ATTTTATAGA AACAGAATAT CTAACAACAC TTATAGCTTA TGTACCTAAA  
     601 AATTCTATAG ATGATTGGTT AAATAATTAT GAAAAATTTT CATCCTATGT  
     651 TGTACCTAGA TCTACAGAAC AATTTAAAGA TTTAATAGAT AAAGATGGAA  
     701 ATACATTATG GAAAGTTTTT GTTTTTAAGA AATTTGCAGA AGATTTTAAA  
     751 AAAGAAGCAA AAGTTAAAAA ATTTGTTGTA AAATCATTTA AATATGATGA  
     801 AAAACAATAT AATGATATGA TGGAATCGAG AACAAAAGTA GAAGCAGAAA  
     851 TCATAAGACA AGAAACTTTT CTAAGACGCA TGTGCTTAGC CGCTTTTTCA  
     901 GATATATTTA TTGCATTCAT TCATATTAAT ATACTTCGAG TCTTTTGTGA  
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     951 ATCTGTATTA CGATTTGGTG TTCCACCTAA TTTTGCTTCA TTTAGTATAA  
    1001 GAATTAATGG AGAAAGTAAA GAAAAAAAAG TCAGAAAAAA ATTATACGAC  
    1051 ATTTTTTCAT CATCTGATTC TATAGGAAAG AATTATATAA AAAGATCTGA  
    1101 TGAAAATGAT GAAGAAATAT ATCCCTACGT TTCGGTGTCC TTTAAAATAT  
    1151 GA  
 
 Aminoacid sequence 7.5.2.
       1 MSEIPMCLFI ACSTRDNTSR EYIYTILKNR LLGSHICIDT NILDVPTNIK  
      51 FCSFDDLLKC ADDLQKYDSY AYGCLKKIEK IAKEYDENIE LKIIYQRQHI  
     101 NIDQYIRRFT WDDAKYPRSR SLTDTIDVMI NNITKLSDEI QIKSSMLNDL  
     151 KEKKKKEVPK NDSNNFFLRN LNEILTPQTV SETDFIETEY LTTLIAYVPK  
     201 NSIDDWLNNY EKFSSYVVPR STEQFKDLID KDGNTLWKVF VFKKFAEDFK  
     251 KEAKVKKFVV KSFKYDEKQY NDMMESRTKV EAEIIRQETF LRRMCLAAFS  
     301 DIFIAFIHIN ILRVFCESVL RFGVPPNFAS FSIRINGESK EKKVRKKLYD  
     351 IFSSSDSIGK NYIKRSDEND EEIYPYVSVS FKI  
 
7.6. PF3D7_0106200 conserved Plasmodium protein, 
unknown function 
  Genomic DNA sequence 7.6.1.
In lower case, non-coding DNA sequences. 
       1 ATGGAAAATA TAAATAGAGT AAATAAATAT GACAACCCAA ATGAAGCTAT  
      51 CAAAAATATG GTTGACAAAA TAATAAATAA GTTGAATAAG ACACAGAAAG  
     101 ATTCTTCTAA AAGGATATAT TATAGCAGgt ttttatattt ttataaatta  
     151 taatataata aaattaatta tatatatata tatatttata aacacataat  
     201 gtacttatgt atgtgaaatg aaaacataat tattttgtgc atttatatat  
     251 atatatatgt atatttattt atatttatat ttatgatttg tttttgtatt  
     301 atatttcttt tgcttatttg atgtacattt taattttttt tttatgaatt  
     351 gaaaccactc ttagGAAGGA AATGATGAAG TACTTTTTAG ATGCTCAGGA  
     401 TATATTTGAA TATCATGATG TGGGGAAAAA AGGAGAAGTT GATATAACAT  
     451 TATTTCCTAA AATGGCTAGA CAATTAAAAC AAGTATATGA TATAAGAGAT  
     501 ATAAATAATT TTAAAAAAGA AATGAAAATT AAAAAAATTT ATAAGATGGA  
     551 TTTACAATTA TTTTTTACTT TATTAAAAAG AAAAATACTT TATTCCATAA  
     601 ATAATAGTAA TAATAATGAA AATGACAATT CATCCTTTAG ACAACATTAT  
     651 GACATTTTAG ATATGAAAAA AAAACAATTA TTAGATGTAG ACGAATTAAG  
     701 AACTTATTTA GGATTAATGG GTGATAAAAT AAATCCAGAT GATTTTAATA  
     751 TTTTATTAAG ATATAACTTG ATAAATAATC ACAGAATAAA TAAAGATGAT  
     801 ATTGTATTAG ATGAAAATAA AGAAATTAAA AATATATCTT TTAATGCGTA  
     851 CGTTGACATG TTAACATGTT ATAAATATAT ATGA  
 
 Aminoacid sequence 7.6.2.
       1 MENINRVNKY DNPNEAIKNM VDKIINKLNK TQKDSSKRIY YSRKEMMKYF  
      51 LDAQDIFEYH DVGKKGEVDI TLFPKMARQL KQVYDIRDIN NFKKEMKIKK  
     101 IYKMDLQLFF TLLKRKILYS INNSNNNEND NSSFRQHYDI LDMKKKQLLD  
     151 VDELRTYLGL MGDKINPDDF NILLRYNLIN NHRINKDDIV LDENKEIKNI  
     201 SFNAYVDMLT CYKYI  
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8. Appendix II: Plasmid maps 
8.1. pUF1-CAS9 
 
The vector pUF1-Cas9 encodes the sequence of the Cas9 endonuclease flanked by nuclear 
localization signals (NLS). Its expression is regulated by the promoter region of the heat 
shock protein 86 (5’ hsp) and the 3’UTR region of the P. berghei dhfr (3’ Pb dhfr). The 
selection marker of the plasmid is the yeast dihydroorotate dehydrogenase gene (ydhodh). 
This plasmid kindly was provided by Dr. José Juan Lopez Rubio [78]. 
 
8.2. pL6 plasmids 
The pL6 plasmid bears the sgRNA-expression cassette. The expression of the sgRNA is 
regulated by the promoter and the 3’UTR region of the P. falciparum U6 snRNA polymerase 
III (5’ U6). Positive selection is achieved with the selection marker human dihydrofolate 
reductase gene (hdhfr) and negative selection marker with the bifunctional yeast cytosine 
deaminase and uridyl phosphoribosyl transferase (yfcu). The original pL6 vector was kindly 
provided by Dr. José Juan Lopez Rubio [78].  
 
874 KpnI (1) 
862 AccI (1) 
3´Pb 860..9 
1 NotI (1) 
Cas9 5156..886 
5158 XhoI (1) 
yDHODH K7 6053..8539 
6018 SpeI (1) 
6007 SacII (1) 
5´hsp 5998..5164 
8553 XbaI (1) 
8557 EcoRI (1) 
8575 NcoI (1) 
8585 AvrII (1) 
AMpR 9231..9889 
pUF1_Cas9 
11096 bp 
2800 SacI (1) 
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 pL6-HRA-guide6 8.2.1.
 
The original pL6 vector was digested with the enzyme BtgZI and the PfATP6 guide 6 
sequence was cloned into the vector using the In Fusion cloning approach (primers [49] and 
[50]). The pfatp6 homology region containing the single nucleotide polymorphisms coding for 
the double mutations A108T and A109T (HRA) was amplified from Dd2 cDNA with the 
primers ATPase6-HRA(-79)-SpeI-for (39), ATPase6-HRA-855-BssHII-rev (40), ATPase6-
620-1080-for (2) (43) and ATPase6- 620-1080-rev (2) (44) and cloned into the vector using 
the restriction enzymes SpeI and BssHII. 
 
 pL6-HRAsi-guide6 8.2.2.
 
The original pL6 vector was digested with the enzyme BtgZI and the PfATP6 guide 6 
sequence was cloned into the vector using the In Fusion cloning approach (primers (49) and 
 
FCU K7 10..2847 
1 NotI (1) 
2866 SpeI (1) 
HRA 2872..3824 
3825 BssHII (1) 
hDHFR K7 3831..5978 
U6 3´ 7506..8032 
Guide6 7408..7427 
U6 upstream 6258..7407 
6252 NcoI (1) 
5979 EcoRI (1) 
pL6-HRA+guide6 
10463 bp 
AmpR 8598..9257 
 
FCU K7 10..2847 
1 NotI (1) 
2866 SpeI (1) 
HRA 2872..3824 
3825 BssHII (1) 
hDHFR K7 3831..5978 
U6 3´ 7506..8032 
Guide6 7408..7427 
U6 upstream 6258..7407 
6252 NcoI (1) 
5979 EcoRI (1) 
pL6-HRA+guide6 
10463 bp 
AmpR 8598..9257 
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(50)). The pfatp6 homology region containing the silent mutations coding for the aminoacids 
residues A108 and A109 (HRA) was amplified from Dd2 cDNA with the primers ATPase6-
HRA(-79)-SpeI-for (39), ATPase6-HRA-855-BssHII-rev [40], ATP6 HRA sil-for (47) and ATP6 
HRA sil-rev (48) cloned into the vector using the restriction enzymes SpeI and BssHII. This 
vector was generated to test the efficacy of the guide 6. 
 
 pL6-HRB-guide7 8.2.3.
 
The original pL6 vector was digested with the enzyme BtgZI and the PfATP6 guide 7 
sequence was cloned into the vector using the In Fusion cloning approach (primers [51] and 
[52]). The pfatp6 homology region containing the single nucleotide polymorphism coding for 
the mutation F972Y, as well as shield mutations (HRB) was amplified from Dd2 cDNA with 
the primers ATPase6-HRB-2269-SpeI-for (41), ATPase6-HRB-3409-BssHII-rev (42), 
ATPase6-shield(guide7)-for (45) and ATPase6-shield(guide7)-rev (46) and cloned into the 
vector using the restriction enzymes SpeI and BssHII 
 
8.3. pARL-gene-HA plasmids 
The coding sequence of the genes present in the DNA locus amplified in the Dd2 parasites 
resistant to 1 µM SC83288 were amplified from Dd2 cDNA and cloned into a pARL-3xHA tag 
(provided by Dr. Sonia Moliner Cubel) using the restriction enzymes XhoI and AvrII. The 
expression is regulated by the PfCRT promoter and the 3’UTR region of the P. berghei DT. 
The original pARL1a+ vector was kindly provided by Prof. Tim Gilberger  [246].  
 
1 NotI (1) 
2866 SpeI (1) 
HRB2 2872..4034 
hDHFR K7 2912..5007 
4035 BssHII (1) 
U6 3´ 7716..8242 
Guide 7 7618..7637 
U6 upstream 6468..7617 
6462 NcoI (1) 
6189 EcoRI (1) 
AmpR 8808..9467 
pL6-HRB+guide7 
10673 bp 
FCU K7 10..2847 
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 pARL-0105800 8.3.1.
 
The primers 800-XhoI-for (25) and 800-AvrII-rev (26) were used for the amplification of the 
gene coding sequence.  
 
 pARL-0105900-HA 8.3.2.
 
The primers 900-XhoI-for (27) and 900-AvrII-rev (28) were used for the amplification of the 
gene coding sequence. 
 
2068 NcoI (1) 
5´UTR PfCRT 562..2060 
561 NotI (1) 
4566 AvrII (1) 
3x HA tag 4581..4673 
hDHFR 5998..6561 
5161 EcoRV (1) 
3´UTR Pb DT 4680..5160 
4674 XmaI (1) 
AmpR 7825..8616 
pARL-0105800-HA 
9259 bp 
2060 XhoI (1) 
Pf3D7_0105800c 2070..4565 
 
561 NotI (1) 
2060 XhoI (1) 
Pf3D7_0105900c 2070..3413 
3414 AvrII (1) 
3x HA tag 3429..3521 
3522 XmaI (1) 
3´UTR Pb DT 3528..4008 
4009 EcoRV (1) 
hDHFR 4846..5409 
AmpR 6673..7464 
pARL-0105900-HA 
8107 bp 
5´UTR PfCRT 562..2060 
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 pARL-0106000-HA 8.3.3.
 
The primers 000-XhoI-for (29) and 000-AvrII-rev (30) were used for the amplification of the 
gene coding sequence. 
 
 pARL-0106100-HA 8.3.4.
 
The primers 100-XhoI-for (31) and 100-AvrII-rev (32) were used for the amplification of the 
gene coding sequence. 
 
2060 XhoI (1) 
5´UTR PfCRT 562..2060 
561 NotI (1) 
Pf3D7_0106000 2070..4835 
3639 EcoRV (3) 
4308 EcoRV (3) 
hDHFR 6268..6831 
5431 EcoRV (3) 
3´UTR Pb DT 4950..5430 
4944 XmaI (1) 
3x HA tag 4851..4943 
4836 AvrII (1) 
AmpR 8095..8886 
pARL-0106000-HA 
9529 bp 
 
561 NotI (1) 
2060 XhoI (1) 
3219 AvrII (1) 
3x HA tag 3234..3326 
3327 XmaI (1) 
3´UTR Pb DT 3333..3813 
3814 EcoRV (1) 
hDHFR 4651..5214 
AmpR 6478..7269 
pARL-0106100-HA 
7912 bp 
5´UTR PfCRT 562..2060 
Pf3D7_0106100 2070..3218 
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 pARL-0106200-HA 8.3.5.
 
The primers 200-XhoI-for (33) and 200-AvrII-rev (34) were used for the amplification of the 
gene coding sequence.  
 
8.4. pHBIRH-ATP6(WT)-HA 
 
The coding sequence of ATP6 was amplified from a Geneart plasmid containing the 
Saccharomyces cerevisiae codon optimized version of pfatp6, tagged with a sequence 
coding for 3xHA tags on the c-terminal end, using the primers ScATPase6-SpeI-for (35) and 
ScATPase6-SacI-rev (36). This fragment was cloned in the pHBIRH vector using the 
restriction enzymes SpeI and SacI. A bi-directional P. falciparum promoter (the intron of 
PlasmoDB: PFC0005w) drives expression of the blasticidin- S-deaminase gene and atp6. 
The original pHBIRH vector was kindly provided by Dr. Christian Epp [211].  
 
561 NotI (1) 
2060 XhoI (1) 
2068 NcoI (1) 
Pf3D7_0106200 2070..2714 
2715 AvrII (1) 
3x HA tag 2730..2822 
2823 XmaI (1) 
3´UTR Pb DT 2829..3309 
3310 EcoRV (1) 
hDHFR 4147..4710 
AmpR 5974..6765 
pARL-0106200-HA 
7408 bp 
5´UTR PfCRT 562..2060 
 
43 SacII (1) 
ATP6 1964..5647 
4037 EcoRI (1) 
4427 AgeI (1) 
5750 SacI (1) 
HA-tag 5657..5737 
AmpR 8208..7549 
pHBIRH-ATPase6 
9227 bp 
Balsticidin-S deaminase 1034..642 
PfC005w 1035..1953 
1954 SpeI (1) 
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8.5. pHBIRH-ATP6(A108T, A109T)-HA 
A similar approach was use as for the generation of the pHBIRH-ATP6(WT)-HA vector. The 
primers ScATPase6-mut1/2-for (37) and ScATPase6-mut1/2-rev (38) were used to generate 
the atp6 fragment bearing the single nucleotide polymorphisms coding for the double 
mutation A108T and A109T. 
 
43 SacII (1) 
ATP6 1964..5647 
4037 EcoRI (1) 
4427 AgeI (1) 
5750 SacI (1) 
HA-tag 5657..5737 
AmpR 8208..7549 
pHBIRH-ATPase6 
9227 bp 
Balsticidin-S deaminase 1034..642 
PfC005w 1035..1953 
1954 SpeI (1) 
Mutations site for A108T, A109T 2285..2290 
Appendix II : Plasmid maps 
Appendix III 
160 
 
9. Appendix III 
To investigate the possible inhibitory effect of SC83288 on protein synthesis, a [35S]-
methionine incorporation assay was performed, together with Dr. Chaitali Chakraborty 
(Zentrum für Molekular Biologie (ZMHB) in Heidelberg, in Prof. Christine Clayton´s lab). 
Treatment with SC83288 for 1 hour at concentrations corresponding to different multiples of 
the IC50 value (0.01x, 0.1x, 1x, 10x and 100x) showed no difference in [
35S]-methionine 
incorporation (Figure 3.35). 
                           
Figure 9.1: [35S]-methionine incorporation assay in P. falciparum 3D7 in presence of 
SC83288. Parasites were starved in labeling medium (DMEM without methionine) and 
treated with various concentrations of SC83288 (0.01x, 0.1x, 1x, 10x or 100x IC50) for 1 hour 
at 37°C, before addition of [35S]-methionine and further incubation for 30 minutes at 37°C. 
Proteins were separated by SDS‐PAGE and the total amount was visualized using 
Coomassie staining (A) and [35S]‐methionine incorporation was visualized by 
autoradiography (B). (C) Quantification of the [35S]‐methionine incorporation in newly 
synthetized proteins. Mean ± SD of 1 experiment, based on quantification on 3 protein 
bands.  
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10. Publications and Conference presentations 
 
The following publications emerged/will emerge from this work: 
 
Pegoraro S, Duffey M, Otto TD, Wang Y, Rösemann R, Baumgartner R, Fehler SK, 
Lucantoni L, Avery VM, Moreno-Sabater A, Mazier D, Vial HJ, Strobl S, Sanchez CP, Lanzer 
M. SC83288 is a clinical development candidate for the treatment of severe malaria. Nat 
Commun. 2017 Jan 31;8:14193. doi: 10.1038/ncomms14193. 
 
Duffey M, Lanzer M. Profiling the antimalarial drug candidate SC83288 against artemisinins 
in Plasmodium falciparum. Manuscript under in review in Malaria Journal. 
 
Duffey M, Staines HM, Krishna S, Lanzer M. The endoplasmic Ca2+ pump (PfATP6) 
mediates resistance to the antimalarial drug candidate SC83288. Manuscript in preparation. 
 
 
The results of this work were presented in the following scientific conferences: 
 
BioMalPar XII: Biology and Pathology of the Malaria Parasite (Heidelberg, Germany). 
18th -20th May 2016. Poster: “SC83288, a novel clinical development candidate for the 
treatment of severe malaria”. 
 
German Center for Infectious Research (DZIF) Annual Meeting (Köln, Germany). 24th -
26th November 2016. Poster: “SC83288, a novel clinical development candidate for the 
treatment of severe malaria”. 
 
28th Annual Molecular Parasitology Meeting (MPM) (Woods Hole, MA, USA). 10th – 14th 
September 2017. Poster: “The endoplasmic Ca2+ pump (PfATP6) mediates the resistance to 
the preclinical drug development candidate SC83288”. 
